[
    [
        {
            "role": "user",
            "content": "Identify and deliver a comprehensive review of the clinical trial study associated with ClinicalTrials.gov Identifier NCT04280705, including its primary aims, experimental design, participant demographics, notable outcomes, and potential applications in advancing therapeutic strategies or medical guidelines."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_article_details",
                    "arguments": {
                        "pmid": ""
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_article_details",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"# Record 1\\nError: Error 400: [\\\"pmids is a mandatory parameter.\\\"]\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Assess the specific outcomes and reported adverse events associated with clinical trial NCT04280705 by providing its unique identifier, while also evaluating the relevance of these findings to current treatment protocols and discussing potential implications for future research directions."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_outcomes",
                    "arguments": {
                        "nct_id": "NCT04280705"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_outcomes",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Url: https://clinicaltrials.gov/study/NCT04280705\\n\\n# Protocol Section\\n\\n## Outcomes Module\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Race\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Ethnicity\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Sex\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Alanine Transaminase (ALT)\\nDescription:\\n  Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Aspartate Transaminase (AST)\\nDescription:\\n  Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Creatinine\\nDescription:\\n  Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Glucose\\nDescription:\\n  Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Hemoglobin\\nDescription:\\n  Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Platelets\\nDescription:\\n  Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Prothrombin Time (PT)\\nDescription:\\n  Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Total Bilirubin\\nDescription:\\n  Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in White Blood Cell Count (WBC)\\nDescription:\\n  Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Neutrophils\\nDescription:\\n  Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Lymphocytes\\nDescription:\\n  Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Monocytes\\nDescription:\\n  Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Basophils\\nDescription:\\n  Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Eosinophils\\nDescription:\\n  Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change in National Early Warning Score (NEWS) From Baseline\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome.\\nTime Frame: Days 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 1\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 3\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 3\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 5\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 5\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 8\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 8\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 11\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 11\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 15\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 15\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 22\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 22\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 29\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Reporting Grade 3 and 4 Clinical and/or\\n  Laboratory Adverse Events (AEs)\\nDescription:\\n  Grade 3 AEs are defined as events that interrupt usual activities of\\n  daily living, or significantly affects clinical status, or may require\\n  intensive therapeutic intervention. Severe events are usually\\n  incapacitating. Grade 4 AEs are defined as events that are potentially\\n  life threatening.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Percentage of Participants Reporting Serious Adverse Events (SAEs)\\nDescription:\\n  An SAE is defined as an AE or suspected adverse reaction is considered\\n  serious if, in the view of either the investigator or the sponsor, it\\n  results in death, a life-threatening AE, inpatient hospitalization or\\n  prolongation of existing hospitalization, a persistent or significant\\n  incapacity or substantial disruption of the ability to conduct normal\\n  life functions, or a congenital anomaly/birth defect.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Discontinued or Temporarily Suspended From\\n  Investigational Therapeutics\\nDescription:\\n  Participants may have been discontinued from investigational\\n  therapeutics due to discharge or death. The halting or slowing of the\\n  infusion for any reason was collected, as was missed doses in the series\\n  of 10 doses.\\nTime Frame: Day 1 through Day 10\\n\\n### Secondary Outcomes\\nMeasure: Duration of Hospitalization\\nDescription:\\n  Duration of hospitalization was determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Duration of New Non-invasive Ventilation or High Flow Oxygen Use\\nDescription:\\n  Duration of new non-invasive ventilation or high flow oxygen use was\\n  measured in days among participants who were not on non-invasive\\n  ventilation or high-flow oxygen use at baseline, determined two ways.\\n  The first includes imputations for participants who died. The second\\n  method is restricted to participants who did not die\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Duration of New Oxygen Use\\nDescription:\\n  Duration of new oxygen use was measured in days among participants who\\n  were not on oxygen at baseline, determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die\\n\\n  .\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO)\\n  Use\\nDescription:\\n  Duration of new ventilator or ECMO use was measured in days among\\n  participants who were not on a ventilator or ECMO at baseline,\\n  determined two ways. The first includes imputations for participants who\\n  died. The second method is restricted to participants who did not die\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Requiring New Non-invasive Ventilation or\\n  High-flow Oxygen Use\\nDescription:\\n  New non-invasive ventilation or high-flow oxygen use was determined as\\n  the percentage of subject not on non-invasive ventilation or high-flow\\n  oxygen at baseline.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Percentage of Participants Requiring New Oxygen Use\\nDescription:\\n  The percentage of participants requiring new oxygen use was determined\\n  as the percentage of participants not requiring oxygen at baseline\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Requiring New Ventilator or Extracorporeal\\n  Membrane Oxygenation (ECMO) Use\\nDescription:\\n  The percentage of participants requiring new ventilator or ECMO use was\\n  determined as the percentage not on a ventilator or ECMO at baseline\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Mean Change in the Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. A positive change indicates a worsening and a negative\\n  change is an improvement.\\nTime Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n### Secondary Outcomes\\nMeasure: 14-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 15.\\nTime Frame: Day 1 through Day 15\\n\\n### Secondary Outcomes\\nMeasure: 29-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 29.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Time to an Improvement by at Least One Category Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least one category was determined\\n  for each participant\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Time to an Improvement of at Least Two Categories Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 1) Death; 2)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 4) Hospitalized, requiring\\n  supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 6)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 7) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 8) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least two categories was\\n  determined for each participant\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours,\\n  Whichever Occurs First\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome. The time to discharge or a\\n  NEWS of less than or equal to 2 was determined for each participant.\\nTime Frame: Day 1 through Day 29\\n\\n# Results Section\\n\\n## Participant Flow Module\\nRecruitment Details:\\n  Participants were recruited at the participating sites from those\\n  admitted with symptoms of COVID-19 confirmed by PCR. Enrollment occurred\\n  between 21FEB2020 and 20APR2020.\\n\\n### Groups\\nId: FG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n  Placebo: The supplied placebo lyophilized formulation is identical in\\n  physical appearance to the active lyophilized formulation and contains\\n  the same inactive ingredients. Alternatively, a placebo of normal saline\\n  of equal volume may be given if there are limitations on matching\\n  placebo supplies.\\n\\n### Groups\\nId: FG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n  Remdesivir: Drug Remdesivir is a single diastereomer monophosphoramidate\\n  prodrug designed for the intracellular delivery of a modified adenine\\n  nucleoside analog GS-441524. In addition to the active ingredient, the\\n  lyophilized formulation of Remdesivir contains the following inactive\\n  ingredients: water for injection, sulfobutylether beta-cyclodextrin\\n  sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.\\n\\n### Periods\\nTitle: Overall Study\\n\\n#### Milestones\\nType: STARTED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 521\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 541\\n\\n#### Milestones\\nType: Received Treatment\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 517\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 531\\n\\n#### Milestones\\nType: COMPLETED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 508\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 517\\n\\n#### Milestones\\nType: NOT COMPLETED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 13\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 24\\n\\n#### Drop Withdraws\\nType: Enrolled but not treated\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 4\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 10\\n\\n#### Drop Withdraws\\nType: Physician Decision\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 1\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 0\\n\\n#### Drop Withdraws\\nType: Withdrawal by Subject\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 7\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 9\\n\\n#### Drop Withdraws\\nType: Adverse Event\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 0\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 4\\n\\n#### Drop Withdraws\\nType: Transferred to another hospital\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 1\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 1\\n\\n## Baseline Characteristics Module\\n\\n### Groups\\nId: BG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n### Groups\\nId: BG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n### Groups\\nId: BG002\\nTitle: Total\\nDescription: Total of all reporting groups\\n\\n### Denoms\\nUnits: Participants\\n\\n#### Counts\\nGroup Id: BG000\\nValue: 521\\n\\n#### Counts\\nGroup Id: BG001\\nValue: 541\\n\\n#### Counts\\nGroup Id: BG002\\nValue: 1062\\n\\n### Measures\\nTitle: Age, Categorical\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: <=18 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 0\\n\\n##### Categories\\nTitle: Between 18 and 65 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 324\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 354\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 678\\n\\n##### Categories\\nTitle: >=65 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 197\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 187\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 384\\n\\n### Measures\\nTitle: Age, Continuous\\nParam Type: MEAN\\nDispersion Type: STANDARD_DEVIATION\\nUnit Of Measure: years\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 59.2\\nSpread: 15.4\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 58.6\\nSpread: 14.6\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 58.9\\nSpread: 15.0\\n\\n### Measures\\nTitle: Sex: Female, Male\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: Female\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 189\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 189\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 378\\n\\n##### Categories\\nTitle: Male\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 332\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 352\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 684\\n\\n### Measures\\nTitle: Ethnicity (NIH/OMB)\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: Hispanic or Latino\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 116\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 134\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 250\\n\\n##### Categories\\nTitle: Not Hispanic or Latino\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 373\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 382\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 755\\n\\n##### Categories\\nTitle: Unknown or Not Reported\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 32\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 25\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 57\\n\\n### Measures\\nTitle: Race (NIH/OMB)\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: American Indian or Alaska Native\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 7\\n\\n##### Categories\\nTitle: Asian\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 56\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 79\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 135\\n\\n##### Categories\\nTitle: Native Hawaiian or Other Pacific Islander\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 4\\n\\n##### Categories\\nTitle: Black or African American\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 117\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 109\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 226\\n\\n##### Categories\\nTitle: White\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 287\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 279\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 566\\n\\n##### Categories\\nTitle: More than one race\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 3\\n\\n##### Categories\\nTitle: Unknown or Not Reported\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 55\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 66\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 121\\n\\n### Measures\\nTitle: Region of Enrollment\\nParam Type: NUMBER\\nUnit Of Measure: participants\\n\\n#### Classes\\nTitle: Greece\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 19\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 14\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 33\\n\\n#### Classes\\nTitle: South Korea\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 12\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 9\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 21\\n\\n#### Classes\\nTitle: Singapore\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 9\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 16\\n\\n#### Classes\\nTitle: United States\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 410\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 427\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 837\\n\\n#### Classes\\nTitle: Japan\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 8\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 15\\n\\n#### Classes\\nTitle: Denmark\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 21\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 22\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 43\\n\\n#### Classes\\nTitle: Mexico\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 6\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 10\\n\\n#### Classes\\nTitle: United Kingdom\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 21\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 25\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 46\\n\\n#### Classes\\nTitle: Germany\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 6\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 13\\n\\n#### Classes\\nTitle: Spain\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 12\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 16\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 28\\n\\n### Measures\\nTitle: Disease severity\\nDescription:\\n  Mild-moderate disease: SpO2 \\\\> 94% and respiratory rate \\\\< 24\\n  breaths/min without supplemental oxygen.\\n\\n  Severe disease: requiring mechanical ventilation, requiring oxygen, a\\n  SpO2 = 94% on room air, or tachypnea (respiratory rate = 24\\n  breaths/min).\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\nTitle: Mild-to-moderate disease severity\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 50\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 55\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 105\\n\\n#### Classes\\nTitle: Severe disease severity\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 471\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 486\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 957\\n\\n## Outcome Measures Module\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 9\\nUpper Limit: 11\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.12\\nCi Upper Limit: 1.49\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Alanine Transaminase (ALT)\\nDescription:\\n  Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: Units/Liter (U/L)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 465\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 465\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14.3\\nSpread: 88\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2.9\\nSpread: 31.5\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 403\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 398\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23.1\\nSpread: 70.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.8\\nSpread: 55.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 327\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 296\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24.2\\nSpread: 79.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 8.9\\nSpread: 54.2\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 227\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 27.7\\nSpread: 89.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.4\\nSpread: 48.4\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 242\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 257\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 28.1\\nSpread: 110.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.7\\nSpread: 47.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 180\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -3.9\\nSpread: 62.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -6.8\\nSpread: 43.7\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Aspartate Transaminase (AST)\\nDescription:\\n  Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: Units/Liter (U/L)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 438\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 445\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 438\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 445\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13.7\\nSpread: 90.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.0\\nSpread: 29.1\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 384\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 380\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.8\\nSpread: 66.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6.0\\nSpread: 58.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 315\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 285\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13.1\\nSpread: 114.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.1\\nSpread: 55.9\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 247\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 219\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11.5\\nSpread: 78.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 51.7\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 236\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 248\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.2\\nSpread: 73.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.3\\nSpread: 60.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 170\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 208\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -18.4\\nSpread: 47.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -14.0\\nSpread: 52.2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Creatinine\\nDescription:\\n  Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: milligrams/deciliter (mg/dL)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 482\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 482\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.037\\nSpread: 0.517\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.038\\nSpread: 0.569\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 418\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 411\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.695\\nSpread: 17.552\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.075\\nSpread: 0.762\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 335\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 309\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.882\\nSpread: 19.637\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.158\\nSpread: 0.951\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 234\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.173\\nSpread: 15.440\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.236\\nSpread: 1.057\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 249\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 262\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.239\\nSpread: 22.755\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.319\\nSpread: 2.147\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 229\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.863\\nSpread: 26.093\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.075\\nSpread: 0.644\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Glucose\\nDescription:\\n  Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: mg/dL\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.2\\nSpread: 53.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.0\\nSpread: 49.4\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 407\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 395\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6.3\\nSpread: 60.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2.1\\nSpread: 63.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 323\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 301\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.2\\nSpread: 73.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.2\\nSpread: 68.0\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 260\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 228\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.0\\nSpread: 70.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.1\\nSpread: 77.4\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 250\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -2.8\\nSpread: 64.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.9\\nSpread: 75.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 180\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 219\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -13.5\\nSpread: 96.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -11.7\\nSpread: 75.4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Hemoglobin\\nDescription:\\n  Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: grams/deciliter (g/dL)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.52\\nSpread: 1.10\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.69\\nSpread: 5.36\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 420\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 406\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.83\\nSpread: 1.22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.99\\nSpread: 5.83\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 334\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 310\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.22\\nSpread: 1.42\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.49\\nSpread: 6.54\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 230\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.66\\nSpread: 1.67\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.29\\nSpread: 1.93\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 253\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 260\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.51\\nSpread: 2.02\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.02\\nSpread: 3.04\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 227\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.02\\nSpread: 2.38\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.21\\nSpread: 7.91\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Platelets\\nDescription:\\n  Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 471\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 474\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 471\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 474\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 39.3\\nSpread: 60.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 46.0\\nSpread: 62.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 419\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 403\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 76.5\\nSpread: 100.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 90.1\\nSpread: 99.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 332\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 308\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 111.8\\nSpread: 137.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 130.8\\nSpread: 128.1\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 229\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 109.3\\nSpread: 149.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 101.0\\nSpread: 145.0\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 252\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 258\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 96.5\\nSpread: 154.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 71.1\\nSpread: 133.3\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 224\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32.7\\nSpread: 124.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 39.6\\nSpread: 107.4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Prothrombin Time (PT)\\nDescription:\\n  Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: seconds\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 339\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 339\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.18\\nSpread: 4.28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.44\\nSpread: 5.22\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 296\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 306\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.30\\nSpread: 4.72\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.15\\nSpread: 5.72\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 246\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 234\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.01\\nSpread: 2.59\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.43\\nSpread: 3.89\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 199\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 182\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.86\\nSpread: 7.85\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.88\\nSpread: 5.68\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 193\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.34\\nSpread: 4.33\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.03\\nSpread: 4.25\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 134\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 163\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.28\\nSpread: 3.20\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.63\\nSpread: 3.37\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Total Bilirubin\\nDescription:\\n  Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: mg/dL\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 451\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 456\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 451\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 456\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.08\\nSpread: 1.25\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.04\\nSpread: 0.75\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 394\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.58\\nSpread: 4.13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.03\\nSpread: 1.03\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 315\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 288\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.22\\nSpread: 2.56\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.01\\nSpread: 1.38\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 247\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.23\\nSpread: 2.79\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.07\\nSpread: 1.48\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 237\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 254\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.00\\nSpread: 1.80\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.09\\nSpread: 1.54\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 178\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 216\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.17\\nSpread: 1.65\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.12\\nSpread: 1.77\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in White Blood Cell Count (WBC)\\nDescription:\\n  Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 474\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 474\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 18.691\\nSpread: 424.837\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -18.970\\nSpread: 301.944\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 419\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 405\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9.886\\nSpread: 566.175\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -28.209\\nSpread: 412.615\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 333\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 310\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 27.223\\nSpread: 479.095\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -45.997\\nSpread: 602.461\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 268\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 230\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.967\\nSpread: 16.042\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -34.702\\nSpread: 574.065\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 252\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 260\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 56.311\\nSpread: 620.551\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -70.884\\nSpread: 600.011\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 226\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.898\\nSpread: 17.801\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.251\\nSpread: 3.987\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Neutrophils\\nDescription:\\n  Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9.429\\nSpread: 260.345\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -8.093\\nSpread: 135.068\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.177\\nSpread: 362.782\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -15.067\\nSpread: 216.532\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 317\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 298\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17.916\\nSpread: 305.321\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -28.179\\nSpread: 365.099\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3.010\\nSpread: 27.502\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -21.773\\nSpread: 354.025\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36.024\\nSpread: 389.093\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -39.988\\nSpread: 333.088\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.269\\nSpread: 7.160\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.840\\nSpread: 3.666\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Lymphocytes\\nDescription:\\n  Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5.883\\nSpread: 118.740\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -7.847\\nSpread: 131.548\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.064\\nSpread: 141.580\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -11.723\\nSpread: 167.428\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 317\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 299\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8.006\\nSpread: 137.149\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -15.455\\nSpread: 194.111\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.393\\nSpread: 1.371\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -12.016\\nSpread: 183.060\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14.793\\nSpread: 159.583\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -23.836\\nSpread: 218.653\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.668\\nSpread: 1.406\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.743\\nSpread: 0.664\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Monocytes\\nDescription:\\n  Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 458\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 458\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.448\\nSpread: 41.304\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.940\\nSpread: 46.752\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 388\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.498\\nSpread: 57.686\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.628\\nSpread: 39.329\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 316\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 299\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.324\\nSpread: 36.626\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.645\\nSpread: 48.636\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.383\\nSpread: 0.744\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.539\\nSpread: 43.454\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6.475\\nSpread: 69.019\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -8.738\\nSpread: 74.365\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.125\\nSpread: 0.485\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.117\\nSpread: 0.340\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Basophils\\nDescription:\\n  Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 455\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 452\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 455\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 452\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.020\\nSpread: 0.257\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.043\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 394\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 380\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.038\\nSpread: 0.501\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.370\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 309\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 293\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.196\\nSpread: 3.132\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.368\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 253\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.024\\nSpread: 0.042\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.028\\nSpread: 0.053\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 235\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 248\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.158\\nSpread: 1.913\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.058\\nSpread: 1.028\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 216\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.040\\nSpread: 0.073\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.029\\nSpread: 0.054\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Eosinophils\\nDescription:\\n  Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 455\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 455\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.634\\nSpread: 10.614\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.016\\nSpread: 0.727\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 397\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 387\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.666\\nSpread: 11.977\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.066\\nSpread: 2.807\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 311\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 293\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.596\\nSpread: 8.875\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.221\\nSpread: 4.108\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 254\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.093\\nSpread: 0.190\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.088\\nSpread: 2.973\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 237\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 251\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.992\\nSpread: 20.365\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.420\\nSpread: 5.378\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 217\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.241\\nSpread: 0.324\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.211\\nSpread: 0.267\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change in National Early Warning Score (NEWS) From Baseline\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized with data at baseline and at each timepoint.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: units on a scale\\nTime Frame: Days 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 499\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 502\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 499\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 502\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.1\\nSpread: 2.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 2.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 447\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 438\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.3\\nSpread: 3.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.4\\nSpread: 2.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 348\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 321\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.3\\nSpread: 3.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.5\\nSpread: 3.2\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 291\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 254\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.3\\nSpread: 4.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.5\\nSpread: 3.5\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 290\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 301\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 4.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.7\\nSpread: 3.6\\n\\n#### Classes\\nTitle: Day 22\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 151\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 120\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 4.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.7\\nSpread: 4.1\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 221\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 251\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -3.2\\nSpread: 4.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.3\\nSpread: 3.2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 1\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 30\\nLower Limit: 26\\nUpper Limit: 34\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 21\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 18\\nLower Limit: 15\\nUpper Limit: 21\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 39\\nLower Limit: 35\\nUpper Limit: 43\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 43\\nLower Limit: 39\\nUpper Limit: 47\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 10\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 14\\nLower Limit: 11\\nUpper Limit: 17\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 3\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 3\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36\\nLower Limit: 32\\nUpper Limit: 40\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 25\\nUpper Limit: 32\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 16\\nLower Limit: 13\\nUpper Limit: 19\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 37\\nLower Limit: 33\\nUpper Limit: 41\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 5\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 5\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 37\\nLower Limit: 33\\nUpper Limit: 41\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 24\\nUpper Limit: 32\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 26\\nLower Limit: 23\\nUpper Limit: 30\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 24\\nUpper Limit: 31\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 8\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 15\\nLower Limit: 12\\nUpper Limit: 18\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 8\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 8\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 33\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 21\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 19\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 10\\nLower Limit: 8\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 30\\nLower Limit: 27\\nUpper Limit: 34\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 11\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 11\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8\\nLower Limit: 6\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 28\\nLower Limit: 25\\nUpper Limit: 32\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 10\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 33\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 44\\nLower Limit: 40\\nUpper Limit: 48\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 15\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 15\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 19\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 8\\nUpper Limit: 13\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 22\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 29\\nLower Limit: 25\\nUpper Limit: 33\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\nLower Limit: 3\\nUpper Limit: 7\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 22\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 22\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8\\nLower Limit: 6\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5\\nLower Limit: 4\\nUpper Limit: 8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 18\\nLower Limit: 15\\nUpper Limit: 22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 23\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 39\\nLower Limit: 35\\nUpper Limit: 43\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Completed study without reporting score\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 29\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 8\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 23\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 20\\nLower Limit: 17\\nUpper Limit: 23\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36\\nLower Limit: 32\\nUpper Limit: 41\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 46\\nLower Limit: 42\\nUpper Limit: 50\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5\\nLower Limit: 3\\nUpper Limit: 7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Completed study without reporting score\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Reporting Grade 3 and 4 Clinical and/or\\n  Laboratory Adverse Events (AEs)\\nDescription:\\n  Grade 3 AEs are defined as events that interrupt usual activities of\\n  daily living, or significantly affects clinical status, or may require\\n  intensive therapeutic intervention. Severe events are usually\\n  incapacitating. Grade 4 AEs are defined as events that are potentially\\n  life threatening.\\nPopulation Description:\\n  The safety population includes all participants with available data post\\n  baseline, analyzed as treated.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 516\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 532\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 57\\nLower Limit: 52.8\\nUpper Limit: 61.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 51\\nLower Limit: 47.0\\nUpper Limit: 55.6\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.058\\nStatistical Method: Barnard's Exact Test\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Percentage of Participants Reporting Serious Adverse Events (SAEs)\\nDescription:\\n  An SAE is defined as an AE or suspected adverse reaction is considered\\n  serious if, in the view of either the investigator or the sponsor, it\\n  results in death, a life-threatening AE, inpatient hospitalization or\\n  prolongation of existing hospitalization, a persistent or significant\\n  incapacity or substantial disruption of the ability to conduct normal\\n  life functions, or a congenital anomaly/birth defect.\\nPopulation Description:\\n  The safety population includes all participants with available data post\\n  baseline, analyzed as treated.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 516\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 532\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 27.7\\nUpper Limit: 35.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 20.9\\nUpper Limit: 28.3\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.010\\nStatistical Method: Barnard's Exact Test\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Discontinued or Temporarily Suspended From\\n  Investigational Therapeutics\\nDescription:\\n  Participants may have been discontinued from investigational\\n  therapeutics due to discharge or death. The halting or slowing of the\\n  infusion for any reason was collected, as was missed doses in the series\\n  of 10 doses.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 10\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Discontinued due to discharge\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 30\\nLower Limit: 26\\nUpper Limit: 34\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 41\\nLower Limit: 37\\nUpper Limit: 45\\n\\n#### Classes\\nTitle: Discontinued due to death\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Any infusions halted or slowed\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Missed any maintenance dose\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 21\\nLower Limit: 18\\nUpper Limit: 25\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 16\\nLower Limit: 13\\nUpper Limit: 19\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of Hospitalization\\nDescription:\\n  Duration of hospitalization was determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Including imputation for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 8\\nUpper Limit: 28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 6\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Restricted to participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 443\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 480\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 7\\nUpper Limit: 27\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 5\\nUpper Limit: 21\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of New Non-invasive Ventilation or High Flow Oxygen Use\\nDescription:\\n  Duration of new non-invasive ventilation or high flow oxygen use was\\n  measured in days among participants who were not on non-invasive\\n  ventilation or high-flow oxygen use at baseline, determined two ways.\\n  The first includes imputations for participants who died. The second\\n  method is restricted to participants who did not die\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on non-invasive ventilation or high-flow oxygen at baseline but\\n  who subsequently required non-invasive or high-flow oxygen.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 64\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 64\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 23.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 10.5\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 50\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 43\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 6\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of New Oxygen Use\\nDescription:\\n  Duration of new oxygen use was measured in days among participants who\\n  were not on oxygen at baseline, determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die\\n\\n  .\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on oxygen at baseline but who subsequently required oxygen.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 28\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 27\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 28\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 27\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5.5\\nLower Limit: 1\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 25\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 24\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.5\\nLower Limit: 2\\nUpper Limit: 5.5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO)\\n  Use\\nDescription:\\n  Duration of new ventilator or ECMO use was measured in days among\\n  participants who were not on a ventilator or ECMO at baseline,\\n  determined two ways. The first includes imputations for participants who\\n  died. The second method is restricted to participants who did not die\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not on\\n  a ventilator or ECMO at baseline but who subsequently required a\\n  ventilator or ECMO.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 82\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 82\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23\\nLower Limit: 12\\nUpper Limit: 28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 21.5\\nLower Limit: 9\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 57\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 39\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 16\\nLower Limit: 9\\nUpper Limit: 24\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 14\\nLower Limit: 5\\nUpper Limit: 26\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Requiring New Non-invasive Ventilation or\\n  High-flow Oxygen Use\\nDescription:\\n  New non-invasive ventilation or high-flow oxygen use was determined as\\n  the percentage of subject not on non-invasive ventilation or high-flow\\n  oxygen at baseline.\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on non-invasive or high-flow oxygen at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 266\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 307\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24\\nLower Limit: 19\\nUpper Limit: 30\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 17\\nLower Limit: 13\\nUpper Limit: 22\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Percentage of Participants Requiring New Oxygen Use\\nDescription:\\n  The percentage of participants requiring new oxygen use was determined\\n  as the percentage of participants not requiring oxygen at baseline\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not\\n  requiring oxygen at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 63\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 75\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 44\\nLower Limit: 33\\nUpper Limit: 57\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 36\\nLower Limit: 26\\nUpper Limit: 47\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Requiring New Ventilator or Extracorporeal\\n  Membrane Oxygenation (ECMO) Use\\nDescription:\\n  The percentage of participants requiring new ventilator or ECMO use was\\n  determined as the percentage not on a ventilator or ECMO at baseline\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not on\\n  a ventilator or ECMO at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 364\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 402\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23\\nLower Limit: 19\\nUpper Limit: 27\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 17\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Mean Change in the Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. A positive change indicates a worsening and a negative\\n  change is an improvement.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized reporting a clinical score. Missing values were imputed using\\n  Last Observation Carried Forward. Clinical scores of 8 were carried\\n  forward from the date of death for participants who died.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: units on a scale\\nTime Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 518\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 533\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nSpread: 0.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.1\\nSpread: 0.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.1\\nSpread: 0.9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.0\\nSpread: 0.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.0\\nSpread: 0.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.2\\nSpread: 1.0\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.1\\nSpread: 1.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 1.1\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 2.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.9\\nSpread: 2.1\\n\\n#### Classes\\nTitle: Day 22\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.9\\nSpread: 2.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.4\\nSpread: 2.2\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -2.3\\nSpread: 2.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.7\\nSpread: 2.3\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: 14-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 15.\\nPopulation Description: The ITT population consists of all participants as randomized.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Proportion of participants\\nTime Frame: Day 1 through Day 15\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.12\\nLower Limit: 0.09\\nUpper Limit: 0.15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.07\\nLower Limit: 0.05\\nUpper Limit: 0.09\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: 29-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 29.\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Proportion of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.15\\nLower Limit: 0.12\\nUpper Limit: 0.19\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.11\\nLower Limit: 0.09\\nUpper Limit: 0.15\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Time to an Improvement by at Least One Category Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least one category was determined\\n  for each participant\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 8\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 6\\nUpper Limit: 8\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.002\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.23\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.08\\nCi Upper Limit: 1.41\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Time to an Improvement of at Least Two Categories Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 1) Death; 2)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 4) Hospitalized, requiring\\n  supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 6)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 7) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 8) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least two categories was\\n  determined for each participant\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 13\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 10\\nUpper Limit: 13\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.12\\nCi Upper Limit: 1.48\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours,\\n  Whichever Occurs First\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome. The time to discharge or a\\n  NEWS of less than or equal to 2 was determined for each participant.\\nPopulation Description: The ITT population includes all participants as randomized.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 10\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 8\\nLower Limit: 7\\nUpper Limit: 9\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.27\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 1.46\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Race\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Asian\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 56\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 79\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.0\\nLower Limit: 9.0\\nUpper Limit: 15.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11.0\\nLower Limit: 9.0\\nUpper Limit: 15.0\\n\\n#### Classes\\nTitle: Black or African American\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 117\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 109\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 10.0\\nUpper Limit: 21.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 7.0\\nUpper Limit: 16.0\\n\\n#### Classes\\nTitle: White\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 287\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 279\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Other\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 61\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 74\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24.0\\nLower Limit: 15.0\\nUpper Limit: NA\\nComment:\\n  A large number of participants at the median estimate resulted in little\\n  variability at the 50th percentile and the methodology described by\\n  Klein and Moeschberger (1997) was unable to compute an upper confidence\\n  limit.\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 6.0\\nUpper Limit: 14.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Asian participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.07\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.73\\nCi Upper Limit: 1.58\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Black or African American participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.25\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.91\\nCi Upper Limit: 1.72\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for White participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.06\\nCi Upper Limit: 1.57\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Race of Other participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.68\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 2.58\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Ethnicity\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized and for whom Ethnicity was reported\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 489\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 516\\n\\n#### Classes\\nTitle: Not Hispanic or Latino\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 373\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 382\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 13.0\\nUpper Limit: 18.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Hispanic or Latino\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 116\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 134\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.5\\nLower Limit: 9.0\\nUpper Limit: 22.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 7.0\\nUpper Limit: 14.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Not Hispanic or Latino participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.31\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 1.55\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Hispanic or Latino participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.28\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.94\\nCi Upper Limit: 1.73\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Sex\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Male\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 332\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Female\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 189\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 8.0\\nUpper Limit: 13.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Male participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.30\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.09\\nCi Upper Limit: 1.56\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Female participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.31\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.03\\nCi Upper Limit: 1.66\\nGroup Ids: OG000, OG001\\n\\n## Adverse Events Module\\nFrequency Threshold: 5\\nTime Frame:\\n  Grade 3 and 4 serious and non-serious adverse events were collected for\\n  29 days after the first dose. Laboratory values were systematically\\n  assessed at Days 1, 3, 5, 8, and 11 while participants were inpatient,\\n  and at Days 15 and 29.\\nDescription:\\n  Given the nature of severity of the underlying illness, participants\\n  were expected to have many symptoms and abnormalities in vital signs and\\n  laboratory values. All Grade 3 and 4 AEs were captured as AEs in this\\n  trial. In addition, any Grade 2 or higher, suspected drug-related\\n  hypersensitivity reaction was to be reported as an AE in this trial. All\\n  cause mortality was calculated for the ITT population, while SAEs and\\n  AEs reflect the as treated population.\\n\\n### Event Groups\\nId: EG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\nDeaths Num Affected: 77\\nDeaths Num At Risk: 521\\nSerious Num Affected: 163\\nSerious Num At Risk: 516\\nOther Num Affected: 295\\nOther Num At Risk: 516\\n\\n### Event Groups\\nId: EG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\nDeaths Num Affected: 59\\nDeaths Num At Risk: 541\\nSerious Num Affected: 131\\nSerious Num At Risk: 532\\nOther Num Affected: 276\\nOther Num At Risk: 532\\n\\n### Serious Events\\nTerm: Coagulopathy\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Febrile neutropenia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Anaemia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac arrest\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 10\\nNum Affected: 10\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Atrial fibrillation\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardio-respiratory arrest\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myocardial infarction\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Supraventricular tachycardia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ventricular tachycardia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute myocardial infarction\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac failure\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiogenic shock\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute coronary syndrome\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Arrhythmia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Palpitations\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulseless electrical activity\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ventricular fibrillation\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac tamponade\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Intestinal ischaemia\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Diarrhoea\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Duodenal perforation\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Gastrointestinal haemorrhage\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Small intestinal perforation\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haematemesis\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Peptic ulcer haemorrhage\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Small intestinal obstruction\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Multiple organ dysfunction syndrome\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pyrexia\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Chest pain\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Death\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hepatitis\\nOrgan System: Hepatobiliary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ischaemic hepatitis\\nOrgan System: Hepatobiliary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Drug hypersensitivity\\nOrgan System: Immune system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Septic shock\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 15\\nNum Affected: 15\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 8\\nNum Affected: 8\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: COVID-19\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: COVID-19 pneumonia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Sepsis\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumonia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Catheter bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Gangrene\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Infectious pleural effusion\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Staphylococcal bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Urinary tract infection\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Bacterial sepsis\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Endocarditis bacterial\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hip fracture\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Infusion related reaction\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Procedural pneumothorax\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Glomerular filtration rate decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemoglobin decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Oxygen saturation decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Blood creatinine increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Lymphocyte count decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acidosis\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Dehydration\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypernatraemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hyponatraemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Decreased appetite\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pain in extremity\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myalgia\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myopathy\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebrovascular accident\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Seizure\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebellar infarction\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebral haemorrhage\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Encephalopathy\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Subarachnoid haemorrhage\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Depressed level of consciousness\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemorrhagic transformation stroke\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hemiparesis\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Intensive care unit acquired weakness\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ischaemic stroke\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Mental status changes\\nOrgan System: Psychiatric disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Psychotic disorder\\nOrgan System: Psychiatric disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute kidney injury\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 12\\nNum Affected: 12\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Renal failure\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Renal impairment\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 59\\nNum Affected: 58\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 36\\nNum Affected: 35\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 14\\nNum Affected: 14\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 8\\nNum Affected: 8\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory distress\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 11\\nNum Affected: 11\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 6\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute respiratory distress syndrome\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumothorax\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulmonary embolism\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypoxia\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumonia aspiration\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Dyspnoea\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory disorder\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Chronic respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemoptysis\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulmonary haemorrhage\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Subcutaneous emphysema\\nOrgan System: Skin and subcutaneous tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Endotracheal intubation\\nOrgan System: Surgical and medical procedures\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 9\\nNum Affected: 9\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 6\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Mechanical ventilation\\nOrgan System: Surgical and medical procedures\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypotension\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Shock\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Deep vein thrombosis\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Embolism venous\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Peripheral artery occlusion\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Shock haemorrhagic\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Glomerular filtration rate decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 81\\nNum Affected: 74\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 59\\nNum Affected: 55\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Haemoglobin decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 69\\nNum Affected: 62\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 51\\nNum Affected: 48\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Lymphocyte count decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 63\\nNum Affected: 54\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 56\\nNum Affected: 44\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Anaemia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 58\\nNum Affected: 52\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 52\\nNum Affected: 42\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Pyrexia\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 37\\nNum Affected: 32\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 52\\nNum Affected: 38\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Hyperglycaemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 43\\nNum Affected: 34\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 36\\nNum Affected: 34\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Blood creatinine increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 41\\nNum Affected: 36\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 33\\nNum Affected: 31\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Blood glucose increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 31\\nNum Affected: 27\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 45\\nNum Affected: 39\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Aspartate aminotransferase increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 35\\nNum Affected: 33\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 19\\nNum Affected: 18\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Lymphopenia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 34\\nNum Affected: 30\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 15\\nNum Affected: 13\\nNum At Risk: 532\\n\\n## More Info Module\\n\\n### Certain Agreement\\nPi Sponsor Employee: False\\nRestriction Type: LTE60\\nRestrictive Agreement: True\\n\\n### Point Of Contact\\nTitle: John Beigel, MD\\nOrganization: Organization:NIAID\\nEmail: jbeigel@niaid.nih.gov\\nPhone: 3014519881\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Access the addresses and contact details for the study sites related to the clinical trial with registration number NCT04280705."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_locations",
                    "arguments": {
                        "nct_id": "NCT04280705"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_locations",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Url: https://clinicaltrials.gov/study/NCT04280705\\n\\n# Protocol Section\\n\\n## Contacts Locations Module\\n\\n### Locations\\nFacility:\\n  University of Alabama at Birmingham School of Medicine - Infectious\\n  Disease\\nCity: Birmingham\\nState: Alabama\\nZip: 35233\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.52066\\nLon: -86.80249\\n\\n### Locations\\nFacility: University of California San Diego Health - Jacobs Medical Center\\nCity: La Jolla\\nState: California\\nZip: 29037\\nCountry: United States\\n\\n#### Geo Point\\nLat: 32.84727\\nLon: -117.2742\\n\\n### Locations\\nFacility: University of California Los Angeles Medical Center - Westwood Clinic\\nCity: Los Angeles\\nState: California\\nZip: 90095\\nCountry: United States\\n\\n#### Geo Point\\nLat: 34.05223\\nLon: -118.24368\\n\\n### Locations\\nFacility: University of California Irvine Medical Center - Infectious Disease\\nCity: Orange\\nState: California\\nZip: 92868-3298\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.78779\\nLon: -117.85311\\n\\n### Locations\\nFacility: VA Palo Alto Health Care System - Infectious Diseases\\nCity: Palo Alto\\nState: California\\nZip: 94304-1207\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.44188\\nLon: -122.14302\\n\\n### Locations\\nFacility:\\n  University of California Davis Medical Center - Internal Medicine -\\n  Infectious Disease\\nCity: Sacramento\\nState: California\\nZip: 95817-1460\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.58157\\nLon: -121.4944\\n\\n### Locations\\nFacility: Naval Medical Center San Diego - Infectious Disease Clinic\\nCity: San Diego\\nState: California\\nZip: 92314\\nCountry: United States\\n\\n#### Geo Point\\nLat: 32.71571\\nLon: -117.16472\\n\\n### Locations\\nFacility:\\n  University of California San Francisco - Zuckerberg San Francisco\\n  General Hospital - Division of Human Immunodeficiency Virus, Infectious\\n  Disease, and Global Medicine\\nCity: San Francisco\\nState: California\\nZip: 94110-2859\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.77493\\nLon: -122.41942\\n\\n### Locations\\nFacility:\\n  Stanford University - Stanford Hospital and Clinics - Pediatrics -\\n  Infectious Diseases\\nCity: Stanford\\nState: California\\nZip: 94305-2200\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.42411\\nLon: -122.16608\\n\\n### Locations\\nFacility: Cedars Sinai Medical Center\\nCity: West Hollywood\\nState: California\\nZip: 90048-1804\\nCountry: United States\\n\\n#### Geo Point\\nLat: 34.09001\\nLon: -118.36174\\n\\n### Locations\\nFacility: Denver Health Division of Hospital Medicine - Main Campus\\nCity: Denver\\nState: Colorado\\nZip: 80204\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.73915\\nLon: -104.9847\\n\\n### Locations\\nFacility: Emory Vaccine Center - The Hope Clinic\\nCity: Decatur\\nState: Georgia\\nZip: 30030-1705\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.77483\\nLon: -84.29631\\n\\n### Locations\\nFacility: Northwestern Hospital - Infectious Disease\\nCity: Chicago\\nState: Illinois\\nZip: 60611-2908\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.85003\\nLon: -87.65005\\n\\n### Locations\\nFacility:\\n  University of Illinois at Chicago College of Medicine - Division of\\n  Infectious Diseases\\nCity: Chicago\\nState: Illinois\\nZip: 60612\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.85003\\nLon: -87.65005\\n\\n### Locations\\nFacility:\\n  Southeast Louisiana Veterans Health Care System - Section of Infectious\\n  Diseases\\nCity: New Orleans\\nState: Louisiana\\nZip: 70119\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.95465\\nLon: -90.07507\\n\\n### Locations\\nFacility:\\n  University of Maryland School of Medicine - Center for Vaccine\\n  Development - Baltimore\\nCity: Baltimore\\nState: Maryland\\nZip: 21201-1509\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.29038\\nLon: -76.61219\\n\\n### Locations\\nFacility: Johns Hopkins Hospital - Medicine - Infectious Diseases\\nCity: Baltimore\\nState: Maryland\\nZip: 21287-0005\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.29038\\nLon: -76.61219\\n\\n### Locations\\nFacility: Walter Reed National Military Medical Center\\nCity: Bethesda\\nState: Maryland\\nZip: 20889\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.98067\\nLon: -77.10026\\n\\n### Locations\\nFacility:\\n  National Institutes of Health - Clinical Center, National Institute of\\n  Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical\\n  Research Section\\nCity: Bethesda\\nState: Maryland\\nZip: 20892-1504\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.98067\\nLon: -77.10026\\n\\n### Locations\\nFacility: Massachusetts General Hospital - Infectious Diseases\\nCity: Boston\\nState: Massachusetts\\nZip: 02114-2621\\nCountry: United States\\n\\n#### Geo Point\\nLat: 42.35843\\nLon: -71.05977\\n\\n### Locations\\nFacility:\\n  University of Massachusetts Medical School - Infectious Diseases and\\n  Immunology\\nCity: Worcester\\nState: Massachusetts\\nZip: 01655-0002\\nCountry: United States\\n\\n#### Geo Point\\nLat: 42.26259\\nLon: -71.80229\\n\\n### Locations\\nFacility:\\n  University of Minnesota Medical Center, Fairview - Infectious Diseases\\n  and International Medicine\\nCity: Minneapolis\\nState: Minnesota\\nZip: 55455-0341\\nCountry: United States\\n\\n#### Geo Point\\nLat: 44.97997\\nLon: -93.26384\\n\\n### Locations\\nFacility: Saint Louis University - Center for Vaccine Development\\nCity: St Louis\\nState: Missouri\\nZip: 63104-1015\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.62727\\nLon: -90.19789\\n\\n### Locations\\nFacility: University of Nebraska Medical Center - Infectious Diseases\\nCity: Omaha\\nState: Nebraska\\nZip: 68105\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.25626\\nLon: -95.94043\\n\\n### Locations\\nFacility:\\n  New York University School of Medicine - Langone Medical Center -\\n  Microbiology - Parasitology\\nCity: New York\\nState: New York\\nZip: 10016-6402\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.71427\\nLon: -74.00597\\n\\n### Locations\\nFacility: University of Rochester Medical Center - Vaccine Research Unit\\nCity: Rochester\\nState: New York\\nZip: 14642-0001\\nCountry: United States\\n\\n#### Geo Point\\nLat: 43.15478\\nLon: -77.61556\\n\\n### Locations\\nFacility: Montefiore Medical Center - Infectious Diseases\\nCity: The Bronx\\nState: New York\\nZip: 10467-2401\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.84985\\nLon: -73.86641\\n\\n### Locations\\nFacility: Duke Human Vaccine Institute - Duke Vaccine and Trials Unit\\nCity: Durham\\nState: North Carolina\\nZip: 27704\\nCountry: United States\\n\\n#### Geo Point\\nLat: 35.99403\\nLon: -78.89862\\n\\n### Locations\\nFacility:\\n  Penn State Health Milton S. Hershey Medical Center - Division of\\n  Infectious Diseases\\nCity: Hershey\\nState: Pennsylvania\\nZip: 17033\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.28592\\nLon: -76.65025\\n\\n### Locations\\nFacility: Hospital of the University of Pennsylvania - Infectious Diseases\\nCity: Philadelphia\\nState: Pennsylvania\\nZip: 19104-4238\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.95238\\nLon: -75.16362\\n\\n### Locations\\nFacility: Vanderbilt University Medical Center - Infectious Diseases\\nCity: Nashville\\nState: Tennessee\\nZip: 37232-0011\\nCountry: United States\\n\\n#### Geo Point\\nLat: 36.16589\\nLon: -86.78444\\n\\n### Locations\\nFacility: Brooke Army Medical Center\\nCity: Fort Sam Houston\\nState: Texas\\nZip: 78234\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.45303\\nLon: -98.4417\\n\\n### Locations\\nFacility: University of Texas Medical Branch - Division of Infectious Disease\\nCity: Galveston\\nState: Texas\\nZip: 77555-0435\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.30135\\nLon: -94.7977\\n\\n### Locations\\nFacility: Baylor College of Medicine - Molecular Virology and Microbiology\\nCity: Houston\\nState: Texas\\nZip: 77030-3411\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.76328\\nLon: -95.36327\\n\\n### Locations\\nFacility:\\n  University of Texas Health Science Center at San Antonio - Infectious\\n  Diseases\\nCity: San Antonio\\nState: Texas\\nZip: 78229-3901\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.42412\\nLon: -98.49363\\n\\n### Locations\\nFacility: University of Virginia - Acute Care Surgery\\nCity: Charlottesville\\nState: Virginia\\nZip: 22908-0816\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.02931\\nLon: -78.47668\\n\\n### Locations\\nFacility: Naval Medical Center Portsmouth - Infectious Disease Division\\nCity: Portsmouth\\nState: Virginia\\nZip: 23708\\nCountry: United States\\n\\n#### Geo Point\\nLat: 36.83543\\nLon: -76.29827\\n\\n### Locations\\nFacility: EvergreenHealth Infectious Disease Service\\nCity: Kirkland\\nState: Washington\\nZip: 98034\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.68149\\nLon: -122.20874\\n\\n### Locations\\nFacility: The University of Washington - Virology Research Clinic\\nCity: Seattle\\nState: Washington\\nZip: 98104\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.60621\\nLon: -122.33207\\n\\n### Locations\\nFacility: Providence Sacred Heart Medical Center\\nCity: Spokane\\nState: Washington\\nZip: 99204\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.65966\\nLon: -117.42908\\n\\n### Locations\\nFacility: Madigan Army Medical Center - Infectious Disease Clinic\\nCity: Tacoma\\nState: Washington\\nZip: 98431\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.25288\\nLon: -122.44429\\n\\n### Locations\\nFacility:\\n  University of Copenhagen - Centre of Excellence for Health, Immunity and\\n  Infections (CHIP) - Department of Infectious Diseases\\nCity: Copenhagen\\nZip: 2100\\nCountry: Denmark\\n\\n#### Geo Point\\nLat: 55.67594\\nLon: 12.56553\\n\\n### Locations\\nFacility:\\n  Universitatsklinikum Bonn, Medizinische Klinik I - Bereich\\n  Infektiologie/HIV der Medizinischen Klinik\\nCity: Bonn\\nState: North Rhine-Westphalia\\nZip: 53127\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 50.73438\\nLon: 7.09549\\n\\n### Locations\\nFacility:\\n  Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches\\n  Studienzentrum fur Infektiologie I\\nCity: Cologne\\nZip: 50937\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 50.93333\\nLon: 6.95\\n\\n### Locations\\nFacility: Universit\\u00e4tsklinikum Frankfurt -Medizinische Klinik II - Infektiologie\\nCity: Frankfurt\\nZip: 60590\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 49.68333\\nLon: 10.53333\\n\\n### Locations\\nFacility: AHEPA University Hospital - 1st Department of Internal Medicine\\nCity: Thessaloniki\\nState: Central Macedonia\\nZip: P.O. 54636\\nCountry: Greece\\n\\n#### Geo Point\\nLat: 40.64361\\nLon: 22.93086\\n\\n### Locations\\nFacility:\\n  Medical School of Athens University - Evangelismos Hospital - Department\\n  of Critical Care and Pulmonary Services\\nCity: Athens\\nZip: GR-10675\\nCountry: Greece\\n\\n#### Geo Point\\nLat: 37.98376\\nLon: 23.72784\\n\\n### Locations\\nFacility:\\n  National Center for Global Health and Medicine Hospital - Disease\\n  Control and Prevention Center\\nCity: Tokyo\\nZip: 162-8655\\nCountry: Japan\\n\\n#### Geo Point\\nLat: 35.6895\\nLon: 139.69171\\n\\n### Locations\\nFacility:\\n  Instituto Nacional de Ciencias Medicas y Nutrici\\u00f3n Salvador Zubir\\u00e1n -\\n  Departamento de Infectologia\\nCity: Mexico City\\nZip: 14080\\nCountry: Mexico\\n\\n#### Geo Point\\nLat: 19.42847\\nLon: -99.12766\\n\\n### Locations\\nFacility:\\n  Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cos\\u00edo\\n  Villegas\\nCity: Mexico City\\nZip: 14080\\nCountry: Mexico\\n\\n#### Geo Point\\nLat: 19.42847\\nLon: -99.12766\\n\\n### Locations\\nFacility: National Centre for Infectious Diseases\\nCity: Singapore\\nZip: 308442\\nCountry: Singapore\\n\\n#### Geo Point\\nLat: 1.28967\\nLon: 103.85007\\n\\n### Locations\\nFacility:\\n  Seoul National University Bundang Hospital - Division of Infectious\\n  Diseases\\nCity: Bundang-gu Seongnam-si\\nState: Gyeonggi-do\\nZip: 13620\\nCountry: South Korea\\n\\n### Locations\\nFacility: Seoul National University Hospital\\nCity: Seoul\\nState: Jongno-gu\\nZip: 03080\\nCountry: South Korea\\n\\n#### Geo Point\\nLat: 37.566\\nLon: 126.9784\\n\\n### Locations\\nFacility: Hospital Clinic Barcelona, Servicio de Salud Internacional\\nCity: Barcelona\\nState: Catalonia\\nZip: 08036\\nCountry: Spain\\n\\n#### Geo Point\\nLat: 41.38879\\nLon: 2.15899\\n\\n### Locations\\nFacility: Hospital Germans Trias i Pujol - Servei Malalties Infeccioses\\nCity: Barcelona\\nState: Catalonia\\nZip: 08916\\nCountry: Spain\\n\\n#### Geo Point\\nLat: 41.38879\\nLon: 2.15899\\n\\n### Locations\\nFacility: Royal Sussex County Hospital - Department of Intensive Care Medicine\\nCity: East Sussex\\nState: Brighton\\nZip: BN2 5BE\\nCountry: United Kingdom\\n\\n### Locations\\nFacility: Saint Thomas' Hospital - Directorate of Infection\\nCity: London\\nState: London, City of\\nZip: SE1 7EH\\nCountry: United Kingdom\\n\\n#### Geo Point\\nLat: 51.50853\\nLon: -0.12574\\n\\n### Locations\\nFacility: Royal Victoria Infirmary - Department of Infectious Diseases\\nCity: Level 6, Ward 19\\nState: Newcastle Upon Tyne\\nZip: NE1 4LP\\nCountry: United Kingdom\\n\\n### Locations\\nFacility: St. James's University Hospital - Infectious Diseases\\nCity: Leeds\\nState: West Yorkshire\\nZip: LS9 7TK\\nCountry: United Kingdom\\n\\n#### Geo Point\\nLat: 53.79648\\nLon: -1.54785\\n\\n### Locations\\nFacility: John Radcliffe Hospital\\nCity: Headington, Oxford\\nZip: OX3 9DU\\nCountry: United Kingdom\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Determine specific single nucleotide polymorphisms within the MAP2K1 gene responsible for the amino acid substitution p.K57N, exhibiting a PolyPhen-2 score classified as \"probably damaging,\" and presenting a REVEL metric exceeding the threshold of 0.75."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_variant_searcher",
                    "arguments": {
                        "query": {
                            "gene": "MAP2K1",
                            "hgvsp": "p.K57N",
                            "polyphen": "D",
                            "cadd": null,
                            "rsid": null,
                            "hgvsc": null,
                            "region": null,
                            "significance": null,
                            "max_frequency": null,
                            "min_frequency": null,
                            "sift": null,
                            "sources": [],
                            "size": 40,
                            "offset": 0
                        }
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_variant_searcher",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"# Record 1\\nId: chr15:g.66727455G>C\\nScore: 25.467617\\nChrom: 15\\n\\n## Cadd\\nLicense: http://bit.ly/2TIuab9\\nPhred: 26.5\\n\\n## Clinvar\\nLicense: http://bit.ly/2SQdcI0\\nVariant Id: 3774514\\nUrl: https://www.ncbi.nlm.nih.gov/clinvar/variation/3774514/\\n\\n### Rcv\\nClinical Significance: Pathogenic\\n\\n## Dbnsfp\\nLicense: http://bit.ly/2VLnQBz\\nGenename: MAP2K1\\nHgvsc: c.171G>C\\n\\n### Polyphen2\\n\\n#### Hdiv\\nPred: D\\nScore: 0.999\\n\\n### Sift\\nPred: D\\nScore: 0.001\\nHgvsp: p.Lys57Asn, p.K57N\\n\\n## Dbsnp\\nLicense: http://bit.ly/2AqoLOc\\nRsid: rs869025608\\nUrl: https://www.ncbi.nlm.nih.gov/snp/rs869025608\\n\\n## Vcf\\nAlt: C\\nPosition: 66727455\\nRef: G\\n\\n## Url\\nEnsembl: https://ensembl.org/Homo_sapiens/Variation/Explore?v=rs869025608\\nUcsc Genome Browser:\\n  https://genome.ucsc.edu/cgi-\\n  bin/hgTracks?db=hg19&position=chr15:66727455-66727456\\nHgnc: https://www.genenames.org/data/gene-symbol-report/#!/symbol/MAP2K1\\n\\n# Record 2\\nId: chr15:g.66727455G>T\\nScore: 25.205482\\nChrom: 15\\n\\n## Cadd\\nLicense: http://bit.ly/2TIuab9\\nPhred: 26.9\\n\\n## Civic\\nLicense: http://bit.ly/2FqS871\\nId: 1272\\nOpen Cravat Url:\\n  https://run.opencravat.org/webapps/variantreport/index.html?alt_base=T&c\\n  hrom=chr15&pos=66435117&ref_base=G\\nUrl: https://civicdb.org/variants/1272/summary\\n\\n## Clinvar\\nLicense: http://bit.ly/2SQdcI0\\nVariant Id: 223140\\nUrl: https://www.ncbi.nlm.nih.gov/clinvar/variation/223140/\\n\\n### Rcv\\nClinical Significance: not provided\\n\\n### Rcv\\nClinical Significance: Pathogenic\\n\\n## Dbnsfp\\nLicense: http://bit.ly/2VLnQBz\\nGenename: MAP2K1\\nHgvsc: c.171G>T\\n\\n### Polyphen2\\n\\n#### Hdiv\\nPred: D\\nScore: 0.999\\n\\n### Sift\\nPred: D\\nScore: 0.001\\nHgvsp: p.Lys57Asn, p.K57N\\n\\n## Dbsnp\\nLicense: http://bit.ly/2AqoLOc\\nRsid: rs869025608\\nUrl: https://www.ncbi.nlm.nih.gov/snp/rs869025608\\n\\n## Vcf\\nAlt: T\\nPosition: 66727455\\nRef: G\\n\\n## Url\\nEnsembl: https://ensembl.org/Homo_sapiens/Variation/Explore?v=rs869025608\\nUcsc Genome Browser:\\n  https://genome.ucsc.edu/cgi-\\n  bin/hgTracks?db=hg19&position=chr15:66727455-66727456\\nHgnc: https://www.genenames.org/data/gene-symbol-report/#!/symbol/MAP2K1\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Retrieve structured data, including primary goals, results, and any adverse reactions, for the medical research study with NCT ID NCT04280705."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_outcomes",
                    "arguments": {
                        "nct_id": "NCT04280705"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_outcomes",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Url: https://clinicaltrials.gov/study/NCT04280705\\n\\n# Protocol Section\\n\\n## Outcomes Module\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Race\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Ethnicity\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Sex\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Alanine Transaminase (ALT)\\nDescription:\\n  Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Aspartate Transaminase (AST)\\nDescription:\\n  Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Creatinine\\nDescription:\\n  Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Glucose\\nDescription:\\n  Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Hemoglobin\\nDescription:\\n  Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Platelets\\nDescription:\\n  Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Prothrombin Time (PT)\\nDescription:\\n  Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Total Bilirubin\\nDescription:\\n  Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in White Blood Cell Count (WBC)\\nDescription:\\n  Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Neutrophils\\nDescription:\\n  Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Lymphocytes\\nDescription:\\n  Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Monocytes\\nDescription:\\n  Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Basophils\\nDescription:\\n  Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Eosinophils\\nDescription:\\n  Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change in National Early Warning Score (NEWS) From Baseline\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome.\\nTime Frame: Days 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 1\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 3\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 3\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 5\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 5\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 8\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 8\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 11\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 11\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 15\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 15\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 22\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 22\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 29\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Reporting Grade 3 and 4 Clinical and/or\\n  Laboratory Adverse Events (AEs)\\nDescription:\\n  Grade 3 AEs are defined as events that interrupt usual activities of\\n  daily living, or significantly affects clinical status, or may require\\n  intensive therapeutic intervention. Severe events are usually\\n  incapacitating. Grade 4 AEs are defined as events that are potentially\\n  life threatening.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Percentage of Participants Reporting Serious Adverse Events (SAEs)\\nDescription:\\n  An SAE is defined as an AE or suspected adverse reaction is considered\\n  serious if, in the view of either the investigator or the sponsor, it\\n  results in death, a life-threatening AE, inpatient hospitalization or\\n  prolongation of existing hospitalization, a persistent or significant\\n  incapacity or substantial disruption of the ability to conduct normal\\n  life functions, or a congenital anomaly/birth defect.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Discontinued or Temporarily Suspended From\\n  Investigational Therapeutics\\nDescription:\\n  Participants may have been discontinued from investigational\\n  therapeutics due to discharge or death. The halting or slowing of the\\n  infusion for any reason was collected, as was missed doses in the series\\n  of 10 doses.\\nTime Frame: Day 1 through Day 10\\n\\n### Secondary Outcomes\\nMeasure: Duration of Hospitalization\\nDescription:\\n  Duration of hospitalization was determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Duration of New Non-invasive Ventilation or High Flow Oxygen Use\\nDescription:\\n  Duration of new non-invasive ventilation or high flow oxygen use was\\n  measured in days among participants who were not on non-invasive\\n  ventilation or high-flow oxygen use at baseline, determined two ways.\\n  The first includes imputations for participants who died. The second\\n  method is restricted to participants who did not die\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Duration of New Oxygen Use\\nDescription:\\n  Duration of new oxygen use was measured in days among participants who\\n  were not on oxygen at baseline, determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die\\n\\n  .\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO)\\n  Use\\nDescription:\\n  Duration of new ventilator or ECMO use was measured in days among\\n  participants who were not on a ventilator or ECMO at baseline,\\n  determined two ways. The first includes imputations for participants who\\n  died. The second method is restricted to participants who did not die\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Requiring New Non-invasive Ventilation or\\n  High-flow Oxygen Use\\nDescription:\\n  New non-invasive ventilation or high-flow oxygen use was determined as\\n  the percentage of subject not on non-invasive ventilation or high-flow\\n  oxygen at baseline.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Percentage of Participants Requiring New Oxygen Use\\nDescription:\\n  The percentage of participants requiring new oxygen use was determined\\n  as the percentage of participants not requiring oxygen at baseline\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Requiring New Ventilator or Extracorporeal\\n  Membrane Oxygenation (ECMO) Use\\nDescription:\\n  The percentage of participants requiring new ventilator or ECMO use was\\n  determined as the percentage not on a ventilator or ECMO at baseline\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Mean Change in the Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. A positive change indicates a worsening and a negative\\n  change is an improvement.\\nTime Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n### Secondary Outcomes\\nMeasure: 14-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 15.\\nTime Frame: Day 1 through Day 15\\n\\n### Secondary Outcomes\\nMeasure: 29-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 29.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Time to an Improvement by at Least One Category Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least one category was determined\\n  for each participant\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Time to an Improvement of at Least Two Categories Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 1) Death; 2)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 4) Hospitalized, requiring\\n  supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 6)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 7) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 8) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least two categories was\\n  determined for each participant\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours,\\n  Whichever Occurs First\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome. The time to discharge or a\\n  NEWS of less than or equal to 2 was determined for each participant.\\nTime Frame: Day 1 through Day 29\\n\\n# Results Section\\n\\n## Participant Flow Module\\nRecruitment Details:\\n  Participants were recruited at the participating sites from those\\n  admitted with symptoms of COVID-19 confirmed by PCR. Enrollment occurred\\n  between 21FEB2020 and 20APR2020.\\n\\n### Groups\\nId: FG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n  Placebo: The supplied placebo lyophilized formulation is identical in\\n  physical appearance to the active lyophilized formulation and contains\\n  the same inactive ingredients. Alternatively, a placebo of normal saline\\n  of equal volume may be given if there are limitations on matching\\n  placebo supplies.\\n\\n### Groups\\nId: FG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n  Remdesivir: Drug Remdesivir is a single diastereomer monophosphoramidate\\n  prodrug designed for the intracellular delivery of a modified adenine\\n  nucleoside analog GS-441524. In addition to the active ingredient, the\\n  lyophilized formulation of Remdesivir contains the following inactive\\n  ingredients: water for injection, sulfobutylether beta-cyclodextrin\\n  sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.\\n\\n### Periods\\nTitle: Overall Study\\n\\n#### Milestones\\nType: STARTED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 521\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 541\\n\\n#### Milestones\\nType: Received Treatment\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 517\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 531\\n\\n#### Milestones\\nType: COMPLETED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 508\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 517\\n\\n#### Milestones\\nType: NOT COMPLETED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 13\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 24\\n\\n#### Drop Withdraws\\nType: Enrolled but not treated\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 4\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 10\\n\\n#### Drop Withdraws\\nType: Physician Decision\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 1\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 0\\n\\n#### Drop Withdraws\\nType: Withdrawal by Subject\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 7\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 9\\n\\n#### Drop Withdraws\\nType: Adverse Event\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 0\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 4\\n\\n#### Drop Withdraws\\nType: Transferred to another hospital\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 1\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 1\\n\\n## Baseline Characteristics Module\\n\\n### Groups\\nId: BG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n### Groups\\nId: BG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n### Groups\\nId: BG002\\nTitle: Total\\nDescription: Total of all reporting groups\\n\\n### Denoms\\nUnits: Participants\\n\\n#### Counts\\nGroup Id: BG000\\nValue: 521\\n\\n#### Counts\\nGroup Id: BG001\\nValue: 541\\n\\n#### Counts\\nGroup Id: BG002\\nValue: 1062\\n\\n### Measures\\nTitle: Age, Categorical\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: <=18 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 0\\n\\n##### Categories\\nTitle: Between 18 and 65 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 324\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 354\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 678\\n\\n##### Categories\\nTitle: >=65 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 197\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 187\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 384\\n\\n### Measures\\nTitle: Age, Continuous\\nParam Type: MEAN\\nDispersion Type: STANDARD_DEVIATION\\nUnit Of Measure: years\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 59.2\\nSpread: 15.4\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 58.6\\nSpread: 14.6\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 58.9\\nSpread: 15.0\\n\\n### Measures\\nTitle: Sex: Female, Male\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: Female\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 189\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 189\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 378\\n\\n##### Categories\\nTitle: Male\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 332\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 352\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 684\\n\\n### Measures\\nTitle: Ethnicity (NIH/OMB)\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: Hispanic or Latino\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 116\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 134\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 250\\n\\n##### Categories\\nTitle: Not Hispanic or Latino\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 373\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 382\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 755\\n\\n##### Categories\\nTitle: Unknown or Not Reported\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 32\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 25\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 57\\n\\n### Measures\\nTitle: Race (NIH/OMB)\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: American Indian or Alaska Native\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 7\\n\\n##### Categories\\nTitle: Asian\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 56\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 79\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 135\\n\\n##### Categories\\nTitle: Native Hawaiian or Other Pacific Islander\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 4\\n\\n##### Categories\\nTitle: Black or African American\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 117\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 109\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 226\\n\\n##### Categories\\nTitle: White\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 287\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 279\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 566\\n\\n##### Categories\\nTitle: More than one race\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 3\\n\\n##### Categories\\nTitle: Unknown or Not Reported\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 55\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 66\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 121\\n\\n### Measures\\nTitle: Region of Enrollment\\nParam Type: NUMBER\\nUnit Of Measure: participants\\n\\n#### Classes\\nTitle: Greece\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 19\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 14\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 33\\n\\n#### Classes\\nTitle: South Korea\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 12\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 9\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 21\\n\\n#### Classes\\nTitle: Singapore\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 9\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 16\\n\\n#### Classes\\nTitle: United States\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 410\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 427\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 837\\n\\n#### Classes\\nTitle: Japan\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 8\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 15\\n\\n#### Classes\\nTitle: Denmark\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 21\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 22\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 43\\n\\n#### Classes\\nTitle: Mexico\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 6\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 10\\n\\n#### Classes\\nTitle: United Kingdom\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 21\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 25\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 46\\n\\n#### Classes\\nTitle: Germany\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 6\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 13\\n\\n#### Classes\\nTitle: Spain\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 12\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 16\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 28\\n\\n### Measures\\nTitle: Disease severity\\nDescription:\\n  Mild-moderate disease: SpO2 \\\\> 94% and respiratory rate \\\\< 24\\n  breaths/min without supplemental oxygen.\\n\\n  Severe disease: requiring mechanical ventilation, requiring oxygen, a\\n  SpO2 = 94% on room air, or tachypnea (respiratory rate = 24\\n  breaths/min).\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\nTitle: Mild-to-moderate disease severity\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 50\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 55\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 105\\n\\n#### Classes\\nTitle: Severe disease severity\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 471\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 486\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 957\\n\\n## Outcome Measures Module\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 9\\nUpper Limit: 11\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.12\\nCi Upper Limit: 1.49\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Alanine Transaminase (ALT)\\nDescription:\\n  Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: Units/Liter (U/L)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 465\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 465\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14.3\\nSpread: 88\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2.9\\nSpread: 31.5\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 403\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 398\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23.1\\nSpread: 70.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.8\\nSpread: 55.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 327\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 296\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24.2\\nSpread: 79.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 8.9\\nSpread: 54.2\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 227\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 27.7\\nSpread: 89.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.4\\nSpread: 48.4\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 242\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 257\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 28.1\\nSpread: 110.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.7\\nSpread: 47.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 180\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -3.9\\nSpread: 62.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -6.8\\nSpread: 43.7\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Aspartate Transaminase (AST)\\nDescription:\\n  Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: Units/Liter (U/L)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 438\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 445\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 438\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 445\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13.7\\nSpread: 90.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.0\\nSpread: 29.1\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 384\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 380\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.8\\nSpread: 66.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6.0\\nSpread: 58.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 315\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 285\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13.1\\nSpread: 114.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.1\\nSpread: 55.9\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 247\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 219\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11.5\\nSpread: 78.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 51.7\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 236\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 248\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.2\\nSpread: 73.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.3\\nSpread: 60.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 170\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 208\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -18.4\\nSpread: 47.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -14.0\\nSpread: 52.2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Creatinine\\nDescription:\\n  Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: milligrams/deciliter (mg/dL)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 482\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 482\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.037\\nSpread: 0.517\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.038\\nSpread: 0.569\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 418\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 411\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.695\\nSpread: 17.552\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.075\\nSpread: 0.762\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 335\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 309\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.882\\nSpread: 19.637\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.158\\nSpread: 0.951\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 234\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.173\\nSpread: 15.440\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.236\\nSpread: 1.057\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 249\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 262\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.239\\nSpread: 22.755\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.319\\nSpread: 2.147\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 229\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.863\\nSpread: 26.093\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.075\\nSpread: 0.644\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Glucose\\nDescription:\\n  Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: mg/dL\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.2\\nSpread: 53.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.0\\nSpread: 49.4\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 407\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 395\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6.3\\nSpread: 60.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2.1\\nSpread: 63.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 323\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 301\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.2\\nSpread: 73.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.2\\nSpread: 68.0\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 260\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 228\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.0\\nSpread: 70.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.1\\nSpread: 77.4\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 250\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -2.8\\nSpread: 64.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.9\\nSpread: 75.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 180\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 219\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -13.5\\nSpread: 96.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -11.7\\nSpread: 75.4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Hemoglobin\\nDescription:\\n  Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: grams/deciliter (g/dL)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.52\\nSpread: 1.10\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.69\\nSpread: 5.36\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 420\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 406\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.83\\nSpread: 1.22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.99\\nSpread: 5.83\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 334\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 310\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.22\\nSpread: 1.42\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.49\\nSpread: 6.54\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 230\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.66\\nSpread: 1.67\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.29\\nSpread: 1.93\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 253\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 260\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.51\\nSpread: 2.02\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.02\\nSpread: 3.04\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 227\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.02\\nSpread: 2.38\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.21\\nSpread: 7.91\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Platelets\\nDescription:\\n  Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 471\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 474\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 471\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 474\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 39.3\\nSpread: 60.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 46.0\\nSpread: 62.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 419\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 403\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 76.5\\nSpread: 100.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 90.1\\nSpread: 99.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 332\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 308\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 111.8\\nSpread: 137.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 130.8\\nSpread: 128.1\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 229\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 109.3\\nSpread: 149.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 101.0\\nSpread: 145.0\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 252\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 258\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 96.5\\nSpread: 154.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 71.1\\nSpread: 133.3\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 224\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32.7\\nSpread: 124.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 39.6\\nSpread: 107.4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Prothrombin Time (PT)\\nDescription:\\n  Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: seconds\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 339\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 339\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.18\\nSpread: 4.28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.44\\nSpread: 5.22\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 296\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 306\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.30\\nSpread: 4.72\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.15\\nSpread: 5.72\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 246\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 234\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.01\\nSpread: 2.59\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.43\\nSpread: 3.89\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 199\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 182\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.86\\nSpread: 7.85\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.88\\nSpread: 5.68\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 193\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.34\\nSpread: 4.33\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.03\\nSpread: 4.25\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 134\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 163\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.28\\nSpread: 3.20\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.63\\nSpread: 3.37\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Total Bilirubin\\nDescription:\\n  Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: mg/dL\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 451\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 456\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 451\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 456\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.08\\nSpread: 1.25\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.04\\nSpread: 0.75\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 394\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.58\\nSpread: 4.13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.03\\nSpread: 1.03\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 315\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 288\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.22\\nSpread: 2.56\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.01\\nSpread: 1.38\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 247\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.23\\nSpread: 2.79\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.07\\nSpread: 1.48\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 237\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 254\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.00\\nSpread: 1.80\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.09\\nSpread: 1.54\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 178\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 216\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.17\\nSpread: 1.65\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.12\\nSpread: 1.77\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in White Blood Cell Count (WBC)\\nDescription:\\n  Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 474\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 474\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 18.691\\nSpread: 424.837\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -18.970\\nSpread: 301.944\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 419\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 405\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9.886\\nSpread: 566.175\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -28.209\\nSpread: 412.615\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 333\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 310\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 27.223\\nSpread: 479.095\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -45.997\\nSpread: 602.461\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 268\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 230\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.967\\nSpread: 16.042\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -34.702\\nSpread: 574.065\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 252\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 260\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 56.311\\nSpread: 620.551\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -70.884\\nSpread: 600.011\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 226\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.898\\nSpread: 17.801\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.251\\nSpread: 3.987\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Neutrophils\\nDescription:\\n  Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9.429\\nSpread: 260.345\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -8.093\\nSpread: 135.068\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.177\\nSpread: 362.782\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -15.067\\nSpread: 216.532\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 317\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 298\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17.916\\nSpread: 305.321\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -28.179\\nSpread: 365.099\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3.010\\nSpread: 27.502\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -21.773\\nSpread: 354.025\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36.024\\nSpread: 389.093\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -39.988\\nSpread: 333.088\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.269\\nSpread: 7.160\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.840\\nSpread: 3.666\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Lymphocytes\\nDescription:\\n  Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5.883\\nSpread: 118.740\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -7.847\\nSpread: 131.548\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.064\\nSpread: 141.580\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -11.723\\nSpread: 167.428\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 317\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 299\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8.006\\nSpread: 137.149\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -15.455\\nSpread: 194.111\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.393\\nSpread: 1.371\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -12.016\\nSpread: 183.060\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14.793\\nSpread: 159.583\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -23.836\\nSpread: 218.653\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.668\\nSpread: 1.406\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.743\\nSpread: 0.664\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Monocytes\\nDescription:\\n  Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 458\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 458\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.448\\nSpread: 41.304\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.940\\nSpread: 46.752\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 388\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.498\\nSpread: 57.686\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.628\\nSpread: 39.329\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 316\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 299\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.324\\nSpread: 36.626\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.645\\nSpread: 48.636\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.383\\nSpread: 0.744\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.539\\nSpread: 43.454\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6.475\\nSpread: 69.019\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -8.738\\nSpread: 74.365\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.125\\nSpread: 0.485\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.117\\nSpread: 0.340\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Basophils\\nDescription:\\n  Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 455\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 452\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 455\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 452\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.020\\nSpread: 0.257\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.043\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 394\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 380\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.038\\nSpread: 0.501\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.370\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 309\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 293\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.196\\nSpread: 3.132\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.368\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 253\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.024\\nSpread: 0.042\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.028\\nSpread: 0.053\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 235\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 248\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.158\\nSpread: 1.913\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.058\\nSpread: 1.028\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 216\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.040\\nSpread: 0.073\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.029\\nSpread: 0.054\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Eosinophils\\nDescription:\\n  Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 455\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 455\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.634\\nSpread: 10.614\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.016\\nSpread: 0.727\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 397\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 387\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.666\\nSpread: 11.977\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.066\\nSpread: 2.807\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 311\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 293\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.596\\nSpread: 8.875\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.221\\nSpread: 4.108\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 254\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.093\\nSpread: 0.190\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.088\\nSpread: 2.973\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 237\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 251\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.992\\nSpread: 20.365\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.420\\nSpread: 5.378\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 217\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.241\\nSpread: 0.324\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.211\\nSpread: 0.267\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change in National Early Warning Score (NEWS) From Baseline\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized with data at baseline and at each timepoint.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: units on a scale\\nTime Frame: Days 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 499\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 502\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 499\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 502\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.1\\nSpread: 2.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 2.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 447\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 438\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.3\\nSpread: 3.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.4\\nSpread: 2.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 348\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 321\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.3\\nSpread: 3.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.5\\nSpread: 3.2\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 291\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 254\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.3\\nSpread: 4.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.5\\nSpread: 3.5\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 290\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 301\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 4.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.7\\nSpread: 3.6\\n\\n#### Classes\\nTitle: Day 22\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 151\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 120\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 4.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.7\\nSpread: 4.1\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 221\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 251\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -3.2\\nSpread: 4.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.3\\nSpread: 3.2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 1\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 30\\nLower Limit: 26\\nUpper Limit: 34\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 21\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 18\\nLower Limit: 15\\nUpper Limit: 21\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 39\\nLower Limit: 35\\nUpper Limit: 43\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 43\\nLower Limit: 39\\nUpper Limit: 47\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 10\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 14\\nLower Limit: 11\\nUpper Limit: 17\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 3\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 3\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36\\nLower Limit: 32\\nUpper Limit: 40\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 25\\nUpper Limit: 32\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 16\\nLower Limit: 13\\nUpper Limit: 19\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 37\\nLower Limit: 33\\nUpper Limit: 41\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 5\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 5\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 37\\nLower Limit: 33\\nUpper Limit: 41\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 24\\nUpper Limit: 32\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 26\\nLower Limit: 23\\nUpper Limit: 30\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 24\\nUpper Limit: 31\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 8\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 15\\nLower Limit: 12\\nUpper Limit: 18\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 8\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 8\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 33\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 21\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 19\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 10\\nLower Limit: 8\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 30\\nLower Limit: 27\\nUpper Limit: 34\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 11\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 11\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8\\nLower Limit: 6\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 28\\nLower Limit: 25\\nUpper Limit: 32\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 10\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 33\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 44\\nLower Limit: 40\\nUpper Limit: 48\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 15\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 15\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 19\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 8\\nUpper Limit: 13\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 22\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 29\\nLower Limit: 25\\nUpper Limit: 33\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\nLower Limit: 3\\nUpper Limit: 7\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 22\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 22\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8\\nLower Limit: 6\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5\\nLower Limit: 4\\nUpper Limit: 8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 18\\nLower Limit: 15\\nUpper Limit: 22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 23\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 39\\nLower Limit: 35\\nUpper Limit: 43\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Completed study without reporting score\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 29\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 8\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 23\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 20\\nLower Limit: 17\\nUpper Limit: 23\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36\\nLower Limit: 32\\nUpper Limit: 41\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 46\\nLower Limit: 42\\nUpper Limit: 50\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5\\nLower Limit: 3\\nUpper Limit: 7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Completed study without reporting score\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Reporting Grade 3 and 4 Clinical and/or\\n  Laboratory Adverse Events (AEs)\\nDescription:\\n  Grade 3 AEs are defined as events that interrupt usual activities of\\n  daily living, or significantly affects clinical status, or may require\\n  intensive therapeutic intervention. Severe events are usually\\n  incapacitating. Grade 4 AEs are defined as events that are potentially\\n  life threatening.\\nPopulation Description:\\n  The safety population includes all participants with available data post\\n  baseline, analyzed as treated.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 516\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 532\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 57\\nLower Limit: 52.8\\nUpper Limit: 61.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 51\\nLower Limit: 47.0\\nUpper Limit: 55.6\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.058\\nStatistical Method: Barnard's Exact Test\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Percentage of Participants Reporting Serious Adverse Events (SAEs)\\nDescription:\\n  An SAE is defined as an AE or suspected adverse reaction is considered\\n  serious if, in the view of either the investigator or the sponsor, it\\n  results in death, a life-threatening AE, inpatient hospitalization or\\n  prolongation of existing hospitalization, a persistent or significant\\n  incapacity or substantial disruption of the ability to conduct normal\\n  life functions, or a congenital anomaly/birth defect.\\nPopulation Description:\\n  The safety population includes all participants with available data post\\n  baseline, analyzed as treated.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 516\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 532\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 27.7\\nUpper Limit: 35.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 20.9\\nUpper Limit: 28.3\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.010\\nStatistical Method: Barnard's Exact Test\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Discontinued or Temporarily Suspended From\\n  Investigational Therapeutics\\nDescription:\\n  Participants may have been discontinued from investigational\\n  therapeutics due to discharge or death. The halting or slowing of the\\n  infusion for any reason was collected, as was missed doses in the series\\n  of 10 doses.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 10\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Discontinued due to discharge\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 30\\nLower Limit: 26\\nUpper Limit: 34\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 41\\nLower Limit: 37\\nUpper Limit: 45\\n\\n#### Classes\\nTitle: Discontinued due to death\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Any infusions halted or slowed\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Missed any maintenance dose\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 21\\nLower Limit: 18\\nUpper Limit: 25\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 16\\nLower Limit: 13\\nUpper Limit: 19\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of Hospitalization\\nDescription:\\n  Duration of hospitalization was determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Including imputation for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 8\\nUpper Limit: 28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 6\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Restricted to participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 443\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 480\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 7\\nUpper Limit: 27\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 5\\nUpper Limit: 21\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of New Non-invasive Ventilation or High Flow Oxygen Use\\nDescription:\\n  Duration of new non-invasive ventilation or high flow oxygen use was\\n  measured in days among participants who were not on non-invasive\\n  ventilation or high-flow oxygen use at baseline, determined two ways.\\n  The first includes imputations for participants who died. The second\\n  method is restricted to participants who did not die\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on non-invasive ventilation or high-flow oxygen at baseline but\\n  who subsequently required non-invasive or high-flow oxygen.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 64\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 64\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 23.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 10.5\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 50\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 43\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 6\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of New Oxygen Use\\nDescription:\\n  Duration of new oxygen use was measured in days among participants who\\n  were not on oxygen at baseline, determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die\\n\\n  .\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on oxygen at baseline but who subsequently required oxygen.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 28\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 27\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 28\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 27\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5.5\\nLower Limit: 1\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 25\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 24\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.5\\nLower Limit: 2\\nUpper Limit: 5.5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO)\\n  Use\\nDescription:\\n  Duration of new ventilator or ECMO use was measured in days among\\n  participants who were not on a ventilator or ECMO at baseline,\\n  determined two ways. The first includes imputations for participants who\\n  died. The second method is restricted to participants who did not die\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not on\\n  a ventilator or ECMO at baseline but who subsequently required a\\n  ventilator or ECMO.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 82\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 82\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23\\nLower Limit: 12\\nUpper Limit: 28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 21.5\\nLower Limit: 9\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 57\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 39\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 16\\nLower Limit: 9\\nUpper Limit: 24\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 14\\nLower Limit: 5\\nUpper Limit: 26\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Requiring New Non-invasive Ventilation or\\n  High-flow Oxygen Use\\nDescription:\\n  New non-invasive ventilation or high-flow oxygen use was determined as\\n  the percentage of subject not on non-invasive ventilation or high-flow\\n  oxygen at baseline.\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on non-invasive or high-flow oxygen at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 266\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 307\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24\\nLower Limit: 19\\nUpper Limit: 30\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 17\\nLower Limit: 13\\nUpper Limit: 22\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Percentage of Participants Requiring New Oxygen Use\\nDescription:\\n  The percentage of participants requiring new oxygen use was determined\\n  as the percentage of participants not requiring oxygen at baseline\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not\\n  requiring oxygen at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 63\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 75\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 44\\nLower Limit: 33\\nUpper Limit: 57\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 36\\nLower Limit: 26\\nUpper Limit: 47\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Requiring New Ventilator or Extracorporeal\\n  Membrane Oxygenation (ECMO) Use\\nDescription:\\n  The percentage of participants requiring new ventilator or ECMO use was\\n  determined as the percentage not on a ventilator or ECMO at baseline\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not on\\n  a ventilator or ECMO at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 364\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 402\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23\\nLower Limit: 19\\nUpper Limit: 27\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 17\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Mean Change in the Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. A positive change indicates a worsening and a negative\\n  change is an improvement.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized reporting a clinical score. Missing values were imputed using\\n  Last Observation Carried Forward. Clinical scores of 8 were carried\\n  forward from the date of death for participants who died.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: units on a scale\\nTime Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 518\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 533\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nSpread: 0.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.1\\nSpread: 0.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.1\\nSpread: 0.9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.0\\nSpread: 0.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.0\\nSpread: 0.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.2\\nSpread: 1.0\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.1\\nSpread: 1.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 1.1\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 2.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.9\\nSpread: 2.1\\n\\n#### Classes\\nTitle: Day 22\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.9\\nSpread: 2.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.4\\nSpread: 2.2\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -2.3\\nSpread: 2.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.7\\nSpread: 2.3\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: 14-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 15.\\nPopulation Description: The ITT population consists of all participants as randomized.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Proportion of participants\\nTime Frame: Day 1 through Day 15\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.12\\nLower Limit: 0.09\\nUpper Limit: 0.15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.07\\nLower Limit: 0.05\\nUpper Limit: 0.09\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: 29-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 29.\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Proportion of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.15\\nLower Limit: 0.12\\nUpper Limit: 0.19\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.11\\nLower Limit: 0.09\\nUpper Limit: 0.15\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Time to an Improvement by at Least One Category Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least one category was determined\\n  for each participant\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 8\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 6\\nUpper Limit: 8\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.002\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.23\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.08\\nCi Upper Limit: 1.41\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Time to an Improvement of at Least Two Categories Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 1) Death; 2)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 4) Hospitalized, requiring\\n  supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 6)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 7) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 8) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least two categories was\\n  determined for each participant\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 13\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 10\\nUpper Limit: 13\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.12\\nCi Upper Limit: 1.48\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours,\\n  Whichever Occurs First\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome. The time to discharge or a\\n  NEWS of less than or equal to 2 was determined for each participant.\\nPopulation Description: The ITT population includes all participants as randomized.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 10\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 8\\nLower Limit: 7\\nUpper Limit: 9\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.27\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 1.46\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Race\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Asian\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 56\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 79\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.0\\nLower Limit: 9.0\\nUpper Limit: 15.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11.0\\nLower Limit: 9.0\\nUpper Limit: 15.0\\n\\n#### Classes\\nTitle: Black or African American\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 117\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 109\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 10.0\\nUpper Limit: 21.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 7.0\\nUpper Limit: 16.0\\n\\n#### Classes\\nTitle: White\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 287\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 279\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Other\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 61\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 74\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24.0\\nLower Limit: 15.0\\nUpper Limit: NA\\nComment:\\n  A large number of participants at the median estimate resulted in little\\n  variability at the 50th percentile and the methodology described by\\n  Klein and Moeschberger (1997) was unable to compute an upper confidence\\n  limit.\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 6.0\\nUpper Limit: 14.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Asian participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.07\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.73\\nCi Upper Limit: 1.58\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Black or African American participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.25\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.91\\nCi Upper Limit: 1.72\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for White participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.06\\nCi Upper Limit: 1.57\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Race of Other participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.68\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 2.58\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Ethnicity\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized and for whom Ethnicity was reported\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 489\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 516\\n\\n#### Classes\\nTitle: Not Hispanic or Latino\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 373\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 382\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 13.0\\nUpper Limit: 18.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Hispanic or Latino\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 116\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 134\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.5\\nLower Limit: 9.0\\nUpper Limit: 22.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 7.0\\nUpper Limit: 14.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Not Hispanic or Latino participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.31\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 1.55\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Hispanic or Latino participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.28\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.94\\nCi Upper Limit: 1.73\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Sex\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Male\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 332\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Female\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 189\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 8.0\\nUpper Limit: 13.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Male participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.30\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.09\\nCi Upper Limit: 1.56\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Female participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.31\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.03\\nCi Upper Limit: 1.66\\nGroup Ids: OG000, OG001\\n\\n## Adverse Events Module\\nFrequency Threshold: 5\\nTime Frame:\\n  Grade 3 and 4 serious and non-serious adverse events were collected for\\n  29 days after the first dose. Laboratory values were systematically\\n  assessed at Days 1, 3, 5, 8, and 11 while participants were inpatient,\\n  and at Days 15 and 29.\\nDescription:\\n  Given the nature of severity of the underlying illness, participants\\n  were expected to have many symptoms and abnormalities in vital signs and\\n  laboratory values. All Grade 3 and 4 AEs were captured as AEs in this\\n  trial. In addition, any Grade 2 or higher, suspected drug-related\\n  hypersensitivity reaction was to be reported as an AE in this trial. All\\n  cause mortality was calculated for the ITT population, while SAEs and\\n  AEs reflect the as treated population.\\n\\n### Event Groups\\nId: EG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\nDeaths Num Affected: 77\\nDeaths Num At Risk: 521\\nSerious Num Affected: 163\\nSerious Num At Risk: 516\\nOther Num Affected: 295\\nOther Num At Risk: 516\\n\\n### Event Groups\\nId: EG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\nDeaths Num Affected: 59\\nDeaths Num At Risk: 541\\nSerious Num Affected: 131\\nSerious Num At Risk: 532\\nOther Num Affected: 276\\nOther Num At Risk: 532\\n\\n### Serious Events\\nTerm: Coagulopathy\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Febrile neutropenia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Anaemia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac arrest\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 10\\nNum Affected: 10\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Atrial fibrillation\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardio-respiratory arrest\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myocardial infarction\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Supraventricular tachycardia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ventricular tachycardia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute myocardial infarction\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac failure\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiogenic shock\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute coronary syndrome\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Arrhythmia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Palpitations\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulseless electrical activity\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ventricular fibrillation\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac tamponade\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Intestinal ischaemia\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Diarrhoea\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Duodenal perforation\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Gastrointestinal haemorrhage\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Small intestinal perforation\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haematemesis\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Peptic ulcer haemorrhage\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Small intestinal obstruction\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Multiple organ dysfunction syndrome\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pyrexia\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Chest pain\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Death\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hepatitis\\nOrgan System: Hepatobiliary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ischaemic hepatitis\\nOrgan System: Hepatobiliary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Drug hypersensitivity\\nOrgan System: Immune system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Septic shock\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 15\\nNum Affected: 15\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 8\\nNum Affected: 8\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: COVID-19\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: COVID-19 pneumonia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Sepsis\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumonia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Catheter bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Gangrene\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Infectious pleural effusion\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Staphylococcal bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Urinary tract infection\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Bacterial sepsis\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Endocarditis bacterial\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hip fracture\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Infusion related reaction\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Procedural pneumothorax\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Glomerular filtration rate decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemoglobin decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Oxygen saturation decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Blood creatinine increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Lymphocyte count decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acidosis\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Dehydration\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypernatraemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hyponatraemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Decreased appetite\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pain in extremity\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myalgia\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myopathy\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebrovascular accident\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Seizure\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebellar infarction\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebral haemorrhage\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Encephalopathy\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Subarachnoid haemorrhage\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Depressed level of consciousness\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemorrhagic transformation stroke\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hemiparesis\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Intensive care unit acquired weakness\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ischaemic stroke\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Mental status changes\\nOrgan System: Psychiatric disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Psychotic disorder\\nOrgan System: Psychiatric disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute kidney injury\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 12\\nNum Affected: 12\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Renal failure\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Renal impairment\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 59\\nNum Affected: 58\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 36\\nNum Affected: 35\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 14\\nNum Affected: 14\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 8\\nNum Affected: 8\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory distress\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 11\\nNum Affected: 11\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 6\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute respiratory distress syndrome\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumothorax\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulmonary embolism\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypoxia\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumonia aspiration\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Dyspnoea\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory disorder\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Chronic respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemoptysis\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulmonary haemorrhage\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Subcutaneous emphysema\\nOrgan System: Skin and subcutaneous tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Endotracheal intubation\\nOrgan System: Surgical and medical procedures\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 9\\nNum Affected: 9\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 6\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Mechanical ventilation\\nOrgan System: Surgical and medical procedures\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypotension\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Shock\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Deep vein thrombosis\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Embolism venous\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Peripheral artery occlusion\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Shock haemorrhagic\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Glomerular filtration rate decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 81\\nNum Affected: 74\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 59\\nNum Affected: 55\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Haemoglobin decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 69\\nNum Affected: 62\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 51\\nNum Affected: 48\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Lymphocyte count decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 63\\nNum Affected: 54\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 56\\nNum Affected: 44\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Anaemia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 58\\nNum Affected: 52\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 52\\nNum Affected: 42\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Pyrexia\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 37\\nNum Affected: 32\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 52\\nNum Affected: 38\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Hyperglycaemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 43\\nNum Affected: 34\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 36\\nNum Affected: 34\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Blood creatinine increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 41\\nNum Affected: 36\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 33\\nNum Affected: 31\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Blood glucose increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 31\\nNum Affected: 27\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 45\\nNum Affected: 39\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Aspartate aminotransferase increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 35\\nNum Affected: 33\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 19\\nNum Affected: 18\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Lymphopenia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 34\\nNum Affected: 30\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 15\\nNum Affected: 13\\nNum At Risk: 532\\n\\n## More Info Module\\n\\n### Certain Agreement\\nPi Sponsor Employee: False\\nRestriction Type: LTE60\\nRestrictive Agreement: True\\n\\n### Point Of Contact\\nTitle: John Beigel, MD\\nOrganization: Organization:NIAID\\nEmail: jbeigel@niaid.nih.gov\\nPhone: 3014519881\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": ": Explore the detailed content of a peer-reviewed article with PubMed ID 34397683 to access its key information."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_article_details",
                    "arguments": {
                        "pmid": "34397683"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_article_details",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"# Record 1\\nPmid: 34397683\\nPmcid: PMC8322536\\nDate: 2021-07-30T00:00:00Z\\nJournal: Medicine (Baltimore)\\nTitle:\\n  Dramatic response to osimertinib combined with crizotinib in EGFR T790 M\\n  mutation only in blood and Met amplification only in tumor tissue\\n  expressive non-small cell lung cancer\\nAbstract:\\n  Abstract\\n\\n  Rationale:\\n\\n  Besides the T790 M mutation, it may coexist with bypass pathway\\n  activation in real clinical cases for patients with EGFR mutations who\\n  resisted to the first- and second-generation tyrosine kinase inhibitors\\n  (TKIs) in non-small cell lung cancer (NSCLC). There are limited clinical\\n  trial data describing the efficacy of osimertinib combined with MET\\n  inhibition in EGFR T790M-mutant NSCLC patients with Met amplification.\\n\\n  Patient concerns:\\n\\n  A non-smoking 53-year-old male patient with lung adenocarcinoma\\n  underwent gefitinib, afatinib, and osimertinib combined with crizotinib\\n  treatment and developed different EGFR resistance mutations.\\n\\n  Diagnoses:\\n\\n  The patient was diagnosed with lung adenocarcinoma (stage cT4N2M0,\\n  IIIB). After resistance to the therapy targeting EGFR exon 21 L858R\\n  point mutation, T790 M mutation was detected in liquid biopsy and Met\\n  amplification was detected via tissue biopsy by next-generation\\n  sequencing (NGS).\\n\\n  Interventions:\\n\\n  The patient received systemic treatments, including chemotherapy,\\n  gefitinib, afatinib, and osimertinib combined with crizotinib.\\n\\n  Outcomes:\\n\\n  The patient died of multisystem organ failure and had an overall\\n  survival of 24 months.\\n\\n  Lessons:\\n\\n  Although osimertinib combined with crizotinib therapy showed dramatic\\n  tumor shrinkage in both the primary tumor and bone metastasis to an EGFR\\n  T790M-mutant NSCLC patient with MET amplification, the progression-free\\n  survival (PFS) was only two months.\\nFull Text:\\n  Introduction\\n\\n  Advanced non-small cell lung cancer with EGFR gene mutations is closely\\n  related to the clinical efficacy of epidermal growth factor receptor\\n  tyrosine kinase inhibitors (EGFR TKIs), but the outcomes are limited by\\n  acquired resistance. The EGFR exon 20 T790 M mutation accounts for 50%\\n  to 60% of the resistance to first- and second-generation TKIs, followed\\n  by bypass pathway activation (e.g., MET or ERRB2 amplification,\\n  mutations in BRAF and PIK3CA), and lineage shifts (e.g., small-cell\\n  transformation, epithelial-to-mesenchymal transition). 'Third-\\n  generation' EGFR TKIs, such as osimertinib, are highly effective in\\n  EGFR-mutant NSCLC patients harboring the EGFR T790 M mutation.\\n  Nevertheless, resistance to third-generation EGFR TKIs can still develop\\n  through further mutations in EGFR and the activation of alternative\\n  pathways. With the development of high-throughput NGS-based liquid\\n  biopsy technology, additional mechanisms, such as EGFR exon 20 C797S,\\n  EGFR L718Q, and EGFR exon 18 G724S mutations were observed. NGS-based\\n  liquid biopsy testing overcomes spatial heterogeneity and can\\n  dynamically monitor tumor genomic evolution and guide decision-making\\n  for treatment strategies in a minimally invasive manner.\\n\\n  Here, we present the case of an EGFR-mutant advanced NSCLC patient who\\n  acquired resistance to first- and second-generation TKIs in a short\\n  time. There were different results of the NGS tests between blood\\n  samples and tumor tissue samples at the same time, that EGFR T790 M\\n  mutation was only found in blood and Met amplification was only found in\\n  tumor tissue. Although there are limited clinical trial data describing\\n  the efficacy of osimertinib combined with MET inhibition in patients\\n  with EGFR T790M-mutant NSCLC, outcomes in a real-world setting are\\n  useful to inform clinical practice. Despite disease progression after\\n  only 3 months, the patient experienced substantial symptomatic\\n  improvement and dramatic tumor regression following osimertinib combined\\n  with crizotinib therapy.\\n\\n  The profile of treatments, images and NGS results of the patient. (A)\\n  Initial Chemotherapy of cisplatin/pemetrexed had a good response to\\n  tumor but caused intolerable adverse reactions. The first NGS suggested\\n  EGFR 21 L858R mutation. (B) The PFS of first-generation EGFR-TKI\\n  gefitinib was only 5 months. (C) The second NGS suggested there was no\\n  T790 M mutation. And the second-generation EGFR-TKI afatinib was\\n  ineffective. (D) The PFS of secondary chemotherapy and plus Bevacizumab\\n  was only 4 months. (E) The third NGS suggested EGFR T790 M mutation was\\n  only in blood and Met amplification was only in tumor tissue.\\n  Osimertinib combined with crizotinib showed dramatic tumor shrinkage.\\n  (F) The PFS of osimertinib combined with crizotinib was only 3 months.\\n  (G) Palliative care for 4 months. p(H) Brain metastasis and the fourth\\n  NGS of EGFR L858R, T790 M/C797S (cis), and MET L1195 V mutations.\\n\\n  Discussion\\n\\n  The most common acquired resistance mechanism against the first- and\\n  second-generation TKIs in EGFR-mutant NSCLC patients might be the T790 M\\n  mutation, and other resistant subclones may also coexist in these\\n  patients. Amplification of the MET proto-oncogene accounts for 5-20% of\\n  acquired resistance to EGFR TKIs. strong expression of c-Met is\\n  associated with poor prognosis of NSCLCs. In this case, we analyzed the\\n  potential resistance to EGFR mutations during sequential use of the\\n  first- and second-generation TKIs (gefitinib and afatinib) in an\\n  advanced lung cancer patient. EGFR T790 M was detected in plasma, and\\n  MET amplification was found in the tumor at the time of resistance to\\n  afatinib. Previous studies have shown that co-occurring genomic events\\n  are detected in up to 93% of EGFR-mutant NSCLCs. Tumor biopsies have a\\n  greater depth of molecular characterization; however, they may be\\n  spatially limited to a minute fragment of patients' overall cancer\\n  burden. The ctDNA comes from multiple disease sites and may illustrate\\n  coexistent subclones; thus, liquid biopsies might provide different\\n  information about tumor heterogeneity.\\n\\n  MET amplification can drive human epidermal growth factor receptor 3\\n  (ERBB 3)-dependent PI3K activation; therefore, it may be involved in\\n  EGFR-TKI resistance. Preclinical studies have demonstrated that in EGFR\\n  T790M-mutant NSCLCs, aberrant c-Met activity can confer resistance to\\n  third-generation EGFR TKIs. This suggests that inhibition of both c-Met\\n  and EGFR T790 M is effective in preventing the growth of EGFR\\n  T790M-mutant NSCLCs with c-Met amplification. A recent case report\\n  showed that combinatorial treatment with a first/third-generation EGFR-\\n  TKI and crizotinib resulted in partial responses in two patients with\\n  newly acquired MET amplification after osimertinib resistance. Moreover,\\n  in a phase I/II trial of capmatinib (a small-molecule MET receptor TKI)\\n  combined with gefitinib in EGFR-mutated tumors after EGFR inhibitor\\n  treatment failed NSCLC, the ORR was 47% in patients with MET gene copy\\n  number (GCN) >= 6 subgroup. In the TATTON study, the objective response\\n  rate was 44% in the group treated with osimertinib combined with\\n  savolitinib (MET-TKI). Our case confirmed these observations and\\n  revealed that EGFR T790 M mutation and MET amplification in different\\n  samples can clinically document coexistent, genetically distinct\\n  subpopulations differentially responding as predicted by their genotype\\n  in real time to therapies. Although the progression-free survival (PFS)\\n  of osimertinib in combination with crizotinib was only 3 months, the\\n  patient experienced substantial symptomatic improvement in chest pain\\n  and achieved partial responses.\\n\\n  Further liquid biopsy provided insight into clonal dynamics after\\n  treatment failure with osimertinib combined with crizotinib, emergence\\n  T790 M/C797S. A previous study reported that the EGFR exon 20 C797S\\n  mutation was a major resistance mechanism to osimertinib. C797S may\\n  disrupt the key cysteine residue at the drug-binding site. Although\\n  fourth-generation EGFR-TKIs such as EAI045 have been developed for the\\n  C797S mutation, there are currently no available drugs against T790\\n  M/C797S in the clinic.\\n\\n  PD-L1 high expression (80%) was detected after treatment with the first-\\n  and second-generation TKIs in this patient. Some studies have shown that\\n  PD-L1 high expression in tumors may predict a poor response to targeted\\n  therapy in EGFR-mutated NSCLCs. The role of immunotherapy as a second-\\n  line therapy in EGFR-mutated NSCLCs after EGFR-TKIs is still\\n  controversial, because there is no overall survival improvement over\\n  docetaxel. The recent results of the IMpower150 phase III trial\\n  indicated that patients in the EGFR-mutated subgroup could benefit from\\n  bevacizumab, a monoclonal antibody directed against vascular endothelial\\n  growth factor (VEGF), chemotherapy, and atezolizumab after EGFR-TKIs.\\n\\n  Conclusion\\n\\n  Herein, our report represents a remarkably interesting case of the\\n  complexity and heterogeneity of EGFR mutations along the treatment\\n  course of different TKIs via NGS-based tumor tissue and liquid biopsy.\\n  The patient underwent gefitinib, afatinib, and osimertinib combined with\\n  crizotinib treatment, and developed different EGFR resistance mutations.\\n  In conclusion, although osimertinib combined with crizotinib showed\\n  dramatic tumor shrinkage both in primary tumor and bone metastasis in\\n  EGFR T790M-mutant NSCLC patients with MET amplification, more studies\\n  should be performed to confirm the clinical benefit in PFS and overall\\n  survival. Repeated NGS testing during treatment may provide insight into\\n  clonal evolution and help to select the optimal drugs to achieve better\\n  overall clinical outcomes.\\nPubmed Url: https://pubmed.ncbi.nlm.nih.gov/34397683/\\nPmc Url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322536/\\nAuthors: Li D, Gui Q, Xu C, Shen M, Chen K\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Retrieve the full text and provide an in-depth synthesis of the clinical trial associated with ClinicalTrials.gov Identifier NCT04756793, emphasizing its research objectives, trial design, primary and secondary outcomes, and any notable implications for future medical advancements."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_article_details",
                    "arguments": {
                        "pmid": ""
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_article_details",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"# Record 1\\nError: Error 400: [\\\"pmids is a mandatory parameter.\\\"]\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Extract the detailed contact information and precise site locations for the clinical research associated with trial identifier NCT04280705, validating all gathered data for accuracy through rigorous comparison with publicly accessible and authoritative sources."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_locations",
                    "arguments": {
                        "nct_id": "NCT04280705"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_locations",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Url: https://clinicaltrials.gov/study/NCT04280705\\n\\n# Protocol Section\\n\\n## Contacts Locations Module\\n\\n### Locations\\nFacility:\\n  University of Alabama at Birmingham School of Medicine - Infectious\\n  Disease\\nCity: Birmingham\\nState: Alabama\\nZip: 35233\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.52066\\nLon: -86.80249\\n\\n### Locations\\nFacility: University of California San Diego Health - Jacobs Medical Center\\nCity: La Jolla\\nState: California\\nZip: 29037\\nCountry: United States\\n\\n#### Geo Point\\nLat: 32.84727\\nLon: -117.2742\\n\\n### Locations\\nFacility: University of California Los Angeles Medical Center - Westwood Clinic\\nCity: Los Angeles\\nState: California\\nZip: 90095\\nCountry: United States\\n\\n#### Geo Point\\nLat: 34.05223\\nLon: -118.24368\\n\\n### Locations\\nFacility: University of California Irvine Medical Center - Infectious Disease\\nCity: Orange\\nState: California\\nZip: 92868-3298\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.78779\\nLon: -117.85311\\n\\n### Locations\\nFacility: VA Palo Alto Health Care System - Infectious Diseases\\nCity: Palo Alto\\nState: California\\nZip: 94304-1207\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.44188\\nLon: -122.14302\\n\\n### Locations\\nFacility:\\n  University of California Davis Medical Center - Internal Medicine -\\n  Infectious Disease\\nCity: Sacramento\\nState: California\\nZip: 95817-1460\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.58157\\nLon: -121.4944\\n\\n### Locations\\nFacility: Naval Medical Center San Diego - Infectious Disease Clinic\\nCity: San Diego\\nState: California\\nZip: 92314\\nCountry: United States\\n\\n#### Geo Point\\nLat: 32.71571\\nLon: -117.16472\\n\\n### Locations\\nFacility:\\n  University of California San Francisco - Zuckerberg San Francisco\\n  General Hospital - Division of Human Immunodeficiency Virus, Infectious\\n  Disease, and Global Medicine\\nCity: San Francisco\\nState: California\\nZip: 94110-2859\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.77493\\nLon: -122.41942\\n\\n### Locations\\nFacility:\\n  Stanford University - Stanford Hospital and Clinics - Pediatrics -\\n  Infectious Diseases\\nCity: Stanford\\nState: California\\nZip: 94305-2200\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.42411\\nLon: -122.16608\\n\\n### Locations\\nFacility: Cedars Sinai Medical Center\\nCity: West Hollywood\\nState: California\\nZip: 90048-1804\\nCountry: United States\\n\\n#### Geo Point\\nLat: 34.09001\\nLon: -118.36174\\n\\n### Locations\\nFacility: Denver Health Division of Hospital Medicine - Main Campus\\nCity: Denver\\nState: Colorado\\nZip: 80204\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.73915\\nLon: -104.9847\\n\\n### Locations\\nFacility: Emory Vaccine Center - The Hope Clinic\\nCity: Decatur\\nState: Georgia\\nZip: 30030-1705\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.77483\\nLon: -84.29631\\n\\n### Locations\\nFacility: Northwestern Hospital - Infectious Disease\\nCity: Chicago\\nState: Illinois\\nZip: 60611-2908\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.85003\\nLon: -87.65005\\n\\n### Locations\\nFacility:\\n  University of Illinois at Chicago College of Medicine - Division of\\n  Infectious Diseases\\nCity: Chicago\\nState: Illinois\\nZip: 60612\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.85003\\nLon: -87.65005\\n\\n### Locations\\nFacility:\\n  Southeast Louisiana Veterans Health Care System - Section of Infectious\\n  Diseases\\nCity: New Orleans\\nState: Louisiana\\nZip: 70119\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.95465\\nLon: -90.07507\\n\\n### Locations\\nFacility:\\n  University of Maryland School of Medicine - Center for Vaccine\\n  Development - Baltimore\\nCity: Baltimore\\nState: Maryland\\nZip: 21201-1509\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.29038\\nLon: -76.61219\\n\\n### Locations\\nFacility: Johns Hopkins Hospital - Medicine - Infectious Diseases\\nCity: Baltimore\\nState: Maryland\\nZip: 21287-0005\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.29038\\nLon: -76.61219\\n\\n### Locations\\nFacility: Walter Reed National Military Medical Center\\nCity: Bethesda\\nState: Maryland\\nZip: 20889\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.98067\\nLon: -77.10026\\n\\n### Locations\\nFacility:\\n  National Institutes of Health - Clinical Center, National Institute of\\n  Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical\\n  Research Section\\nCity: Bethesda\\nState: Maryland\\nZip: 20892-1504\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.98067\\nLon: -77.10026\\n\\n### Locations\\nFacility: Massachusetts General Hospital - Infectious Diseases\\nCity: Boston\\nState: Massachusetts\\nZip: 02114-2621\\nCountry: United States\\n\\n#### Geo Point\\nLat: 42.35843\\nLon: -71.05977\\n\\n### Locations\\nFacility:\\n  University of Massachusetts Medical School - Infectious Diseases and\\n  Immunology\\nCity: Worcester\\nState: Massachusetts\\nZip: 01655-0002\\nCountry: United States\\n\\n#### Geo Point\\nLat: 42.26259\\nLon: -71.80229\\n\\n### Locations\\nFacility:\\n  University of Minnesota Medical Center, Fairview - Infectious Diseases\\n  and International Medicine\\nCity: Minneapolis\\nState: Minnesota\\nZip: 55455-0341\\nCountry: United States\\n\\n#### Geo Point\\nLat: 44.97997\\nLon: -93.26384\\n\\n### Locations\\nFacility: Saint Louis University - Center for Vaccine Development\\nCity: St Louis\\nState: Missouri\\nZip: 63104-1015\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.62727\\nLon: -90.19789\\n\\n### Locations\\nFacility: University of Nebraska Medical Center - Infectious Diseases\\nCity: Omaha\\nState: Nebraska\\nZip: 68105\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.25626\\nLon: -95.94043\\n\\n### Locations\\nFacility:\\n  New York University School of Medicine - Langone Medical Center -\\n  Microbiology - Parasitology\\nCity: New York\\nState: New York\\nZip: 10016-6402\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.71427\\nLon: -74.00597\\n\\n### Locations\\nFacility: University of Rochester Medical Center - Vaccine Research Unit\\nCity: Rochester\\nState: New York\\nZip: 14642-0001\\nCountry: United States\\n\\n#### Geo Point\\nLat: 43.15478\\nLon: -77.61556\\n\\n### Locations\\nFacility: Montefiore Medical Center - Infectious Diseases\\nCity: The Bronx\\nState: New York\\nZip: 10467-2401\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.84985\\nLon: -73.86641\\n\\n### Locations\\nFacility: Duke Human Vaccine Institute - Duke Vaccine and Trials Unit\\nCity: Durham\\nState: North Carolina\\nZip: 27704\\nCountry: United States\\n\\n#### Geo Point\\nLat: 35.99403\\nLon: -78.89862\\n\\n### Locations\\nFacility:\\n  Penn State Health Milton S. Hershey Medical Center - Division of\\n  Infectious Diseases\\nCity: Hershey\\nState: Pennsylvania\\nZip: 17033\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.28592\\nLon: -76.65025\\n\\n### Locations\\nFacility: Hospital of the University of Pennsylvania - Infectious Diseases\\nCity: Philadelphia\\nState: Pennsylvania\\nZip: 19104-4238\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.95238\\nLon: -75.16362\\n\\n### Locations\\nFacility: Vanderbilt University Medical Center - Infectious Diseases\\nCity: Nashville\\nState: Tennessee\\nZip: 37232-0011\\nCountry: United States\\n\\n#### Geo Point\\nLat: 36.16589\\nLon: -86.78444\\n\\n### Locations\\nFacility: Brooke Army Medical Center\\nCity: Fort Sam Houston\\nState: Texas\\nZip: 78234\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.45303\\nLon: -98.4417\\n\\n### Locations\\nFacility: University of Texas Medical Branch - Division of Infectious Disease\\nCity: Galveston\\nState: Texas\\nZip: 77555-0435\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.30135\\nLon: -94.7977\\n\\n### Locations\\nFacility: Baylor College of Medicine - Molecular Virology and Microbiology\\nCity: Houston\\nState: Texas\\nZip: 77030-3411\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.76328\\nLon: -95.36327\\n\\n### Locations\\nFacility:\\n  University of Texas Health Science Center at San Antonio - Infectious\\n  Diseases\\nCity: San Antonio\\nState: Texas\\nZip: 78229-3901\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.42412\\nLon: -98.49363\\n\\n### Locations\\nFacility: University of Virginia - Acute Care Surgery\\nCity: Charlottesville\\nState: Virginia\\nZip: 22908-0816\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.02931\\nLon: -78.47668\\n\\n### Locations\\nFacility: Naval Medical Center Portsmouth - Infectious Disease Division\\nCity: Portsmouth\\nState: Virginia\\nZip: 23708\\nCountry: United States\\n\\n#### Geo Point\\nLat: 36.83543\\nLon: -76.29827\\n\\n### Locations\\nFacility: EvergreenHealth Infectious Disease Service\\nCity: Kirkland\\nState: Washington\\nZip: 98034\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.68149\\nLon: -122.20874\\n\\n### Locations\\nFacility: The University of Washington - Virology Research Clinic\\nCity: Seattle\\nState: Washington\\nZip: 98104\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.60621\\nLon: -122.33207\\n\\n### Locations\\nFacility: Providence Sacred Heart Medical Center\\nCity: Spokane\\nState: Washington\\nZip: 99204\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.65966\\nLon: -117.42908\\n\\n### Locations\\nFacility: Madigan Army Medical Center - Infectious Disease Clinic\\nCity: Tacoma\\nState: Washington\\nZip: 98431\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.25288\\nLon: -122.44429\\n\\n### Locations\\nFacility:\\n  University of Copenhagen - Centre of Excellence for Health, Immunity and\\n  Infections (CHIP) - Department of Infectious Diseases\\nCity: Copenhagen\\nZip: 2100\\nCountry: Denmark\\n\\n#### Geo Point\\nLat: 55.67594\\nLon: 12.56553\\n\\n### Locations\\nFacility:\\n  Universitatsklinikum Bonn, Medizinische Klinik I - Bereich\\n  Infektiologie/HIV der Medizinischen Klinik\\nCity: Bonn\\nState: North Rhine-Westphalia\\nZip: 53127\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 50.73438\\nLon: 7.09549\\n\\n### Locations\\nFacility:\\n  Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches\\n  Studienzentrum fur Infektiologie I\\nCity: Cologne\\nZip: 50937\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 50.93333\\nLon: 6.95\\n\\n### Locations\\nFacility: Universit\\u00e4tsklinikum Frankfurt -Medizinische Klinik II - Infektiologie\\nCity: Frankfurt\\nZip: 60590\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 49.68333\\nLon: 10.53333\\n\\n### Locations\\nFacility: AHEPA University Hospital - 1st Department of Internal Medicine\\nCity: Thessaloniki\\nState: Central Macedonia\\nZip: P.O. 54636\\nCountry: Greece\\n\\n#### Geo Point\\nLat: 40.64361\\nLon: 22.93086\\n\\n### Locations\\nFacility:\\n  Medical School of Athens University - Evangelismos Hospital - Department\\n  of Critical Care and Pulmonary Services\\nCity: Athens\\nZip: GR-10675\\nCountry: Greece\\n\\n#### Geo Point\\nLat: 37.98376\\nLon: 23.72784\\n\\n### Locations\\nFacility:\\n  National Center for Global Health and Medicine Hospital - Disease\\n  Control and Prevention Center\\nCity: Tokyo\\nZip: 162-8655\\nCountry: Japan\\n\\n#### Geo Point\\nLat: 35.6895\\nLon: 139.69171\\n\\n### Locations\\nFacility:\\n  Instituto Nacional de Ciencias Medicas y Nutrici\\u00f3n Salvador Zubir\\u00e1n -\\n  Departamento de Infectologia\\nCity: Mexico City\\nZip: 14080\\nCountry: Mexico\\n\\n#### Geo Point\\nLat: 19.42847\\nLon: -99.12766\\n\\n### Locations\\nFacility:\\n  Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cos\\u00edo\\n  Villegas\\nCity: Mexico City\\nZip: 14080\\nCountry: Mexico\\n\\n#### Geo Point\\nLat: 19.42847\\nLon: -99.12766\\n\\n### Locations\\nFacility: National Centre for Infectious Diseases\\nCity: Singapore\\nZip: 308442\\nCountry: Singapore\\n\\n#### Geo Point\\nLat: 1.28967\\nLon: 103.85007\\n\\n### Locations\\nFacility:\\n  Seoul National University Bundang Hospital - Division of Infectious\\n  Diseases\\nCity: Bundang-gu Seongnam-si\\nState: Gyeonggi-do\\nZip: 13620\\nCountry: South Korea\\n\\n### Locations\\nFacility: Seoul National University Hospital\\nCity: Seoul\\nState: Jongno-gu\\nZip: 03080\\nCountry: South Korea\\n\\n#### Geo Point\\nLat: 37.566\\nLon: 126.9784\\n\\n### Locations\\nFacility: Hospital Clinic Barcelona, Servicio de Salud Internacional\\nCity: Barcelona\\nState: Catalonia\\nZip: 08036\\nCountry: Spain\\n\\n#### Geo Point\\nLat: 41.38879\\nLon: 2.15899\\n\\n### Locations\\nFacility: Hospital Germans Trias i Pujol - Servei Malalties Infeccioses\\nCity: Barcelona\\nState: Catalonia\\nZip: 08916\\nCountry: Spain\\n\\n#### Geo Point\\nLat: 41.38879\\nLon: 2.15899\\n\\n### Locations\\nFacility: Royal Sussex County Hospital - Department of Intensive Care Medicine\\nCity: East Sussex\\nState: Brighton\\nZip: BN2 5BE\\nCountry: United Kingdom\\n\\n### Locations\\nFacility: Saint Thomas' Hospital - Directorate of Infection\\nCity: London\\nState: London, City of\\nZip: SE1 7EH\\nCountry: United Kingdom\\n\\n#### Geo Point\\nLat: 51.50853\\nLon: -0.12574\\n\\n### Locations\\nFacility: Royal Victoria Infirmary - Department of Infectious Diseases\\nCity: Level 6, Ward 19\\nState: Newcastle Upon Tyne\\nZip: NE1 4LP\\nCountry: United Kingdom\\n\\n### Locations\\nFacility: St. James's University Hospital - Infectious Diseases\\nCity: Leeds\\nState: West Yorkshire\\nZip: LS9 7TK\\nCountry: United Kingdom\\n\\n#### Geo Point\\nLat: 53.79648\\nLon: -1.54785\\n\\n### Locations\\nFacility: John Radcliffe Hospital\\nCity: Headington, Oxford\\nZip: OX3 9DU\\nCountry: United Kingdom\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Extract detailed information about the research facilities involved in clinical trial NCT04280705, categorizing each by country and specifying the type of institution (e.g., hospital, university, private lab), as well as the primary investigators name and area of expertise."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_locations",
                    "arguments": {
                        "nct_id": "NCT04280705"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_locations",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Url: https://clinicaltrials.gov/study/NCT04280705\\n\\n# Protocol Section\\n\\n## Contacts Locations Module\\n\\n### Locations\\nFacility:\\n  University of Alabama at Birmingham School of Medicine - Infectious\\n  Disease\\nCity: Birmingham\\nState: Alabama\\nZip: 35233\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.52066\\nLon: -86.80249\\n\\n### Locations\\nFacility: University of California San Diego Health - Jacobs Medical Center\\nCity: La Jolla\\nState: California\\nZip: 29037\\nCountry: United States\\n\\n#### Geo Point\\nLat: 32.84727\\nLon: -117.2742\\n\\n### Locations\\nFacility: University of California Los Angeles Medical Center - Westwood Clinic\\nCity: Los Angeles\\nState: California\\nZip: 90095\\nCountry: United States\\n\\n#### Geo Point\\nLat: 34.05223\\nLon: -118.24368\\n\\n### Locations\\nFacility: University of California Irvine Medical Center - Infectious Disease\\nCity: Orange\\nState: California\\nZip: 92868-3298\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.78779\\nLon: -117.85311\\n\\n### Locations\\nFacility: VA Palo Alto Health Care System - Infectious Diseases\\nCity: Palo Alto\\nState: California\\nZip: 94304-1207\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.44188\\nLon: -122.14302\\n\\n### Locations\\nFacility:\\n  University of California Davis Medical Center - Internal Medicine -\\n  Infectious Disease\\nCity: Sacramento\\nState: California\\nZip: 95817-1460\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.58157\\nLon: -121.4944\\n\\n### Locations\\nFacility: Naval Medical Center San Diego - Infectious Disease Clinic\\nCity: San Diego\\nState: California\\nZip: 92314\\nCountry: United States\\n\\n#### Geo Point\\nLat: 32.71571\\nLon: -117.16472\\n\\n### Locations\\nFacility:\\n  University of California San Francisco - Zuckerberg San Francisco\\n  General Hospital - Division of Human Immunodeficiency Virus, Infectious\\n  Disease, and Global Medicine\\nCity: San Francisco\\nState: California\\nZip: 94110-2859\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.77493\\nLon: -122.41942\\n\\n### Locations\\nFacility:\\n  Stanford University - Stanford Hospital and Clinics - Pediatrics -\\n  Infectious Diseases\\nCity: Stanford\\nState: California\\nZip: 94305-2200\\nCountry: United States\\n\\n#### Geo Point\\nLat: 37.42411\\nLon: -122.16608\\n\\n### Locations\\nFacility: Cedars Sinai Medical Center\\nCity: West Hollywood\\nState: California\\nZip: 90048-1804\\nCountry: United States\\n\\n#### Geo Point\\nLat: 34.09001\\nLon: -118.36174\\n\\n### Locations\\nFacility: Denver Health Division of Hospital Medicine - Main Campus\\nCity: Denver\\nState: Colorado\\nZip: 80204\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.73915\\nLon: -104.9847\\n\\n### Locations\\nFacility: Emory Vaccine Center - The Hope Clinic\\nCity: Decatur\\nState: Georgia\\nZip: 30030-1705\\nCountry: United States\\n\\n#### Geo Point\\nLat: 33.77483\\nLon: -84.29631\\n\\n### Locations\\nFacility: Northwestern Hospital - Infectious Disease\\nCity: Chicago\\nState: Illinois\\nZip: 60611-2908\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.85003\\nLon: -87.65005\\n\\n### Locations\\nFacility:\\n  University of Illinois at Chicago College of Medicine - Division of\\n  Infectious Diseases\\nCity: Chicago\\nState: Illinois\\nZip: 60612\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.85003\\nLon: -87.65005\\n\\n### Locations\\nFacility:\\n  Southeast Louisiana Veterans Health Care System - Section of Infectious\\n  Diseases\\nCity: New Orleans\\nState: Louisiana\\nZip: 70119\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.95465\\nLon: -90.07507\\n\\n### Locations\\nFacility:\\n  University of Maryland School of Medicine - Center for Vaccine\\n  Development - Baltimore\\nCity: Baltimore\\nState: Maryland\\nZip: 21201-1509\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.29038\\nLon: -76.61219\\n\\n### Locations\\nFacility: Johns Hopkins Hospital - Medicine - Infectious Diseases\\nCity: Baltimore\\nState: Maryland\\nZip: 21287-0005\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.29038\\nLon: -76.61219\\n\\n### Locations\\nFacility: Walter Reed National Military Medical Center\\nCity: Bethesda\\nState: Maryland\\nZip: 20889\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.98067\\nLon: -77.10026\\n\\n### Locations\\nFacility:\\n  National Institutes of Health - Clinical Center, National Institute of\\n  Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical\\n  Research Section\\nCity: Bethesda\\nState: Maryland\\nZip: 20892-1504\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.98067\\nLon: -77.10026\\n\\n### Locations\\nFacility: Massachusetts General Hospital - Infectious Diseases\\nCity: Boston\\nState: Massachusetts\\nZip: 02114-2621\\nCountry: United States\\n\\n#### Geo Point\\nLat: 42.35843\\nLon: -71.05977\\n\\n### Locations\\nFacility:\\n  University of Massachusetts Medical School - Infectious Diseases and\\n  Immunology\\nCity: Worcester\\nState: Massachusetts\\nZip: 01655-0002\\nCountry: United States\\n\\n#### Geo Point\\nLat: 42.26259\\nLon: -71.80229\\n\\n### Locations\\nFacility:\\n  University of Minnesota Medical Center, Fairview - Infectious Diseases\\n  and International Medicine\\nCity: Minneapolis\\nState: Minnesota\\nZip: 55455-0341\\nCountry: United States\\n\\n#### Geo Point\\nLat: 44.97997\\nLon: -93.26384\\n\\n### Locations\\nFacility: Saint Louis University - Center for Vaccine Development\\nCity: St Louis\\nState: Missouri\\nZip: 63104-1015\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.62727\\nLon: -90.19789\\n\\n### Locations\\nFacility: University of Nebraska Medical Center - Infectious Diseases\\nCity: Omaha\\nState: Nebraska\\nZip: 68105\\nCountry: United States\\n\\n#### Geo Point\\nLat: 41.25626\\nLon: -95.94043\\n\\n### Locations\\nFacility:\\n  New York University School of Medicine - Langone Medical Center -\\n  Microbiology - Parasitology\\nCity: New York\\nState: New York\\nZip: 10016-6402\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.71427\\nLon: -74.00597\\n\\n### Locations\\nFacility: University of Rochester Medical Center - Vaccine Research Unit\\nCity: Rochester\\nState: New York\\nZip: 14642-0001\\nCountry: United States\\n\\n#### Geo Point\\nLat: 43.15478\\nLon: -77.61556\\n\\n### Locations\\nFacility: Montefiore Medical Center - Infectious Diseases\\nCity: The Bronx\\nState: New York\\nZip: 10467-2401\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.84985\\nLon: -73.86641\\n\\n### Locations\\nFacility: Duke Human Vaccine Institute - Duke Vaccine and Trials Unit\\nCity: Durham\\nState: North Carolina\\nZip: 27704\\nCountry: United States\\n\\n#### Geo Point\\nLat: 35.99403\\nLon: -78.89862\\n\\n### Locations\\nFacility:\\n  Penn State Health Milton S. Hershey Medical Center - Division of\\n  Infectious Diseases\\nCity: Hershey\\nState: Pennsylvania\\nZip: 17033\\nCountry: United States\\n\\n#### Geo Point\\nLat: 40.28592\\nLon: -76.65025\\n\\n### Locations\\nFacility: Hospital of the University of Pennsylvania - Infectious Diseases\\nCity: Philadelphia\\nState: Pennsylvania\\nZip: 19104-4238\\nCountry: United States\\n\\n#### Geo Point\\nLat: 39.95238\\nLon: -75.16362\\n\\n### Locations\\nFacility: Vanderbilt University Medical Center - Infectious Diseases\\nCity: Nashville\\nState: Tennessee\\nZip: 37232-0011\\nCountry: United States\\n\\n#### Geo Point\\nLat: 36.16589\\nLon: -86.78444\\n\\n### Locations\\nFacility: Brooke Army Medical Center\\nCity: Fort Sam Houston\\nState: Texas\\nZip: 78234\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.45303\\nLon: -98.4417\\n\\n### Locations\\nFacility: University of Texas Medical Branch - Division of Infectious Disease\\nCity: Galveston\\nState: Texas\\nZip: 77555-0435\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.30135\\nLon: -94.7977\\n\\n### Locations\\nFacility: Baylor College of Medicine - Molecular Virology and Microbiology\\nCity: Houston\\nState: Texas\\nZip: 77030-3411\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.76328\\nLon: -95.36327\\n\\n### Locations\\nFacility:\\n  University of Texas Health Science Center at San Antonio - Infectious\\n  Diseases\\nCity: San Antonio\\nState: Texas\\nZip: 78229-3901\\nCountry: United States\\n\\n#### Geo Point\\nLat: 29.42412\\nLon: -98.49363\\n\\n### Locations\\nFacility: University of Virginia - Acute Care Surgery\\nCity: Charlottesville\\nState: Virginia\\nZip: 22908-0816\\nCountry: United States\\n\\n#### Geo Point\\nLat: 38.02931\\nLon: -78.47668\\n\\n### Locations\\nFacility: Naval Medical Center Portsmouth - Infectious Disease Division\\nCity: Portsmouth\\nState: Virginia\\nZip: 23708\\nCountry: United States\\n\\n#### Geo Point\\nLat: 36.83543\\nLon: -76.29827\\n\\n### Locations\\nFacility: EvergreenHealth Infectious Disease Service\\nCity: Kirkland\\nState: Washington\\nZip: 98034\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.68149\\nLon: -122.20874\\n\\n### Locations\\nFacility: The University of Washington - Virology Research Clinic\\nCity: Seattle\\nState: Washington\\nZip: 98104\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.60621\\nLon: -122.33207\\n\\n### Locations\\nFacility: Providence Sacred Heart Medical Center\\nCity: Spokane\\nState: Washington\\nZip: 99204\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.65966\\nLon: -117.42908\\n\\n### Locations\\nFacility: Madigan Army Medical Center - Infectious Disease Clinic\\nCity: Tacoma\\nState: Washington\\nZip: 98431\\nCountry: United States\\n\\n#### Geo Point\\nLat: 47.25288\\nLon: -122.44429\\n\\n### Locations\\nFacility:\\n  University of Copenhagen - Centre of Excellence for Health, Immunity and\\n  Infections (CHIP) - Department of Infectious Diseases\\nCity: Copenhagen\\nZip: 2100\\nCountry: Denmark\\n\\n#### Geo Point\\nLat: 55.67594\\nLon: 12.56553\\n\\n### Locations\\nFacility:\\n  Universitatsklinikum Bonn, Medizinische Klinik I - Bereich\\n  Infektiologie/HIV der Medizinischen Klinik\\nCity: Bonn\\nState: North Rhine-Westphalia\\nZip: 53127\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 50.73438\\nLon: 7.09549\\n\\n### Locations\\nFacility:\\n  Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches\\n  Studienzentrum fur Infektiologie I\\nCity: Cologne\\nZip: 50937\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 50.93333\\nLon: 6.95\\n\\n### Locations\\nFacility: Universit\\u00e4tsklinikum Frankfurt -Medizinische Klinik II - Infektiologie\\nCity: Frankfurt\\nZip: 60590\\nCountry: Germany\\n\\n#### Geo Point\\nLat: 49.68333\\nLon: 10.53333\\n\\n### Locations\\nFacility: AHEPA University Hospital - 1st Department of Internal Medicine\\nCity: Thessaloniki\\nState: Central Macedonia\\nZip: P.O. 54636\\nCountry: Greece\\n\\n#### Geo Point\\nLat: 40.64361\\nLon: 22.93086\\n\\n### Locations\\nFacility:\\n  Medical School of Athens University - Evangelismos Hospital - Department\\n  of Critical Care and Pulmonary Services\\nCity: Athens\\nZip: GR-10675\\nCountry: Greece\\n\\n#### Geo Point\\nLat: 37.98376\\nLon: 23.72784\\n\\n### Locations\\nFacility:\\n  National Center for Global Health and Medicine Hospital - Disease\\n  Control and Prevention Center\\nCity: Tokyo\\nZip: 162-8655\\nCountry: Japan\\n\\n#### Geo Point\\nLat: 35.6895\\nLon: 139.69171\\n\\n### Locations\\nFacility:\\n  Instituto Nacional de Ciencias Medicas y Nutrici\\u00f3n Salvador Zubir\\u00e1n -\\n  Departamento de Infectologia\\nCity: Mexico City\\nZip: 14080\\nCountry: Mexico\\n\\n#### Geo Point\\nLat: 19.42847\\nLon: -99.12766\\n\\n### Locations\\nFacility:\\n  Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cos\\u00edo\\n  Villegas\\nCity: Mexico City\\nZip: 14080\\nCountry: Mexico\\n\\n#### Geo Point\\nLat: 19.42847\\nLon: -99.12766\\n\\n### Locations\\nFacility: National Centre for Infectious Diseases\\nCity: Singapore\\nZip: 308442\\nCountry: Singapore\\n\\n#### Geo Point\\nLat: 1.28967\\nLon: 103.85007\\n\\n### Locations\\nFacility:\\n  Seoul National University Bundang Hospital - Division of Infectious\\n  Diseases\\nCity: Bundang-gu Seongnam-si\\nState: Gyeonggi-do\\nZip: 13620\\nCountry: South Korea\\n\\n### Locations\\nFacility: Seoul National University Hospital\\nCity: Seoul\\nState: Jongno-gu\\nZip: 03080\\nCountry: South Korea\\n\\n#### Geo Point\\nLat: 37.566\\nLon: 126.9784\\n\\n### Locations\\nFacility: Hospital Clinic Barcelona, Servicio de Salud Internacional\\nCity: Barcelona\\nState: Catalonia\\nZip: 08036\\nCountry: Spain\\n\\n#### Geo Point\\nLat: 41.38879\\nLon: 2.15899\\n\\n### Locations\\nFacility: Hospital Germans Trias i Pujol - Servei Malalties Infeccioses\\nCity: Barcelona\\nState: Catalonia\\nZip: 08916\\nCountry: Spain\\n\\n#### Geo Point\\nLat: 41.38879\\nLon: 2.15899\\n\\n### Locations\\nFacility: Royal Sussex County Hospital - Department of Intensive Care Medicine\\nCity: East Sussex\\nState: Brighton\\nZip: BN2 5BE\\nCountry: United Kingdom\\n\\n### Locations\\nFacility: Saint Thomas' Hospital - Directorate of Infection\\nCity: London\\nState: London, City of\\nZip: SE1 7EH\\nCountry: United Kingdom\\n\\n#### Geo Point\\nLat: 51.50853\\nLon: -0.12574\\n\\n### Locations\\nFacility: Royal Victoria Infirmary - Department of Infectious Diseases\\nCity: Level 6, Ward 19\\nState: Newcastle Upon Tyne\\nZip: NE1 4LP\\nCountry: United Kingdom\\n\\n### Locations\\nFacility: St. James's University Hospital - Infectious Diseases\\nCity: Leeds\\nState: West Yorkshire\\nZip: LS9 7TK\\nCountry: United Kingdom\\n\\n#### Geo Point\\nLat: 53.79648\\nLon: -1.54785\\n\\n### Locations\\nFacility: John Radcliffe Hospital\\nCity: Headington, Oxford\\nZip: OX3 9DU\\nCountry: United Kingdom\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": ": Conduct a comprehensive exploration of academic databases to locate peer-reviewed research analyzing the relationship between Parkinsons disease progression, the influence of the LRRK2 G2019S mutation, and any potential environmental or lifestyle modifiers."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_article_searcher",
                    "arguments": {
                        "request": {
                            "genes": [
                                "LRRK2"
                            ],
                            "variants": [
                                "G2019S"
                            ],
                            "diseases": [
                                "Parkinsons disease"
                            ],
                            "chemicals": [],
                            "keywords": [
                                "disease progression",
                                "environmental modifiers",
                                "lifestyle modifiers"
                            ]
                        }
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_article_searcher",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"[]\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Extract the title, abstract, and full text (if accessible) of the scientific article linked to PubMed ID 34397683, ensuring the abstract includes a detailed account of the primary methodologies employed, and cross-reference the extracted methodologies with common techniques in the field to validate their relevance."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_article_details",
                    "arguments": {
                        "pmid": "34397683"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_article_details",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"# Record 1\\nPmid: 34397683\\nPmcid: PMC8322536\\nDate: 2021-07-30T00:00:00Z\\nJournal: Medicine (Baltimore)\\nTitle:\\n  Dramatic response to osimertinib combined with crizotinib in EGFR T790 M\\n  mutation only in blood and Met amplification only in tumor tissue\\n  expressive non-small cell lung cancer\\nAbstract:\\n  Abstract\\n\\n  Rationale:\\n\\n  Besides the T790 M mutation, it may coexist with bypass pathway\\n  activation in real clinical cases for patients with EGFR mutations who\\n  resisted to the first- and second-generation tyrosine kinase inhibitors\\n  (TKIs) in non-small cell lung cancer (NSCLC). There are limited clinical\\n  trial data describing the efficacy of osimertinib combined with MET\\n  inhibition in EGFR T790M-mutant NSCLC patients with Met amplification.\\n\\n  Patient concerns:\\n\\n  A non-smoking 53-year-old male patient with lung adenocarcinoma\\n  underwent gefitinib, afatinib, and osimertinib combined with crizotinib\\n  treatment and developed different EGFR resistance mutations.\\n\\n  Diagnoses:\\n\\n  The patient was diagnosed with lung adenocarcinoma (stage cT4N2M0,\\n  IIIB). After resistance to the therapy targeting EGFR exon 21 L858R\\n  point mutation, T790 M mutation was detected in liquid biopsy and Met\\n  amplification was detected via tissue biopsy by next-generation\\n  sequencing (NGS).\\n\\n  Interventions:\\n\\n  The patient received systemic treatments, including chemotherapy,\\n  gefitinib, afatinib, and osimertinib combined with crizotinib.\\n\\n  Outcomes:\\n\\n  The patient died of multisystem organ failure and had an overall\\n  survival of 24 months.\\n\\n  Lessons:\\n\\n  Although osimertinib combined with crizotinib therapy showed dramatic\\n  tumor shrinkage in both the primary tumor and bone metastasis to an EGFR\\n  T790M-mutant NSCLC patient with MET amplification, the progression-free\\n  survival (PFS) was only two months.\\nFull Text:\\n  Introduction\\n\\n  Advanced non-small cell lung cancer with EGFR gene mutations is closely\\n  related to the clinical efficacy of epidermal growth factor receptor\\n  tyrosine kinase inhibitors (EGFR TKIs), but the outcomes are limited by\\n  acquired resistance. The EGFR exon 20 T790 M mutation accounts for 50%\\n  to 60% of the resistance to first- and second-generation TKIs, followed\\n  by bypass pathway activation (e.g., MET or ERRB2 amplification,\\n  mutations in BRAF and PIK3CA), and lineage shifts (e.g., small-cell\\n  transformation, epithelial-to-mesenchymal transition). 'Third-\\n  generation' EGFR TKIs, such as osimertinib, are highly effective in\\n  EGFR-mutant NSCLC patients harboring the EGFR T790 M mutation.\\n  Nevertheless, resistance to third-generation EGFR TKIs can still develop\\n  through further mutations in EGFR and the activation of alternative\\n  pathways. With the development of high-throughput NGS-based liquid\\n  biopsy technology, additional mechanisms, such as EGFR exon 20 C797S,\\n  EGFR L718Q, and EGFR exon 18 G724S mutations were observed. NGS-based\\n  liquid biopsy testing overcomes spatial heterogeneity and can\\n  dynamically monitor tumor genomic evolution and guide decision-making\\n  for treatment strategies in a minimally invasive manner.\\n\\n  Here, we present the case of an EGFR-mutant advanced NSCLC patient who\\n  acquired resistance to first- and second-generation TKIs in a short\\n  time. There were different results of the NGS tests between blood\\n  samples and tumor tissue samples at the same time, that EGFR T790 M\\n  mutation was only found in blood and Met amplification was only found in\\n  tumor tissue. Although there are limited clinical trial data describing\\n  the efficacy of osimertinib combined with MET inhibition in patients\\n  with EGFR T790M-mutant NSCLC, outcomes in a real-world setting are\\n  useful to inform clinical practice. Despite disease progression after\\n  only 3 months, the patient experienced substantial symptomatic\\n  improvement and dramatic tumor regression following osimertinib combined\\n  with crizotinib therapy.\\n\\n  The profile of treatments, images and NGS results of the patient. (A)\\n  Initial Chemotherapy of cisplatin/pemetrexed had a good response to\\n  tumor but caused intolerable adverse reactions. The first NGS suggested\\n  EGFR 21 L858R mutation. (B) The PFS of first-generation EGFR-TKI\\n  gefitinib was only 5 months. (C) The second NGS suggested there was no\\n  T790 M mutation. And the second-generation EGFR-TKI afatinib was\\n  ineffective. (D) The PFS of secondary chemotherapy and plus Bevacizumab\\n  was only 4 months. (E) The third NGS suggested EGFR T790 M mutation was\\n  only in blood and Met amplification was only in tumor tissue.\\n  Osimertinib combined with crizotinib showed dramatic tumor shrinkage.\\n  (F) The PFS of osimertinib combined with crizotinib was only 3 months.\\n  (G) Palliative care for 4 months. p(H) Brain metastasis and the fourth\\n  NGS of EGFR L858R, T790 M/C797S (cis), and MET L1195 V mutations.\\n\\n  Discussion\\n\\n  The most common acquired resistance mechanism against the first- and\\n  second-generation TKIs in EGFR-mutant NSCLC patients might be the T790 M\\n  mutation, and other resistant subclones may also coexist in these\\n  patients. Amplification of the MET proto-oncogene accounts for 5-20% of\\n  acquired resistance to EGFR TKIs. strong expression of c-Met is\\n  associated with poor prognosis of NSCLCs. In this case, we analyzed the\\n  potential resistance to EGFR mutations during sequential use of the\\n  first- and second-generation TKIs (gefitinib and afatinib) in an\\n  advanced lung cancer patient. EGFR T790 M was detected in plasma, and\\n  MET amplification was found in the tumor at the time of resistance to\\n  afatinib. Previous studies have shown that co-occurring genomic events\\n  are detected in up to 93% of EGFR-mutant NSCLCs. Tumor biopsies have a\\n  greater depth of molecular characterization; however, they may be\\n  spatially limited to a minute fragment of patients' overall cancer\\n  burden. The ctDNA comes from multiple disease sites and may illustrate\\n  coexistent subclones; thus, liquid biopsies might provide different\\n  information about tumor heterogeneity.\\n\\n  MET amplification can drive human epidermal growth factor receptor 3\\n  (ERBB 3)-dependent PI3K activation; therefore, it may be involved in\\n  EGFR-TKI resistance. Preclinical studies have demonstrated that in EGFR\\n  T790M-mutant NSCLCs, aberrant c-Met activity can confer resistance to\\n  third-generation EGFR TKIs. This suggests that inhibition of both c-Met\\n  and EGFR T790 M is effective in preventing the growth of EGFR\\n  T790M-mutant NSCLCs with c-Met amplification. A recent case report\\n  showed that combinatorial treatment with a first/third-generation EGFR-\\n  TKI and crizotinib resulted in partial responses in two patients with\\n  newly acquired MET amplification after osimertinib resistance. Moreover,\\n  in a phase I/II trial of capmatinib (a small-molecule MET receptor TKI)\\n  combined with gefitinib in EGFR-mutated tumors after EGFR inhibitor\\n  treatment failed NSCLC, the ORR was 47% in patients with MET gene copy\\n  number (GCN) >= 6 subgroup. In the TATTON study, the objective response\\n  rate was 44% in the group treated with osimertinib combined with\\n  savolitinib (MET-TKI). Our case confirmed these observations and\\n  revealed that EGFR T790 M mutation and MET amplification in different\\n  samples can clinically document coexistent, genetically distinct\\n  subpopulations differentially responding as predicted by their genotype\\n  in real time to therapies. Although the progression-free survival (PFS)\\n  of osimertinib in combination with crizotinib was only 3 months, the\\n  patient experienced substantial symptomatic improvement in chest pain\\n  and achieved partial responses.\\n\\n  Further liquid biopsy provided insight into clonal dynamics after\\n  treatment failure with osimertinib combined with crizotinib, emergence\\n  T790 M/C797S. A previous study reported that the EGFR exon 20 C797S\\n  mutation was a major resistance mechanism to osimertinib. C797S may\\n  disrupt the key cysteine residue at the drug-binding site. Although\\n  fourth-generation EGFR-TKIs such as EAI045 have been developed for the\\n  C797S mutation, there are currently no available drugs against T790\\n  M/C797S in the clinic.\\n\\n  PD-L1 high expression (80%) was detected after treatment with the first-\\n  and second-generation TKIs in this patient. Some studies have shown that\\n  PD-L1 high expression in tumors may predict a poor response to targeted\\n  therapy in EGFR-mutated NSCLCs. The role of immunotherapy as a second-\\n  line therapy in EGFR-mutated NSCLCs after EGFR-TKIs is still\\n  controversial, because there is no overall survival improvement over\\n  docetaxel. The recent results of the IMpower150 phase III trial\\n  indicated that patients in the EGFR-mutated subgroup could benefit from\\n  bevacizumab, a monoclonal antibody directed against vascular endothelial\\n  growth factor (VEGF), chemotherapy, and atezolizumab after EGFR-TKIs.\\n\\n  Conclusion\\n\\n  Herein, our report represents a remarkably interesting case of the\\n  complexity and heterogeneity of EGFR mutations along the treatment\\n  course of different TKIs via NGS-based tumor tissue and liquid biopsy.\\n  The patient underwent gefitinib, afatinib, and osimertinib combined with\\n  crizotinib treatment, and developed different EGFR resistance mutations.\\n  In conclusion, although osimertinib combined with crizotinib showed\\n  dramatic tumor shrinkage both in primary tumor and bone metastasis in\\n  EGFR T790M-mutant NSCLC patients with MET amplification, more studies\\n  should be performed to confirm the clinical benefit in PFS and overall\\n  survival. Repeated NGS testing during treatment may provide insight into\\n  clonal evolution and help to select the optimal drugs to achieve better\\n  overall clinical outcomes.\\nPubmed Url: https://pubmed.ncbi.nlm.nih.gov/34397683/\\nPmc Url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322536/\\nAuthors: Li D, Gui Q, Xu C, Shen M, Chen K\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Identify and summarize detailed information about the experimental protocols, participant demographics, funding sources, ethical considerations, and statistical analysis techniques utilized in the clinical trial associated with NCT ID NCT03478891."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_outcomes",
                    "arguments": {
                        "nct_id": "NCT03478891"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_outcomes",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Url: https://clinicaltrials.gov/study/NCT03478891\\n\\n# Protocol Section\\n\\n## Outcomes Module\\n\\n### Primary Outcomes\\nMeasure:\\n  Number of Subjects Experiencing Infusion Reaction During Product\\n  Administration\\nDescription:\\n  Possible infusion reaction symptoms: unusually tired/feeling unwell,\\n  muscles aches, headache, chills, rigors, nausea, fever, joint pain,\\n  urticaria/rash, and pruritus. Also information was collected if\\n  administration was slowed down or stopped for reactogenicity reasons.\\nTime Frame: About 30 minutes of product administration\\n\\n### Primary Outcomes\\nMeasure:\\n  Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms\\n  Within 3 Days of Product Administration\\nDescription:\\n  Subjects recorded 3-day systemic reactogenicity symptoms in a diary\\n  after study product administration. Solicited systemic symptoms include:\\n  unusually tired/feeling unwell, muscles aches, headache, chills, nausea,\\n  fever and joint pain. Subjects recorded highest measured temperature\\n  daily. Clinicians reviewed the diary with the subject and collected\\n  resolution information for any symptoms that were not resolved within 3\\n  days. Subjects were counted once for each symptom at the worst severity\\n  if they indicated experiencing the symptom at any severity during the\\n  reporting period. The number reported for \\\"Any Systemic Symptom\\\" is the\\n  number of subjects experiencing any systemic symptom as reported at the\\n  worst severity. Solicited reactogenicity was recorded without an\\n  attribution assessment. Grading was done by Division of AIDS Table for\\n  Grading the Severity of Adult and Pediatric Adverse Events Version 2.1.\\nTime Frame: 3 days after product administration\\n\\n### Primary Outcomes\\nMeasure:\\n  Number of Subjects Reporting Local Reactogenicity Signs and Symptoms\\n  Within 7 Days of Product Administration\\nDescription:\\n  Local reactogenicity symptoms were assessed and recorded by clinicians.\\n  Solicited local symptoms include pain/tenderness, swelling, redness,\\n  bruising, and pruritus (itchiness) at the product administration site.\\n  Clinicians assessed the study product administration site for local\\n  symptoms on the day of product administration after completion of the\\n  administration and on Days 1, 2 and 7 post administration. Subjects were\\n  counted once for each symptom at the worst severity if they experienced\\n  the symptom at any severity during the reporting period. If symptoms\\n  were experienced, clinicians collected resolution information for any\\n  symptom that wasn't resolved within 7 days. The number reported for \\\"Any\\n  Local Symptom\\\" is the number of subjects reporting any local symptom as\\n  reported at the worst severity. Solicited reactogenicity was recorded\\n  without attribution assessment. Grading was done by Division of AIDS\\n  Table for Grading the Severity of Adult and Pediatric Adverse Events\\n  Version 2.1.\\nTime Frame: 7 days after product administration\\n\\n### Primary Outcomes\\nMeasure:\\n  Number of Subjects Reporting 1 or More Unsolicited Non-Serious Adverse\\n  Events\\nDescription:\\n  Unsolicited adverse events (AEs) collected during the period from study\\n  product administration at Day 0 through 28 days after product\\n  administration. After the indicated time period through the last\\n  expected study visit at 24 weeks after product administration, only new\\n  chronic medical conditions collected as unsolicited AEs.\\n\\n  The number reported is the number of subjects who experienced at least\\n  one AE in the reporting period. A subject with multiple experiences of\\n  the same event is counted once using the event of worst severity. The\\n  relationship between an AE and the product was assessed by the\\n  investigator on the basis of his or her clinical judgment and the\\n  protocol-specific definitions of Related - There is a reasonable\\n  possibility that the AE may be related to the study product and Not\\n  Related - There is not a reasonable possibility that the AE is related\\n  to the study product.\\nTime Frame: Through 24 weeks after product administration\\n\\n### Primary Outcomes\\nMeasure: Number of Subjects Reporting Serious Adverse Events\\nDescription:\\n  Serious adverse events (SAEs) collected during the period from study\\n  product administration at Day 0 through 24 weeks after product\\n  administration. Grading done by Division of AIDS Table for Grading the\\n  Severity of Adult and Pediatric Adverse Events Version 2.1. The\\n  relationship between a SAE and the product was assessed by the\\n  investigator on the basis of his or her clinical judgment and the\\n  protocol-specific definitions of Related - There is a reasonable\\n  possibility that the SAE may be related to the study product and Not\\n  Related - There is not a reasonable possibility that the SAE is related\\n  to the study product.\\nTime Frame: Through 24 weeks after product administration\\n\\n### Secondary Outcomes\\nMeasure: Maximum Observed Serum Concentration (Cmax) of MAb114\\nDescription:\\n  Cmax is the peak serum concentration that MAb114 achieves after it has\\n  been administered; it is determined as a maximum value on the summary\\n  pharmacokinetic (PK) curve for each study group.\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n### Secondary Outcomes\\nMeasure: Time to Reach Maximum Observed Serum Concentration (Tmax) of MAb114\\nDescription:\\n  Tmax is the time it takes to reach Cmax of MAb114 after it has been\\n  administered; it is determined based on the summary PK curve for each\\n  study group.\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n### Secondary Outcomes\\nMeasure: Mean Serum Concentration of MAb114\\nDescription:\\n  The mean of individual subject MAb114 serum concentrations by\\n  administered dose group\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n### Secondary Outcomes\\nMeasure: Overall IV Half-life (T1/2) of MAb114\\nDescription:\\n  Half-life (T1/2) is the time required for half of the drug to be\\n  eliminated from the serum.\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-56 days post-infusion\\n\\n### Secondary Outcomes\\nMeasure: Area Under the Curve (AUC0-28D)\\nDescription:\\n  The AUC0-28D represents the total drug exposure in 28 days after MAb114\\n  administration; it is determined based on the summary PK curve for each\\n  group.\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n### Secondary Outcomes\\nMeasure: Volume of Distribution (Vd) at Steady-state\\nDescription:\\n  Theoretical volume that would be necessary to contain the total amount\\n  of administered drug at the same concentration as observed in plasma. It\\n  represents the degree to which a drug is distributed in body tissue\\n  rather than the plasma and calculated based in the PK curve for each\\n  study group.\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n### Secondary Outcomes\\nMeasure: MAb114 Clearance Rate\\nDescription:\\n  Rate of MAb114 elimination divided by the plasma MAb114 concentration;\\n  determined based on the summary PK curve for each study group.\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n### Secondary Outcomes\\nMeasure: Number of Subjects Who Produced Anti-drug Antibodies to MAb114\\nDescription: Serum samples collected 28 days and 56 days after MAb114 administration\\nTime Frame: Days 28 and 56 post-infusion\\n\\n# Results Section\\n\\n## Participant Flow Module\\nRecruitment Details:\\n  Healthy adults were recruited at the NIH Clinical Center in Bethesda,\\n  Maryland\\n\\n### Groups\\nId: FG000\\nTitle: Group 1: 5 mg/kg IV\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n### Groups\\nId: FG001\\nTitle: Group 2: 25 mg/kg IV\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n### Groups\\nId: FG002\\nTitle: Group 3: 50 mg/kg IV\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n### Periods\\nTitle: Overall Study\\n\\n#### Milestones\\nType: STARTED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 3\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 5\\n\\n##### Achievements\\nGroup Id: FG002\\nNum Subjects: 11\\n\\n#### Milestones\\nType: Received MAb114\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 3\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 5\\n\\n##### Achievements\\nGroup Id: FG002\\nComment:\\n  One Group 3 subject discontinued prior to MAb114 infusion due to\\n  inadequate venous access\\nNum Subjects: 10\\n\\n#### Milestones\\nType: COMPLETED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 2\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 5\\n\\n##### Achievements\\nGroup Id: FG002\\nNum Subjects: 8\\n\\n#### Milestones\\nType: NOT COMPLETED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 1\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 0\\n\\n##### Achievements\\nGroup Id: FG002\\nNum Subjects: 3\\n\\n#### Drop Withdraws\\nType: Enrolled, but product never administered\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 0\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 0\\n\\n##### Reasons\\nGroup Id: FG002\\nNum Subjects: 1\\n\\n#### Drop Withdraws\\nType: Moved from area\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 0\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 0\\n\\n##### Reasons\\nGroup Id: FG002\\nNum Subjects: 1\\n\\n#### Drop Withdraws\\nType: Lost to Follow-up\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 1\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 0\\n\\n##### Reasons\\nGroup Id: FG002\\nNum Subjects: 1\\n\\n## Baseline Characteristics Module\\nPopulation Description: All enrolled subjects\\n\\n### Groups\\nId: BG000\\nTitle: Group 1: 5 mg/kg IV\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n### Groups\\nId: BG001\\nTitle: Group 2: 25 mg/kg IV\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n### Groups\\nId: BG002\\nTitle: Group 3: 50 mg/kg IV\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n### Groups\\nId: BG003\\nTitle: Total\\nDescription: Total of all reporting groups\\n\\n### Denoms\\nUnits: Participants\\n\\n#### Counts\\nGroup Id: BG000\\nValue: 3\\n\\n#### Counts\\nGroup Id: BG001\\nValue: 5\\n\\n#### Counts\\nGroup Id: BG002\\nValue: 11\\n\\n#### Counts\\nGroup Id: BG003\\nValue: 19\\n\\n### Measures\\nTitle: Age, Continuous\\nParam Type: MEAN\\nDispersion Type: STANDARD_DEVIATION\\nUnit Of Measure: years\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 39.7\\nSpread: 7.4\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 36.4\\nSpread: 9.8\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 39.0\\nSpread: 13.9\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 38.4\\nSpread: 11.7\\n\\n### Measures\\nTitle: Age, Customized\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\nTitle: 21-30 years\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 5\\n\\n#### Classes\\nTitle: 31-40 years\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 6\\n\\n#### Classes\\nTitle: 41-50 years\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 4\\n\\n#### Classes\\nTitle: 51-60 years\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 4\\n\\n### Measures\\nTitle: Sex: Female, Male\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: Female\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 12\\n\\n##### Categories\\nTitle: Male\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 7\\n\\n### Measures\\nTitle: Ethnicity (NIH/OMB)\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: Hispanic or Latino\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 2\\n\\n##### Categories\\nTitle: Not Hispanic or Latino\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 10\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 17\\n\\n##### Categories\\nTitle: Unknown or Not Reported\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 0\\n\\n### Measures\\nTitle: Race (NIH/OMB)\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: American Indian or Alaska Native\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 0\\n\\n##### Categories\\nTitle: Asian\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 1\\n\\n##### Categories\\nTitle: Native Hawaiian or Other Pacific Islander\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 0\\n\\n##### Categories\\nTitle: Black or African American\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 1\\n\\n##### Categories\\nTitle: White\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 14\\n\\n##### Categories\\nTitle: More than one race\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 3\\n\\n##### Categories\\nTitle: Unknown or Not Reported\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 0\\n\\n### Measures\\nTitle: Region of Enrollment\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\nTitle: United States\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 11\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 19\\n\\n### Measures\\nTitle: Weight\\nParam Type: MEAN\\nDispersion Type: STANDARD_DEVIATION\\nUnit Of Measure: kg\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 88\\nSpread: 8.8\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 66.3\\nSpread: 12.6\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 73.5\\nSpread: 12.4\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 73.9\\nSpread: 13.4\\n\\n### Measures\\nTitle: Education\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: College or University\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 3\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 8\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 13\\n\\n##### Categories\\nTitle: Advanced Degree\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 3\\n\\n##### Measurements\\nGroup Id: BG003\\nValue: 6\\n\\n## Outcome Measures Module\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle:\\n  Number of Subjects Experiencing Infusion Reaction During Product\\n  Administration\\nDescription:\\n  Possible infusion reaction symptoms: unusually tired/feeling unwell,\\n  muscles aches, headache, chills, rigors, nausea, fever, joint pain,\\n  urticaria/rash, and pruritus. Also information was collected if\\n  administration was slowed down or stopped for reactogenicity reasons.\\nPopulation Description:\\n  Subjects who received MAb114 (N=18), where \\\"N\\\" signifies number of\\n  subjects analyzed for this outcome measure.\\nReporting Status: POSTED\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\nTime Frame: About 30 minutes of product administration\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=10)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 10\\n\\n#### Classes\\nTitle: Number who experienced infusion reaction\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n#### Classes\\nTitle: Number who completed infusion in about 30 min\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 10\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle:\\n  Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms\\n  Within 3 Days of Product Administration\\nDescription:\\n  Subjects recorded 3-day systemic reactogenicity symptoms in a diary\\n  after study product administration. Solicited systemic symptoms include:\\n  unusually tired/feeling unwell, muscles aches, headache, chills, nausea,\\n  fever and joint pain. Subjects recorded highest measured temperature\\n  daily. Clinicians reviewed the diary with the subject and collected\\n  resolution information for any symptoms that were not resolved within 3\\n  days. Subjects were counted once for each symptom at the worst severity\\n  if they indicated experiencing the symptom at any severity during the\\n  reporting period. The number reported for \\\"Any Systemic Symptom\\\" is the\\n  number of subjects experiencing any systemic symptom as reported at the\\n  worst severity. Solicited reactogenicity was recorded without an\\n  attribution assessment. Grading was done by Division of AIDS Table for\\n  Grading the Severity of Adult and Pediatric Adverse Events Version 2.1.\\nPopulation Description:\\n  Subjects who received MAb114 (N=18), where \\\"N\\\" signifies number of\\n  subjects analyzed for this outcome measure.\\nReporting Status: POSTED\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\nTime Frame: 3 days after product administration\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=10)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG003\\nTitle: Overall (n=18)\\nDescription:\\n  Total number of subjects who received a single IV infusion of a Human\\n  Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 10\\n\\n##### Counts\\nGroup Id: OG003\\nValue: 18\\n\\n#### Classes\\nTitle: Malaise\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 8\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 15\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 2\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 3\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Myalgia\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 9\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 16\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 2\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Headache\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 8\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 14\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 2\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 4\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Chills\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 9\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 16\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 2\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Nausea\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 9\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 16\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 2\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Fever\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 10\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 18\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Joint Pain\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 9\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 16\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 2\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Any systemic symptom reported\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 8\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 14\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 2\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 4\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle:\\n  Number of Subjects Reporting Local Reactogenicity Signs and Symptoms\\n  Within 7 Days of Product Administration\\nDescription:\\n  Local reactogenicity symptoms were assessed and recorded by clinicians.\\n  Solicited local symptoms include pain/tenderness, swelling, redness,\\n  bruising, and pruritus (itchiness) at the product administration site.\\n  Clinicians assessed the study product administration site for local\\n  symptoms on the day of product administration after completion of the\\n  administration and on Days 1, 2 and 7 post administration. Subjects were\\n  counted once for each symptom at the worst severity if they experienced\\n  the symptom at any severity during the reporting period. If symptoms\\n  were experienced, clinicians collected resolution information for any\\n  symptom that wasn't resolved within 7 days. The number reported for \\\"Any\\n  Local Symptom\\\" is the number of subjects reporting any local symptom as\\n  reported at the worst severity. Solicited reactogenicity was recorded\\n  without attribution assessment. Grading was done by Division of AIDS\\n  Table for Grading the Severity of Adult and Pediatric Adverse Events\\n  Version 2.1.\\nPopulation Description:\\n  Subjects who received MAb114 (N=18), where \\\"N\\\" signifies number of\\n  subjects analyzed for this outcome measure.\\nReporting Status: POSTED\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\nTime Frame: 7 days after product administration\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=10)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG003\\nTitle: Overall (n=18)\\nDescription:\\n  Total number of subjects who received a single IV infusion of a Human\\n  Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 10\\n\\n##### Counts\\nGroup Id: OG003\\nValue: 18\\n\\n#### Classes\\nTitle: Pain/Tenderness\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 10\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 18\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Bruising\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 10\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 18\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Swelling\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 10\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 18\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Redness\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 10\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 18\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Pruritis\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 10\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 18\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Any Local Symptoms Reported\\n\\n##### Categories\\nTitle: None\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 10\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 18\\n\\n##### Categories\\nTitle: Mild\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Moderate\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n##### Categories\\nTitle: Severe\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle:\\n  Number of Subjects Reporting 1 or More Unsolicited Non-Serious Adverse\\n  Events\\nDescription:\\n  Unsolicited adverse events (AEs) collected during the period from study\\n  product administration at Day 0 through 28 days after product\\n  administration. After the indicated time period through the last\\n  expected study visit at 24 weeks after product administration, only new\\n  chronic medical conditions collected as unsolicited AEs.\\n\\n  The number reported is the number of subjects who experienced at least\\n  one AE in the reporting period. A subject with multiple experiences of\\n  the same event is counted once using the event of worst severity. The\\n  relationship between an AE and the product was assessed by the\\n  investigator on the basis of his or her clinical judgment and the\\n  protocol-specific definitions of Related - There is a reasonable\\n  possibility that the AE may be related to the study product and Not\\n  Related - There is not a reasonable possibility that the AE is related\\n  to the study product.\\nPopulation Description:\\n  Subjects who received MAb114 (N=18), where \\\"N\\\" signifies number of\\n  subjects analyzed for this outcome measure.\\nReporting Status: POSTED\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\nTime Frame: Through 24 weeks after product administration\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=10)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG003\\nTitle: Overall (n=18)\\nDescription:\\n  Total number of subjects who received a single IV infusion of a Human\\n  Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 10\\n\\n##### Counts\\nGroup Id: OG003\\nValue: 18\\n\\n#### Classes\\nTitle: Related to MAb114 Administration\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Not Related to MAb114 Administration\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 5\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 7\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Number of Subjects Reporting Serious Adverse Events\\nDescription:\\n  Serious adverse events (SAEs) collected during the period from study\\n  product administration at Day 0 through 24 weeks after product\\n  administration. Grading done by Division of AIDS Table for Grading the\\n  Severity of Adult and Pediatric Adverse Events Version 2.1. The\\n  relationship between a SAE and the product was assessed by the\\n  investigator on the basis of his or her clinical judgment and the\\n  protocol-specific definitions of Related - There is a reasonable\\n  possibility that the SAE may be related to the study product and Not\\n  Related - There is not a reasonable possibility that the SAE is related\\n  to the study product.\\nPopulation Description:\\n  Subjects who received MAb114 (N=18), where \\\"N\\\" signifies number of\\n  subjects analyzed for this outcome measure.\\nReporting Status: POSTED\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\nTime Frame: Through 24 weeks after product administration\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=10)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG003\\nTitle: Overall (n=18)\\nDescription:\\n  Total number of subjects who received a single IV infusion of a Human\\n  Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 10\\n\\n##### Counts\\nGroup Id: OG003\\nValue: 18\\n\\n#### Classes\\nTitle: Related to MAb114 Administration\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 0\\n\\n#### Classes\\nTitle: Not Related to MAb114 Administration\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 1\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 1\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Maximum Observed Serum Concentration (Cmax) of MAb114\\nDescription:\\n  Cmax is the peak serum concentration that MAb114 achieves after it has\\n  been administered; it is determined as a maximum value on the summary\\n  pharmacokinetic (PK) curve for each study group.\\nPopulation Description: Subjects with 28 days of pharmacokinetic data.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: \\u00b5g/mL\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=5)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 5\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 198.45\\nSpread: 45.15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 829.38\\nSpread: 237.40\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 1961.21\\nSpread: 339.83\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Time to Reach Maximum Observed Serum Concentration (Tmax) of MAb114\\nDescription:\\n  Tmax is the time it takes to reach Cmax of MAb114 after it has been\\n  administered; it is determined based on the summary PK curve for each\\n  study group.\\nPopulation Description: Subjects with 28 days of pharmacokinetic data.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: hours\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=5)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 5\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3.21\\nSpread: 1.56\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2.99\\nSpread: 2.16\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 2.75\\nSpread: 1.63\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Mean Serum Concentration of MAb114\\nDescription:\\n  The mean of individual subject MAb114 serum concentrations by\\n  administered dose group\\nPopulation Description: Subjects with 28 days of pharmacokinetic data.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: \\u00b5g/mL\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=5)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 5\\n\\n#### Classes\\nTitle: Concentration at Day 7\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 52.60\\nSpread: 22.19\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 373.12\\nSpread: 75.32\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 692.64\\nSpread: 201.63\\n\\n#### Classes\\nTitle: Concentration at Day 14\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 42.90\\nSpread: 5.53\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 272.91\\nSpread: 46.16\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 629.34\\nSpread: 118.19\\n\\n#### Classes\\nTitle: Concentration at Day 28\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 25.46\\nSpread: 5.96\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 180.19\\nSpread: 38.82\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 427.21\\nSpread: 88.43\\n\\n#### Classes\\nTitle: Average Concentration Days 0-28\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 52.87\\nSpread: 10.87\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 306.65\\nSpread: 32.14\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 663.87\\nSpread: 129.55\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Overall IV Half-life (T1/2) of MAb114\\nDescription:\\n  Half-life (T1/2) is the time required for half of the drug to be\\n  eliminated from the serum.\\nPopulation Description:\\n  Subjects with 56 days of pharmacokinetic data. No standard deviation\\n  reported for a Group 3 single subject data.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: days\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-56 days post-infusion\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=1)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG003\\nTitle: Overall (n=9)\\nDescription:\\n  Total number of subjects who received a single IV infusion of a Human\\n  Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 1\\n\\n##### Counts\\nGroup Id: OG003\\nValue: 9\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 20.1\\nSpread: 6.9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 26.7\\nSpread: 3.8\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 23.6\\n\\n##### Measurements\\nGroup Id: OG003\\nValue: 24.2\\nSpread: 1.8\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Area Under the Curve (AUC0-28D)\\nDescription:\\n  The AUC0-28D represents the total drug exposure in 28 days after MAb114\\n  administration; it is determined based on the summary PK curve for each\\n  group.\\nPopulation Description: Subjects with 28 days of pharmacokinetic data.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: \\u00b5g x day/mL\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=5)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 5\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1480\\nSpread: 304\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 8586\\nSpread: 900\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 18588\\nSpread: 3627\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Volume of Distribution (Vd) at Steady-state\\nDescription:\\n  Theoretical volume that would be necessary to contain the total amount\\n  of administered drug at the same concentration as observed in plasma. It\\n  represents the degree to which a drug is distributed in body tissue\\n  rather than the plasma and calculated based in the PK curve for each\\n  study group.\\nPopulation Description: Subjects with 28 days of pharmacokinetic data.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: Liters\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=5)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 5\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5.08\\nSpread: 0.88\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.93\\nSpread: 0.50\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 4.16\\nSpread: 0.74\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: MAb114 Clearance Rate\\nDescription:\\n  Rate of MAb114 elimination divided by the plasma MAb114 concentration;\\n  determined based on the summary PK curve for each study group.\\nPopulation Description: Subjects with 28 days of pharmacokinetic data.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: mL/day\\nTime Frame:\\n  Pre-infusion (baseline), end of infusion (0h), 1 hr, 3 hr, 6 hr, 24 hr,\\n  48 hr and 7-28 days post-infusion\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=5)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 5\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 199\\nSpread: 45\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 108\\nSpread: 21\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 115\\nSpread: 15\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Number of Subjects Who Produced Anti-drug Antibodies to MAb114\\nDescription: Serum samples collected 28 days and 56 days after MAb114 administration\\nPopulation Description: Subjects with serum samples collected at 28 days and 56 days.\\nReporting Status: POSTED\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\nTime Frame: Days 28 and 56 post-infusion\\n\\n#### Groups\\nId: OG000\\nTitle: Group 1: 5 mg/kg IV (n=3)\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG001\\nTitle: Group 2: 25 mg/kg IV (n=5)\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Groups\\nId: OG002\\nTitle: Group 3: 50 mg/kg IV (n=5)\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 5\\n\\n#### Classes\\nTitle: Day 28: Subjects with Anti-drug antibodies\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 5\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n#### Classes\\nTitle: Day 56: Subjects with Anti-drug antibodies\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 3\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 5\\n\\n##### Counts\\nGroup Id: OG002\\nValue: 1\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: OG002\\nValue: 0\\n\\n## Adverse Events Module\\nFrequency Threshold: 5\\nTime Frame:\\n  Solicited adverse events (AEs) included systemic AEs reported by\\n  subjects at the worst severity through 3 days post product\\n  administration; and local administration site AEs reported at the worst\\n  severity through 7 days post product administration. Unsolicited AEs\\n  were reported from the date of product administration through 28 days\\n  thereafter, and new chronic medical conditions and SAEs with onset any\\n  time following the date of product administration through 24 weeks.\\nDescription:\\n  Solicited AEs collected through systematic assessment and unsolicited\\n  AEs collected through non-systematic assessment represent the number and\\n  percentage of subjects reporting the event. The total number of subjects\\n  affected in Other AEs includes subjects reporting at least one solicited\\n  and/or unsolicited AE. A subject with multiple experiences of the same\\n  event is counted once using the event of worst severity. Solicited\\n  events are reported separately from unsolicited events.\\n\\n### Event Groups\\nId: EG000\\nTitle: Group 1: 5 mg/kg IV\\nDescription:\\n  Group 1 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\nDeaths Num Affected: 0\\nDeaths Num At Risk: 3\\nSerious Num Affected: 0\\nSerious Num At Risk: 3\\nOther Num Affected: 0\\nOther Num At Risk: 3\\n\\n### Event Groups\\nId: EG001\\nTitle: Group 2: 25 mg/kg IV\\nDescription:\\n  Group 2 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\nDeaths Num Affected: 0\\nDeaths Num At Risk: 5\\nSerious Num Affected: 0\\nSerious Num At Risk: 5\\nOther Num Affected: 3\\nOther Num At Risk: 5\\n\\n### Event Groups\\nId: EG002\\nTitle: Group 3: 50 mg/kg IV\\nDescription:\\n  Group 3 subjects received a single IV infusion of a Human Monoclonal\\n  Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50\\n  mg/kg.\\n\\n  VRC-EBOMAB092-00-AB (MAb114): VRC-EBOMAB092-00-AB (MAb114) is a human\\n  immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire\\n  ebolavirus (EBOV) glycoprotein (GP).\\nDeaths Num Affected: 0\\nDeaths Num At Risk: 10\\nSerious Num Affected: 1\\nSerious Num At Risk: 10\\nOther Num Affected: 5\\nOther Num At Risk: 10\\n\\n### Serious Events\\nTerm: Syncope\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 0\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Hordeolum\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 1\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 0\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Dyspepsia\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 1\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 0\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Abdominal pain\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 0\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Anaemia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 0\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Alanine aminotransferase increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 0\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Hypertension\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 0\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Upper respiratory tract infection\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 0\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 3\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Malaise\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 1\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 2\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Myalgia\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 1\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Headache\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 2\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 2\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Chills\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 1\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Nausea\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 1\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n### Other Events\\nTerm: Joint Pain\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (22.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Affected: 0\\nNum At Risk: 3\\n\\n#### Stats\\nGroup Id: EG001\\nNum Affected: 1\\nNum At Risk: 5\\n\\n#### Stats\\nGroup Id: EG002\\nNum Affected: 1\\nNum At Risk: 10\\n\\n## More Info Module\\n\\n### Certain Agreement\\nPi Sponsor Employee: True\\n\\n### Point Of Contact\\nTitle: Martin Gaudinski, MD\\nOrganization:\\n  Vaccine Research Center, National Institute of Allergy and Infectious\\n  Diseases, National Institutes of Health\\nEmail: martin.gaudinski@nih.gov\\nPhone: 301-451-8715\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Extract detailed reference materials and citations for the clinical study identified by NCT04280705."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_references",
                    "arguments": {
                        "nct_id": "NCT04280705"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_references",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Url: https://clinicaltrials.gov/study/NCT04280705\\n\\n# Protocol Section\\n\\n## References Module\\n\\n### References\\nPmid: 38657001\\nType: DERIVED\\nCitation:\\n  Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R,\\n  Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R,\\n  Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El\\n  Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Clifford Lane\\n  H, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study\\n  Group Members. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood\\n  Biomarkers Associated With Severe Disease Outcomes That Improve in\\n  Response to Remdesivir. J Infect Dis. 2024 Sep 23;230(3):624-634. doi:\\n  10.1093/infdis/jiae198.\\n\\n### References\\nPmid: 37466213\\nType: DERIVED\\nCitation:\\n  Hedskog C, Rodriguez L, Roychoudhury P, Huang ML, Jerome KR, Hao L,\\n  Ireton RC, Li J, Perry JK, Han D, Camus G, Greninger AL, Gale M Jr,\\n  Porter DP. Viral Resistance Analyses From the Remdesivir Phase 3\\n  Adaptive COVID-19 Treatment Trial-1 (ACTT-1). J Infect Dis. 2023 Nov\\n  2;228(9):1263-1273. doi: 10.1093/infdis/jiad270.\\n\\n### References\\nPmid: 36695483\\nType: DERIVED\\nCitation:\\n  Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N,\\n  Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M.\\n  Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev.\\n  2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.\\n\\n### References\\nPmid: 36442063\\nType: DERIVED\\nCitation:\\n  Potter GE, Bonnett T, Rubenstein K, Lindholm DA, Rapaka RR, Doernberg\\n  SB, Lye DC, Mularski RA, Hynes NA, Kline S, Paules CI, Wolfe CR, Frank\\n  MG, Rouphael NG, Deye GA, Sweeney DA, Colombo RE, Davey RT Jr, Mehta AK,\\n  Whitaker JA, Castro JG, Amin AN, Colombo CJ, Levine CB, Jain MK, Maves\\n  RC, Marconi VC, Grossberg R, Hozayen S, Burgess TH, Atmar RL, Ganesan A,\\n  Gomez CA, Benson CA, Lopez de Castilla D, Ahuja N, George SL, Nayak SU,\\n  Cohen SH, Lalani T, Short WR, Erdmann N, Tomashek KM, Tebas P. Temporal\\n  Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc\\n  Observational Study of Remdesivir Group Participants in the Adaptive\\n  COVID-19 Treatment Trial. Ann Intern Med. 2022 Dec;175(12):1716-1727.\\n  doi: 10.7326/M22-2116. Epub 2022 Nov 29.\\n\\n### References\\nPmid: 34473343\\nType: DERIVED\\nCitation:\\n  Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M,\\n  Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C,\\n  Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N.\\n  SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.\\n  Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi:\\n  10.1002/14651858.CD013825.pub2.\\n\\n### References\\nPmid: 34350582\\nType: DERIVED\\nCitation:\\n  Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V,\\n  Metzendorf MI, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the\\n  treatment of COVID-19. Cochrane Database Syst Rev. 2021 Aug\\n  5;8(8):CD014962. doi: 10.1002/14651858.CD014962.\\n\\n### References\\nPmid: 33240091\\nType: DERIVED\\nCitation:\\n  Sultana J, Crisafulli S, Gabbay F, Lynn E, Shakir S, Trifiro G.\\n  Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Front\\n  Pharmacol. 2020 Nov 6;11:588654. doi: 10.3389/fphar.2020.588654.\\n  eCollection 2020.\\n\\n### References\\nPmid: 32969710\\nType: DERIVED\\nCitation:\\n  Maleszewski JJ, Young PM, Ackerman MJ, Halushka MK. Urgent Need for\\n  Studies of the Late Effects of SARS-CoV-2 on the Cardiovascular System.\\n  Circulation. 2021 Mar 30;143(13):1271-1273. doi:\\n  10.1161/CIRCULATIONAHA.120.051362. Epub 2020 Sep 24. No abstract\\n  available.\\n\\n### References\\nPmid: 32445440\\nType: DERIVED\\nCitation:\\n  Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann\\n  E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW,\\n  Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA,\\n  Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM,\\n  Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren\\n  J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M,\\n  Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members.\\n  Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med.\\n  2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct\\n  8.\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Search for documented nucleotide changes in the BRCA1 gene, focusing on ClinVar and Cosmic as specific sources, and filter results by clinical significance, including only variants classified as pathogenic or likely pathogenic."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_variant_searcher",
                    "arguments": {
                        "query": {
                            "gene": "BRCA1",
                            "hgvsp": null,
                            "hgvsc": null,
                            "rsid": null,
                            "region": null,
                            "significance": [
                                "pathogenic",
                                "likely pathogenic"
                            ],
                            "max_frequency": null,
                            "min_frequency": null,
                            "cadd": null,
                            "polyphen": null,
                            "sift": null,
                            "sources": [
                                "clinvar",
                                "cosmic"
                            ],
                            "size": 40,
                            "offset": 0
                        }
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_variant_searcher",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Error executing tool variant_searcher: 1 validation error for variant_searcherArguments\\nquery.significance\\n  Input should be 'pathogenic', 'likely pathogenic', 'uncertain significance', 'likely benign' or 'benign' [type=enum, input_value=['pathogenic', 'likely pathogenic'], input_type=list]\\n    For further information visit https://errors.pydantic.dev/2.11/v/enum\"}], \"isError\": true}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Identify and provide detailed information on currently active research initiatives that specifically investigate the effectiveness of lifestyle interventions in the management of Type 2 Diabetes, with explicit focus on studies targeting middle-aged adults. Ensure that the condition is \"Type 2 Diabetes,\" the intervention involves \"lifestyle changes,\" the participant demographic pertains to \"middle-aged\" individuals, and the \"sponsor category\" is explicitly classified as \"non-profit.\" Provide a clear breakdown of these parameters for each study."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_searcher",
                    "arguments": {
                        "query": {
                            "conditions": [
                                "Type 2 Diabetes"
                            ],
                            "interventions": [
                                "lifestyle changes"
                            ],
                            "recruiting_status": "OPEN",
                            "age_group": "ADULT",
                            "sponsor_type": "ACADEMIC",
                            "study_type": null,
                            "nct_ids": null,
                            "lat": null,
                            "long": null,
                            "distance": null,
                            "min_date": null,
                            "max_date": null,
                            "date_field": null,
                            "phase": null,
                            "primary_purpose": null,
                            "intervention_type": null,
                            "study_design": null,
                            "sort": null,
                            "next_page_hash": null
                        }
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_searcher",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Error:\\n  Error 400: Error parsing query in advanced filter: Unknown area name:\\n  `SponsorType`\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Search for active clinical trials that investigate the efficacy of experimental antiviral therapies specifically targeting respiratory infections, ensuring you use \"respiratory infection\" as the identified condition, \"antiviral therapy\" as the specified intervention type, and filter results by a recruiting status of \"ACTIVE, not recruiting.\" Once identified, organize the extracted findings according to the earliest estimated study completion date, ensuring logical prioritization and analysis of timelines."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_searcher",
                    "arguments": {
                        "query": {
                            "conditions": [
                                "respiratory infection"
                            ],
                            "terms": null,
                            "interventions": null,
                            "recruiting_status": "OPEN",
                            "study_type": null,
                            "nct_ids": null,
                            "lat": null,
                            "long": null,
                            "distance": null,
                            "min_date": null,
                            "max_date": null,
                            "date_field": "COMPLETION",
                            "phase": null,
                            "age_group": null,
                            "primary_purpose": null,
                            "intervention_type": "DRUG",
                            "sponsor_type": null,
                            "study_design": null,
                            "sort": "COMPLETION_DATE",
                            "next_page_hash": null
                        }
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_searcher",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"# Record 1\\nNct Number: NCT05553743\\nStudy Title:\\n  Researchers At UC San Diego Are Learning About the Benefits of Human\\n  Milk and How It Influences Infant and Child Health\\nStudy Url: https://clinicaltrials.gov/study/NCT05553743\\nStudy Status: RECRUITING\\nBrief Summary:\\n  The purpose of the UCSD Human Milk Biorepository is to establish and\\n  maintain a repository of breast milk samples that can be used to learn\\n  more about how breast milk influences infant and child health.\\nStudy Results: NO\\nConditions: Breastfeeding|COVID-19 Infection|COVID-19 Vaccine|Remdesivir|Antibiotics\\nInterventions: BIOLOGICAL: COVID-19 Exposure|DRUG: Antibiotic\\nPhases:\\nEnrollment: 5000\\nStudy Type: OBSERVATIONAL\\nStudy Design: Observational Model: |Time Perspective: p\\nStart Date: 2014-03-27\\nCompletion Date: 2040-03\\n\\n# Record 2\\nNct Number: NCT07152587\\nStudy Title:\\n  Randomized Adaptive Platform Trial of Pathogen-Directed Anti-\\n  inflammatory Therapy in Severe Community-Acquired Pneumonia(Core\\n  Protocal)\\nStudy Url: https://clinicaltrials.gov/study/NCT07152587\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  Severe community-acquired pneumonia (sCAP) has a high mortality rate of\\n  25-50%. Excessive host inflammatory responses contribute to poor\\n  outcomes. Corticosteroid therapy may provide benefit; however, the\\n  optimal dosage remains unclear, and it is uncertain whether all\\n  etiologies (e.g., Pneumocystis jirovecii, adenovirus, influenza) of sCAP\\n  can benefit equally.\\n\\n  This study will first establish a comprehensive trial platform based on\\n  a prospective sCAP cohort, embedding a randomized, multifactorial,\\n  adaptive platform trial (APT). The response-adaptive design will\\n  increase the likelihood of patients being assigned to more effective\\n  treatment arms, while Bayesian statistical modeling will dynamically\\n  assess the efficacy of interventions, allowing early achievement of\\n  study endpoints.\\n\\n  At the starting stage, two pathogen-specific APTs will be conducted,\\n  focusing on adenovirus- and pneumocystis Jirovecii-induced sCAP.\\n  Patients admitted to the ICU with confirmed diagnoses of adenovirus or\\n  pneumocystis Jirovecii-associated sCAP will be randomized into a control\\n  group or one of two corticosteroid dosage groups. The primary endpoint\\n  will be 28-day all-cause mortality. Completion of these APTs will\\n  provide a theoretical basis for novel anti-inflammatory strategies in\\n  sCAP.\\n\\n  Moreover, this platform will serve as an essential research\\n  infrastructure for the efficient evaluation of new therapeutic options\\n  in the event of emerging or re-emerging respiratory pathogens causing\\n  sCAP in the future.\\nStudy Results: NO\\nConditions: Severe Community-acquired Pneumonia (sCAP)\\nInterventions:\\n  DRUG: Low dose steroids|DRUG: Moderate dose steroids|DRUG: Saline (0.9%\\n  NaCl)\\nPhases: PHASE2|PHASE3\\nEnrollment: 1500\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT\\nStart Date: 2025-09-08\\nCompletion Date: 2035-12-31\\n\\n# Record 3\\nNct Number: NCT05348148\\nStudy Title:\\n  Comparison of the Effects for Lightening the Shiners Among Different\\n  Treatments for Rhinitis\\nStudy Url: https://clinicaltrials.gov/study/NCT05348148\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Background: Shiners are caused when blood and other fluids accumulate in\\n  the infraorbital groove. It develops resulting from lots of problems. In\\n  patient with rhinitis, either allergic rhinitis or non-allergic\\n  rhinitis, shiners are believed to be caused by venous stasis resulting\\n  from nasal congestion. This study is aiming that comparison of the\\n  effectiveness of treatment of rhinitis (either allergic rhinitis or non-\\n  allergic rhinitis) to lighten not only the rhinitis but also the\\n  shiners. Randomized control studies.\\n\\n  Design: The investigators will recruit children (6-12 y/0), adolescent\\n  (13-18 y/o), or adults (19-65 y/o) with either allergic rhinitis or non-\\n  allergic rhinitis, and patients will be randomly assigned to groups\\n  (oral antihistamine, combined nasal corticosteroids with oral\\n  antihistamine, combined nasal corticosteroids with oral antihistamine\\n  plus nasal decongestant, combined nasal corticosteroids with oral\\n  antihistamine plus nasal irrigation, combined oral antihistamine with\\n  nasal irrigation, or nasal antihistamine only). Digital image will be\\n  recorded and analyzed to compare the change of shiners between before\\n  and after treatment for rhinitis. The clinical data were collected\\n  including patient's data, history, laboratory data, Pediatric\\n  Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), Adolescent\\n  Rhinoconjunctivitis Quality of Life Questionnaire (AdolRQLQ), or mini\\n  Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ), and\\n  medications. The primary outcome is to answer whether the levels of\\n  shiners can be alleviated by using therapies in patient with rhinitis.\\n  And the secondary outcome is to figure out which therapies work most\\n  effectively.\\n\\n  Keywords: allergic rhinitis, vasomotor rhinitis, shiners, nasal\\n  corticosteroids\\nStudy Results: NO\\nConditions: Allergic Rhinitis|Vasomotor Rhinitis\\nInterventions:\\n  DRUG: Oral Levocetirizine|DRUG: Combined Intranasal Mometasone Furoate\\n  with oral Levocetirizine|DRUG: Combined Intranasal Mometasone Furoate\\n  with oral Levocetirizine plus intranasal Oxymetazoline\\nPhases: NA\\nEnrollment: 450\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE\\n  (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\nStart Date: 2020-06-16\\nCompletion Date: 2032-03-31\\n\\n# Record 4\\nNct Number: NCT07079150\\nStudy Title:\\n  Real-world Study Evaluating the Long-term Outcomes of Pegylated\\n  Interferon \\u03b1-2b Treatment in the Families With Clusters of HBV Infection\\n  and Unfavorable Prognosis - A Prospective, Controlled, Multicenter,\\n  Cohort Study\\nStudy Url: https://clinicaltrials.gov/study/NCT07079150\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Chronic hepatitis B can develop into cirrhosis and liver cancer, which\\n  seriously endangers the life and health of people. In China, HBV is\\n  mainly transmitted from mother to child, showing the phenomenon of\\n  family clusters. Similarly, cirrhosis and hepatocellular carcinoma occur\\n  in familial clusters. Familial clusters of HBV infection with\\n  unfavorable prognoses refers to HBV-infected patients from two\\n  consecutive generations of blood relatives, with at least one family\\n  member diagnosed with hepatitis B-related cirrhosis or hepatocellular\\n  carcinoma (HCC). Previous family investigations have shown that the risk\\n  and harm of HBV-related cirrhosis and hepatocellular carcinoma are\\n  significantly higher in families with familial clusters of HBV infection\\n  with unfavorable prognoses than in the general population.\\n\\n  Currently, antiviral drugs used for CHB mainly include nucleoside\\n  analogues (NAs) and interferon-alpha (mainly pegylated interferon-alpha,\\n  Peg IFN). NAs mainly inhibits viral replication by blocking the reverse\\n  transcription process, but it cannot effectively inhibit the expression\\n  of viral proteins such as HBsAg, and rarely achieves clinical cure.\\n  Multiple clinical studies have shown that the use of NAs reduces the\\n  incidence of cirrhosis decompensation, HCC, and death in patients with\\n  CHB compared to untreated or placebo-treated patients. Despite long-term\\n  treatment with first-line NAs drugs, CHB patients continue to be at risk\\n  of developing hepatocellular carcinoma. Peg IFN \\u03b1-2b injection is the\\n  first-line drug of choice for antiviral treatment of chronic hepatitis\\n  B, and its main mechanism of action includes anti-HBV, anti-fibrosis,\\n  anti-tumor and regulation of immune response. In 2024, a randomized\\n  controlled multicenter study showed that Peg IFN \\u03b1-2b combined with NAs\\n  therapy could effectively prevent hepatocellular carcinoma in CHB\\n  patients. There is sufficient evidence in clinical practice that long-\\n  term antiviral therapy, whether NAs or Peg IFN \\u03b1-2b, reduces the risk of\\n  cirrhosis, hepatocellular carcinoma, and death in patients with CHB. In\\n  conclusion, early antiviral therapy can reduce the risk of developing\\n  hepatitis B cirrhosis and hepatocellular carcinoma in CHB patients with\\n  familial clusters of HBV infection with unfavorable prognoses.\\n\\n  The goal of this observational study is to explore the evaluation of\\n  pegylated interferon \\u03b1-2b combined with first-line NAs on the long-term\\n  outcome of CHB antiviral therapy with cirrhosis and HCC progression as\\n  the main observation targets, compared with only use of NAs in the\\n  context of familial clusters of HBV infection with unfavorable\\n  prognoses. It is intended to provide high-quality evidence-based medical\\n  evidence for the treatment and follow-up of CHB, explore optimal\\n  clinical decision-making, and provide global clinical data for the\\n  improvement and evaluation of this difficult-to-treat population. The\\n  main question it aims to answer is: Can Peg IFN-\\u03b1-2B combined with NAs\\n  therapy improve the long-term outcomes of this particular population of\\n  familial clusters of HBV infection with unfavorable prognoses compared\\n  to first-line NAs monotherapy? Patients with familial clusters of HBV\\n  infection with unfavorable prognoses using Peg IFN-\\u03b1-2B combined with\\n  NAs therapy and NAs monotherapy will be collected laboratory and medical\\n  examination data at specified follow-up points, and recorded adverse\\n  events and drug combinations in detail for 7 years.\\nStudy Results: NO\\nConditions: Hepatitis B, Chronic (CHB)|Hepatitis B|Hepatitis B Virus (HBV)\\nInterventions: DRUG: Peg IFN-\\u03b1-2b\\nPhases:\\nEnrollment: 1500\\nStudy Type: OBSERVATIONAL\\nStudy Design: Observational Model: |Time Perspective: p\\nStart Date: 2025-01-01\\nCompletion Date: 2032-01\\n\\n# Record 5\\nNct Number: NCT06441006\\nStudy Title:\\n  Program for Rifampicin-Resistant Disease With Stratified Medicine for\\n  Tuberculosis\\nStudy Url: https://clinicaltrials.gov/study/NCT06441006\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  PRISM-TB is an international, seamless, multicenter, open-label,\\n  randomized, controlled, pragmatic, stratified medicine, treatment\\n  shortening, multi-arm multi-stage (MAMS), noninferiority Phase 2/3\\n  clinical trial for fluoroquinolone-susceptible multidrug-\\n  resistant/rifampin-resistant pulmonary tuberculosis (FQ-S MDR/RR-TB). In\\n  Stage 1, participants will be randomized among one of three treatment\\n  arms (one control and two experimental). Following the interim analysis\\n  (at the end of Stage 1) based on DOOR outcome comparisons and the\\n  entirety of the data, one of the four possible experimental strategies\\n  will be identified and continue into Stage 2. In Stage 2, participants\\n  will be randomized among one of two treatment arms (one control and one\\n  experimental).\\n\\n  The trial objective is to identify, among participants with\\n  fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant\\n  tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17\\n  weeks for participants stratified to receive shorter treatment and 17 or\\n  24 weeks for participants stratified to receive longer treatment, as\\n  defined by a prespecified stratification algorithm, and to evaluate\\n  whether this BPaLM strategy has noninferior efficacy to the control\\n  strategy at Week 73.\\nStudy Results: NO\\nConditions:\\n  Tuberculosis, Pulmonary|Tuberculosis, Multidrug-Resistant|Tuberculosis,\\n  MDR\\nInterventions:\\n  DRUG: Bedaquiline|DRUG: Linezolid|DRUG: Pretomanid|DRUG:\\n  Moxifloxacin|DRUG: Control Arm FQ-S MDR/RR-TB regimen, designed\\n  according to latest international guidelines\\nPhases: PHASE2|PHASE3\\nEnrollment: 400\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2025-09\\nCompletion Date: 2031-08\\n\\n# Record 6\\nNct Number: NCT06667700\\nStudy Title:\\n  A Clinical Study of Molnupiravir to Prevent Severe Illness From\\n  Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk\\n  (MK-4482-023)\\nStudy Url: https://clinicaltrials.gov/study/NCT06667700\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Researchers are looking for other ways to prevent severe illness from\\n  COVID-19. COVID-19 is a virus that most often causes mild flu or cold-\\n  like symptoms. However, people with certain health conditions or other\\n  factors have a high risk (chance) of getting severely ill from COVID-19,\\n  which can require a hospital stay or lead to death. Some people who are\\n  high risk for severe illness may be unable to take certain treatments\\n  for COVID-19 because they are not available to them, or they take other\\n  medicines that may react with a treatment and cause an unwanted effect.\\n\\n  Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19\\n  virus from copying itself in the body (multiplying). The goal of this\\n  study is to learn if molnupiravir prevents severe illness from COVID-19\\n  more than placebo in people who are high risk.\\nStudy Results: NO\\nConditions: Coronavirus Disease (COVID-19)\\nInterventions: DRUG: Molnupiravir|DRUG: Placebo\\nPhases: PHASE3\\nEnrollment: 3082\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE\\n  (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT\\nStart Date: 2024-12-02\\nCompletion Date: 2031-01-26\\n\\n# Record 7\\nNct Number: NCT04725110\\nStudy Title:\\n  Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of\\n  COVID-19 Acute Respiratory Distress Syndrome\\nStudy Url: https://clinicaltrials.gov/study/NCT04725110\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  Acute treatment of COVID-ARDS with direct topical lung instilled T3\\n  therapy for patients on mechanical ventilation.\\nStudy Results: NO\\nConditions: Covid19|SARS-CoV Infection|ARDS|ARDS, Human\\nInterventions: DRUG: Instilled T3|OTHER: Placebo Therapy\\nPhases: PHASE2\\nEnrollment: 250\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2026-01-15\\nCompletion Date: 2031-10-15\\n\\n# Record 8\\nNct Number: NCT06441955\\nStudy Title:\\n  Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial\\n  Acceleration Program.\\nStudy Url: https://clinicaltrials.gov/study/NCT06441955\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Investigators are conducting a study on alternative treatments for\\n  patients who have received an current or previous positive COVID-19\\n  diagnosis with mild-serve symptoms or undiagnosable condition after\\n  testing positive for severe acute COVID-19 infection and are\\n  experiencing long-haul symptoms. The symptoms of long COVID can include\\n  extreme tiredness (fatigue), shortness of breath, memory and\\n  concentration issues (brain fog), heart palpitations, dizziness, joint\\n  pain, muscle aches, cough, headaches, anxiety, and depression.\\n\\n  It's important to note that there are various other symptoms that\\n  individuals can experience after a COVID-19 infection, such as loss of\\n  smell, chest pain or tightness, difficulty sleeping (insomnia), pins and\\n  needles, depression, anxiety, tinnitus, earaches, nausea, diarrhea,\\n  stomach aches, loss of appetite, cough, headaches, sore throat, and\\n  changes to the sense of smell or taste.\\n\\n  To be included in the study, participants must have had symptoms for\\n  more than 4 weeks. The goal of the study is to measure biomarkers,\\n  identify new ones through clinical trials, and individualize and\\n  optimize treatment plans, which may or may not include COVID-19 post-\\n  market antivirals, vaccines, and medical care.\\n\\n  It's essential to conduct thorough clinical trials to understand the\\n  long-term effects of COVID-19 and to develop personalized treatment\\n  plans for individuals experiencing long-haul symptoms.\\nStudy Results: NO\\nConditions: COVID-19, Long Haul\\nInterventions:\\n  DRUG: Ritonavir-Boosted Nirmatrelvir (Paxlovid)|DIAGNOSTIC_TEST:\\n  Physiological Evaluation|BIOLOGICAL: Moderna COVID-19\\n  Vaccine|BEHAVIORAL: Biopsychological|BEHAVIORAL: Behavioral (e.g.,\\n  Psychotherapy, Lifestyle Counseling)|GENETIC: Genetic (including gene\\n  transfer, stem cell and recombinant DNA)|COMBINATION_PRODUCT:\\n  Multidisciplinary approach\\nPhases: PHASE4\\nEnrollment: 100\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: BASIC_SCIENCE\\nStart Date: 2024-03-01\\nCompletion Date: 2030-09-30\\n\\n# Record 9\\nNct Number: NCT06494878\\nStudy Title:\\n  The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue\\n  Morbidity\\nStudy Url: https://clinicaltrials.gov/study/NCT06494878\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  The goal of the PARTUM trial is to determine if taking low-dose aspirin\\n  daily for 6 weeks after delivery is similar (non-inferior) to usual care\\n  low-molecular-weight heparin injections to prevent venous\\n  thromboembolism (VTE: blood clots in the legs or lungs) for postpartum\\n  individuals with VTE risk factors.\\nStudy Results: NO\\nConditions:\\n  Venous Thromboembolism|Postpartum Period|Aspirin|Low Molecular Weight\\n  Heparin\\nInterventions: DRUG: Aspirin|DRUG: Low-molecular-weight heparin\\nPhases: PHASE3\\nEnrollment: 8805\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: PREVENTION\\nStart Date: 2025-04\\nCompletion Date: 2030-12\\n\\n# Record 10\\nNct Number: NCT06814496\\nStudy Title:\\n  Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing\\n  Tumors\\nStudy Url: https://clinicaltrials.gov/study/NCT06814496\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Phase I study to examine safety of the addition of concurrent tarlatamab\\n  with standard palliative and consolidative RT regimens , with a main\\n  cohort of N=20-24 patients with extracranial anatomic radiation sites.\\n\\n  I) After lead in of 10 patients demonstrating safety of treatment, allow\\n  for expansion to cranial sites of disease (N=6-10) with continued\\n  enrollment in main cohort II) If toxicity criteria is not met in\\n  concurrent RT tarlatamab cohort, we will continue with sequential RT,\\n  either A) delivered within 7 days prior to cycle 1 day 1, or B)\\n  delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days\\n  with no drug during RT, to examine safety in a temporally spaced\\n  setting.\\n\\n  III) If sequential tarlatamab and radiation is not deemed safe, we would\\n  allow for continued enrollment to assess efficacy of drug sans radiation\\n  treatment, enriching for tumors not of small cell lung cancer histology\\n  and allowing for patients without sites amenable to RT.\\n\\n  A nested phase II study will attempt to assess for ORR and safety of\\n  study intervention amongst tumors not of small cell lung cancer\\n  histology.\\nStudy Results: NO\\nConditions:\\n  Melanoma|Medullary Thyroid Cancer|Sinonasal Undifferentiated\\n  Carcinoma|Esthesioneuroblastoma|Bladder Cancer|Testicular\\n  Cancer|Glioblastoma Multiforme|Cervical Cancer|Large Cell Neuroendocrine\\n  Carcinoma of the Lung|Non Small Cell Lung Cancer|Merkel Cell Carcinoma\\nInterventions:\\n  DRUG: Tarlatamab|RADIATION: Concurrent Radiation Therapy|RADIATION:\\n  Sequential Radiation therapy\\nPhases: PHASE1|PHASE2\\nEnrollment: 30\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2025-09\\nCompletion Date: 2030-05\\n\\n# Record 11\\nNct Number: NCT07076225\\nStudy Title: Ultra-Short Regimen for Elderly DS-TB\\nStudy Url: https://clinicaltrials.gov/study/NCT07076225\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  Tuberculosis (TB) remains one of the leading global public health\\n  concerns and is among the top ten causes of death from a single\\n  infectious agent. China ranks third worldwide in total TB burden, with a\\n  substantial proportion of cases classified as drug-susceptible TB (DS-\\n  TB). Despite the availability of effective standard treatment regimens,\\n  the current 6-month therapy duration poses challenges in terms of\\n  patient adherence, resource allocation, and overall treatment success.\\n\\n  In recent years, ultrashort-course regimens for DS-TB have been proposed\\n  and evaluated in clinical studies, showing promising results in\\n  improving adherence, reducing treatment duration, and maintaining or\\n  even enhancing treatment efficacy. However, these regimens have\\n  primarily been studied in younger populations, with limited data\\n  available for elderly patients. Older adults often present with age-\\n  related physiological changes, multiple comorbidities, and an increased\\n  risk of adverse drug reactions, which may affect both the efficacy and\\n  safety of treatment.\\n\\n  Therefore, this study aims to assess the therapeutic effectiveness and\\n  safety profile of a novel ultrashort-course regimen for drug-susceptible\\n  pulmonary TB specifically in patients aged 65 years and older.\\nStudy Results: NO\\nConditions: Pulmonary Tuberculosis\\nInterventions:\\n  DRUG: Bedaquiline (B)|DRUG: Sitafloxacin (S)|DRUG: Linezolid (L)|DRUG:\\n  Pyrazinamide (Z)|DRUG: Isoniazid (H)|DRUG: Rifampicin (R)|DRUG:\\n  Ethambutol (E)\\nPhases: PHASE3\\nEnrollment: 300\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE\\n  (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT\\nStart Date: 2025-07-25\\nCompletion Date: 2030-07-31\\n\\n# Record 12\\nNct Number: NCT06946264\\nStudy Title:\\n  Characterization of Bronchodilator Response in Children With\\n  Bronchiolitis Using Phenotypic and Genotypic Features\\nStudy Url: https://clinicaltrials.gov/study/NCT06946264\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Bronchiolitis is the leading cause of pediatric morbidity and healthcare\\n  costs. Despite the commonplace use of bronchodilator treatments, like\\n  albuterol, in conditions like asthma, their efficacy in bronchiolitis\\n  remains controversial due to the heterogeneity in patient response.\\n  Although studies indicate that bronchodilators do not enhance outcomes\\n  in bronchiolitis, meta-analyses can obscure the heterogeneity of\\n  treatment effects. While bronchodilator response genetics have not been\\n  explored in bronchiolitis, treatment effectiveness variations often\\n  depend on genomic factors. Genome-wide association studies (GWAS) have\\n  linked genetic variants with bronchodilator response and outcomes in\\n  childhood asthma, suggesting a bronchodilator-responsive genotype. This\\n  proposal aims to extend this paradigm to bronchiolitis, addressing the\\n  gap in knowledge where GWAS and clinical characteristics intersect. The\\n  proposed study's objective is to characterize phenotypic and genotypic\\n  variations of children with bronchiolitis and their association with\\n  bronchodilator response. We hypothesize that children with bronchiolitis\\n  who exhibit clinical and historical characteristics associated with\\n  atopy and specific physical findings have genetic variants linked to\\n  bronchodilator response. To achieve this, we propose to (Aim 1) define\\n  airway responsiveness to bronchodilator treatment in children with\\n  bronchiolitis using the change in respiratory score, (Aim 2a) identify\\n  the associations between candidate genetic variants and bronchodilator\\n  response among children with bronchiolitis, and (Aim 2b) determine the\\n  associations between candidate genetic variants and clinical patient\\n  data to identify bronchodilator-responsive children with bronchiolitis.\\n  A prospective, double-blind, randomized, placebo-controlled trial of a\\n  single albuterol dose in children aged 3 to 24 months presenting with\\n  bronchiolitis to the emergency department will be conducted to achieve\\n  these aims. Patient information and respiratory assessment outcomes will\\n  be collected before and after intervention. Blood, urine, DNA buccal\\n  swabs, and nasopharyngeal swabs will also be collected. Completion of\\n  these aims will result in a novel clinical prediction model for\\n  bronchodilator response determination in bronchiolitis, integrating\\n  clinical, physical, and genetic data. Furthermore, this research\\n  supports the candidates' career development goals of advancing training\\n  in clinical trial research design and execution and becoming an expert\\n  in clinical and translational methods to enhance pediatric emergency\\n  department health and outcomes. Ultimately, this work will inform an R01\\n  application to validate an evidence-based prediction rule for\\n  identifying bronchodilator-responsive children with bronchiolitis\\n  through a multi-center emergency medicine research network, optimizing\\n  therapeutic approaches, and reducing resource use in those with a low\\n  likelihood of bronchodilator response.\\nStudy Results: NO\\nConditions: Bronchiolitis|Bronchodilator Agents\\nInterventions:\\n  DRUG: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution|DRUG:\\n  Sodium Chloride 0.9% Inhl 3Ml\\nPhases: PHASE3\\nEnrollment: 400\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT\\nStart Date: 2022-07-08\\nCompletion Date: 2030-12-31\\n\\n# Record 13\\nNct Number: NCT06619561\\nStudy Title:\\n  A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-\\n  Versus-Host Disease (cGVHD)\\nStudy Url: https://clinicaltrials.gov/study/NCT06619561\\nStudy Status: RECRUITING\\nBrief Summary:\\n  The purpose of this study is to determine if vimseltinib is safe,\\n  tolerable and works effectively to treat adults with active moderate to\\n  severe cGVHD. Participants will be treated with vimseltinib in 28-day\\n  treatment cycles for approximately 2 years.\\nStudy Results: NO\\nConditions: Chronic Graft-Versus-Host Disease (cGVHD)\\nInterventions: DRUG: Vimseltinib\\nPhases: PHASE2\\nEnrollment: 36\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary\\n  Purpose: TREATMENT\\nStart Date: 2024-11-21\\nCompletion Date: 2029-10\\n\\n# Record 14\\nNct Number: NCT06860542\\nStudy Title:\\n  Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in\\n  Checkpoint Inhibitor Pneumonitis\\nStudy Url: https://clinicaltrials.gov/study/NCT06860542\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  The introduction of immune checkpoint inhibitors (immunotherapy) that\\n  stimulate our immune system to recognize and attack cancer cells has\\n  been one of the most exciting advances in oncology over the last decade.\\n  These medications are now employed across almost half of cancer types\\n  and settings, however they come with a cost. In some patients, instead\\n  of attacking cancer cells alone, the stimulated immune system damages\\n  healthy tissues (immune related adverse events), with one of the most\\n  severe and potentially deadly such complications being immune attack on\\n  the lungs, or checkpoint inhibitor pneumonitis (CIP). When treated\\n  promptly with oral or intravenous steroids, acute CIP improves in many\\n  cases, however for approximately one-fifth of patients the lung\\n  inflammation is difficult to control, resulting in recurrent shortness\\n  of breath, the need for extended courses of oral or intravenous\\n  steroids, impacting quality of life and cancer therapy decisions. The\\n  goal of the trial is to assess whether use of inhaled steroids, a type\\n  of medication commonly used in asthma patients, for one year after a\\n  first diagnosis of CIP may help the lung inflammation resolve and not\\n  return, without the repeated use of oral or intravenous medications that\\n  carry more side effects.\\nStudy Results: NO\\nConditions: Pneumonitis|Immune-related Adverse Event\\nInterventions:\\n  DRUG: Arm 2- Budesonide (Pulmicort\\u00ae Turbuhaler\\u00ae) + Usual care|OTHER: Arm\\n  1- Usual care\\nPhases: PHASE2\\nEnrollment: 94\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2025-09-01\\nCompletion Date: 2030-09-01\\n\\n# Record 15\\nNct Number: NCT03228667\\nStudy Title:\\n  QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have\\n  Previously Received Treatment With Immune Checkpoint Inhibitors\\nStudy Url: https://clinicaltrials.gov/study/NCT03228667\\nStudy Status: RECRUITING\\nBrief Summary:\\n  This Phase 2b, multicohort, open-label clinical trial (QUILT-3.055)\\n  evaluates combination immunotherapies in patients with various advanced\\n  solid tumors who have progressed following prior PD-1/PD-L1 checkpoint\\n  inhibitor therapy. The trial includes six cohorts:\\n\\n  Cohorts 1-4: Patients who progressed after an initial response (PR or\\n  CR) to prior PD-1/PD-L1 therapy, receiving combination therapy with\\n  N-803 and a PD-1/PD-L1 checkpoint inhibitor. (Closed to enrollment)\\n\\n  Cohort 5: Patients who progressed while receiving treatment in cohorts\\n  1-4; they receive combination therapy with N-803, a PD-1/PD-L1\\n  checkpoint inhibitor, and PD-L1 t-haNK cells.(Closed to enrollment)\\n\\n  Cohort 6A \\\\& 6B: Patients with acquired resistance to prior PD-1/PD-L1\\n  therapy; they receive combination therapy with N-803, docetaxel, and\\n  either pembrolizumab (6A) or nivolumab (6B).\\n\\n  Treatment is administered for up to two years or until disease\\n  progression, and participants are closely monitored for adverse events\\n  (AEs), including immune-related AEs, with specific dose modifications\\n  outlined. The primary endpoint is objective response rate (ORR) assessed\\n  by RECIST v1.1. The study uses Simon's two-stage design for cohorts 1-3\\n  to determine the optimal dose and further assesses safety and efficacy\\n  endpoints for all cohorts.\\nStudy Results: NO\\nConditions:\\n  Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Urothelial\\n  Carcinoma|Head and Neck Squamous Cell Carcinoma|Merkel Cell\\n  Carcinoma|Melanoma|Renal Cell Carcinoma|Gastric Cancer|Cervical\\n  Cancer|Hepatocellular Carcinoma|Microsatellite Instability|Mismatch\\n  Repair Deficiency|Colorectal Cancer\\nInterventions:\\n  DRUG: N-803 + Pembrolizumab|DRUG: N-803 + Nivolumab|DRUG: N-803 +\\n  Atezolizumab|DRUG: N-803 + Avelumab|DRUG: N-803 + Durvalumab|DRUG: N-803\\n  + Pembrolizumab + PD-L1 t-haNK|DRUG: N-803 + Nivolumab + PD-L1\\n  t-haNK|DRUG: N-803 + Atezolizumab + PD-L1 t-haNK|DRUG: N-803 + Avelumab\\n  + PD-L1 t-haNK|DRUG: N-803 + Durvalumab + PD-L1 t-haNK|DRUG: N-803 +\\n  Docetaxel + Pembrolizumab|DRUG: N-803 + Docetaxel + Nivolumab\\nPhases: PHASE2\\nEnrollment: 40\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2018-12-11\\nCompletion Date: 2030-12-31\\n\\n# Record 16\\nNct Number: NCT04310930\\nStudy Title: Finding the Optimal Regimen for Mycobacterium Abscessus Treatment\\nStudy Url: https://clinicaltrials.gov/study/NCT04310930\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Mycobacterium abscessus (MABS) is a group of rapid-growing, multi-drug\\n  resistant non-tuberculous mycobacteria (NTM) causing infections in\\n  humans. MABS pulmonary disease (MABS-PD) can result in significant\\n  morbidity, increased healthcare utilisation, accelerated lung function\\n  decline, impaired quality of life, more challenging lung\\n  transplantation, and increased mortality. While the overall numbers\\n  affected is small, the prevalence of infections is increasing worldwide.\\n  The Finding the Optimal Regimen for Mycobacterium abscessus Treatment\\n  (FORMaT) trial aims to produce high quality evidence for the best\\n  treatment regimens to maximise health outcomes and minimise toxicity and\\n  treatment burden, as well as developing biomarkers (serology, gene\\n  expression signatures, and radiology) to guide decisions for starting\\n  treatment and measuring disease severity in patients with MABS PD.\\nStudy Results: NO\\nConditions: Pulmonary Disease Due to Mycobacteria (Diagnosis)\\nInterventions:\\n  DRUG: Amikacin|DRUG: Tigecycline|DRUG: Imipenem|DRUG: Cefoxitin|DRUG:\\n  Azithromycin|DRUG: Clarithromycin|DRUG: Clofazimine|DRUG:\\n  Ethambutol|DRUG: Amikacin|DRUG: Linezolid|DRUG: co-trimoxazole|DRUG:\\n  Doxycycline|DRUG: Moxifloxacin|DRUG: Bedaquiline|DRUG: Rifabutin\\nPhases: PHASE2|PHASE3\\nEnrollment: 300\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2020-03-02\\nCompletion Date: 2030-06-30\\n\\n# Record 17\\nNct Number: NCT06881927\\nStudy Title:\\n  Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients\\n  Patients Admitted to the Intensive Care Unit for Septic Shock and/or\\n  Acute Respiratory Failure\\nStudy Url: https://clinicaltrials.gov/study/NCT06881927\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  Kidney transplantation is the treatment of choice for end-stage chronic\\n  kidney disease. Kidney transplantation is at the first rank of solid\\n  organ transplantation in France, with 3,376 grafts performed in 2022.\\n  Immunosuppressive therapy, required to prevent graft rejection, exposes\\n  graft recipients to complications related to decreased immunity,\\n  including opportunistic infections and neoplastic complications.\\n\\n  After the earlt post-transplantation period, up to 10% of kidney\\n  transplant recipients will require admission to the intensive care unit\\n  (ICU). The main reasons for admission are septic shock and acute\\n  hypoxemic respiratory failure. ICU stay has a significant impact on\\n  these patients with a mortality rate reaching 40%, that remains\\n  increased even after ICU discharge. Furthermore, an impact on graft\\n  function has been demonstrated, with deterioration of graft function in\\n  1/3 of patients, and among those, up to one in two will require\\n  resumption of renal replacement therapy (RRT).\\n\\n  Although the occurrence of septic shock or acute respiratory failure\\n  related to an infection is more common and severe, the optimal\\n  management strategy for immunosuppressors is not defined in kidney\\n  transplant recipients admitted to the ICU in those settings.\\n\\n  Maintain a high level of immunosuppressive therapies may hinder the\\n  recovery from the acute critical condition. Furthermore, these\\n  treatments have a narrow therapeutic index; for instance, the management\\n  of calcineurin inhibitors is challenging in the ICU due to\\n  pharmacodynamic changes associated with the acute situation\\n  (distribution volume, organ failure) and the numerous potential drug\\n  interactions that carry inherent risks of overdose.\\n\\n  the investigators hypothesize that a reduction in the level of\\n  immunosuppressive treatments could promote recovery in kidney transplant\\n  recipients admitted to the ICU for septic shock and/or acute hypoxemic\\n  respiratory failure, without adversely affecting the risk of rejection\\n  or long-term renal prognosis.\\nStudy Results: NO\\nConditions:\\n  Sepsis and Septic Shock|Acute Respiratory Failure|Kidney Transplant\\n  Recipients|Immunosuppressive Agents\\nInterventions:\\n  DRUG: Hydrocortisone Hemisuccinate: 200 mg per day.|OTHER: reduction of\\n  the level of immunosuppression\\nPhases: PHASE4\\nEnrollment: 212\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: SUPPORTIVE_CARE\\nStart Date: 2025-06-01\\nCompletion Date: 2029-06-01\\n\\n# Record 18\\nNct Number: NCT06350448\\nStudy Title: Washed Microbiota Transplantation for Rhinitis\\nStudy Url: https://clinicaltrials.gov/study/NCT06350448\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  The common symptoms of rhinitis include nasal itching, sneezing,\\n  anterior or posterior nasal leakage, and nasal congestion. Rhinitis can\\n  be classified as allergic rhinitis (AR) and non-allergic rhinitis (NAR)\\n  based on the presence of a specific allergen. Increasing evidence showed\\n  that gut microbiota can influence the development of AR. Although few\\n  studies have reported the association between NAR and gut microbiota, we\\n  found that washed microbiota transplantation (WMT) could improve nasal\\n  symptoms, whether it is AR or NAR. This clinical trial aims to evaluate\\n  the efficacy and safety of WMT for rhinitis.\\nStudy Results: NO\\nConditions: Rhinitis\\nInterventions: DRUG: Washed Microbiota Transplantation\\nPhases: NA\\nEnrollment: 40\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary\\n  Purpose: TREATMENT\\nStart Date: 2024-05-01\\nCompletion Date: 2029-08-01\\n\\n# Record 19\\nNct Number: NCT07115043\\nStudy Title:\\n  A Study to Investigate Safety of AZD6750 in Adult Participants With\\n  Select Advanced or Metastatic Solid Tumors\\nStudy Url: https://clinicaltrials.gov/study/NCT07115043\\nStudy Status: RECRUITING\\nBrief Summary:\\n  A Study to Investigate Safety of AZD6750 in Adult Participants With\\n  Select Advanced or Metastatic Solid Tumors\\nStudy Results: NO\\nConditions:\\n  Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma (Skin)|Renal\\n  Cell Carcinoma|Merkel Cell Carcinoma|Triple Negative Breast Cancer|Head\\n  and Neck Squamous Cell Carcinoma|Gastric Cancer/Gastroesophageal\\n  Junction Cancer|High Grade Serous Ovarian Carcinoma\\nInterventions: DRUG: AZD6750|DRUG: rilvegostomig\\nPhases: PHASE1|PHASE2\\nEnrollment: 60\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2025-07-29\\nCompletion Date: 2029-04-09\\n\\n# Record 20\\nNct Number: NCT06981078\\nStudy Title:\\n  A Study to Assess the Efficacy and Safety of Verekitug in Participants\\n  With COPD\\nStudy Url: https://clinicaltrials.gov/study/NCT06981078\\nStudy Status: RECRUITING\\nBrief Summary:\\n  The purpose of this study is to assess the efficacy and safety of\\n  verekitug (UPB-101) in participants with moderate-to-severe Chronic\\n  Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.\\nStudy Results: NO\\nConditions: Chronic Obstructive Pulmonary Disease\\nInterventions: DRUG: Verekitug|OTHER: Placebo\\nPhases: PHASE2\\nEnrollment: 666\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2025-07-02\\nCompletion Date: 2029-08\\n\\n# Record 21\\nNct Number: NCT07118696\\nStudy Title:\\n  Evaluating a Shorter, Rifampicin-Based Treatment for People With Less\\n  Severe Tuberculosis Disease\\nStudy Url: https://clinicaltrials.gov/study/NCT07118696\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-\\n  inferiority trial to compare the 6-month standard treatment for DS-TB\\n  with a 4-month optimised- rifampicin based regimen provided to\\n  individuals with limited disease severity.\\nStudy Results: NO\\nConditions: Pulmonary TB\\nInterventions: DRUG: Extra 600mg of Rifampicin|DRUG: Placebo\\nPhases: PHASE3\\nEnrollment: 1000\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2026-02-01\\nCompletion Date: 2030-01-31\\n\\n# Record 22\\nNct Number: NCT06905522\\nStudy Title: A PAN-USR TB Multi-Center Trial\\nStudy Url: https://clinicaltrials.gov/study/NCT06905522\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  Tuberculosis (TB) remains a major public health issue and one of the top\\n  ten causes of death from a single infectious disease worldwide. China is\\n  among the countries with the highest TB burden, ranking third globally\\n  for total TB cases and second for drug-resistant TB cases. PAN-TB is an\\n  innovative concept in TB treatment, aiming to develop a universal\\n  regimen effective for all forms of active TB, including both drug-\\n  susceptible and drug-resistant strains. The primary goal of the PAN-TB\\n  regimen is to simplify the treatment process, reduce costs, and improve\\n  treatment success rates. The ideal Target Regimen Profile (TRP) for PAN-\\n  TB includes superior efficacy compared to standard treatment for non-\\n  drug-resistant TB, a reduced treatment duration from the current 4-6\\n  months to 2-3 months, and improved safety and tolerability. This project\\n  aims to explore a new ultra-short-course treatment regimen for both\\n  drug-sensitive (DS-TB) and drug-resistant TB (MDR/RR-TB), which aligns\\n  with the latest trends in TB treatment both domestically and\\n  internationally. The regimen also has significant practical implications\\n  for enhancing treatment efficacy and reducing patient burden.\\n  Furthermore, the study will explore the identification of new biomarkers\\n  closely linked to treatment outcomes over the course of full-cycle\\n  therapy.\\nStudy Results: NO\\nConditions: Pulmonary Tuberculosis\\nInterventions:\\n  DRUG: Bedaquiline (B)|DRUG: Sitafloxacin (S)|DRUG: Linezolid (L)|DRUG:\\n  Pyrazinamide (Z)|DRUG: Isoniazid (H)|DRUG: Rifampicin (R)|DRUG:\\n  Ethambutol (E)|DRUG: Moxifloxacin (M)|DRUG: Pretomanid (Pa)\\nPhases: PHASE3\\nEnrollment: 610\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2025-04-15\\nCompletion Date: 2029-12\\n\\n# Record 23\\nNct Number: NCT06576830\\nStudy Title: Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia\\nStudy Url: https://clinicaltrials.gov/study/NCT06576830\\nStudy Status: RECRUITING\\nBrief Summary:\\n  The purpose of this study is to compare the use of short acting opioids\\n  (fentanyl/hydromorphone) with long acting opioids (methadone) for pain\\n  control following tonsillectomy surgery in children and adolescents.\\nStudy Results: NO\\nConditions:\\n  Pain, Postoperative|Tonsillar Hypertrophy|Tonsillitis|Pediatric Sleep\\n  Apnea|Sleep-Disordered Breathing\\nInterventions: DRUG: Methadone|DRUG: Fentanyl/Hydromorphone\\nPhases: PHASE4\\nEnrollment: 440\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE\\n  (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose:\\n  TREATMENT\\nStart Date: 2024-11-21\\nCompletion Date: 2029-06-01\\n\\n# Record 24\\nNct Number: NCT06172660\\nStudy Title: Real-World Effectiveness of Perinatal RSV Immunoprophylaxis\\nStudy Url: https://clinicaltrials.gov/study/NCT06172660\\nStudy Status: RECRUITING\\nBrief Summary:\\n  The purpose of this study is to continue evaluating how well the RSV\\n  vaccines work as they are currently being used in routine clinical\\n  practice. Some of the questions that the investigators hope to answer\\n  with this study are: 1) What is the overall effectiveness of these\\n  vaccines? 2) How long does immunity last? 3) How effective are the\\n  vaccines against new strains? 3) Does the vaccine's effectiveness vary\\n  by age?\\nStudy Results: NO\\nConditions: RSV Infection\\nInterventions: DRUG: Nirsevimab\\nPhases:\\nEnrollment: 3750\\nStudy Type: OBSERVATIONAL\\nStudy Design: Observational Model: |Time Perspective: p\\nStart Date: 2024-10-28\\nCompletion Date: 2028-12-30\\n\\n# Record 25\\nNct Number: NCT07076862\\nStudy Title:\\n  Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of SARS-CoV-2\\n  Infection (PASC)\\nStudy Url: https://clinicaltrials.gov/study/NCT07076862\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  This study uses total-body \\\\[\\u00b9\\u2078F\\\\]F-AraG PET/CT imaging to investigate\\n  immune activation and vascular changes in individuals with post-acute\\n  sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID.\\n  Participants will undergo dynamic PET/CT imaging along with blood\\n  biomarker assessments and symptom evaluations. The study aims to\\n  characterize sites of immunological perturbation, correlate PET imaging\\n  findings with peripheral blood markers, and evaluate longitudinal\\n  changes in tissue-based immune activity in relation to symptom patterns\\n  over time. Data from this study will improve understanding of tissue-\\n  level immune dysregulation in PASC and support future clinical tools for\\n  assessing and managing this condition.\\nStudy Results: NO\\nConditions: PASC Post Acute Sequelae of COVID-19\\nInterventions:\\n  DRUG: A.1 - [\\u00b9\\u2078F]F-AraG PET/CT (90-min dynamic + 4-h static)|DRUG: A.2 -\\n  [\\u00b9\\u2078F]F-AraG PET/CT (60-min dynamic only)|DRUG: B.1 - [\\u00b9\\u2078F]F-AraG PET/CT\\n  (90-min dynamic + 4-h static)|DRUG: B.2 - [\\u00b9\\u2078F]F-AraG PET/CT (60-min\\n  dynamic only)\\nPhases: EARLY_PHASE1\\nEnrollment: 51\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: BASIC_SCIENCE\\nStart Date: 2025-12\\nCompletion Date: 2029-12\\n\\n# Record 26\\nNct Number: NCT06325293\\nStudy Title:\\n  A Trial of Placebo Versus Macrolide for Mycoplasma Pneumoniae Childhood\\n  Pneumonia: MYTHIC Study\\nStudy Url: https://clinicaltrials.gov/study/NCT06325293\\nStudy Status: RECRUITING\\nBrief Summary:\\n  The goal of this clinical trial is to compare a placebo (a look-alike\\n  substance that contains no active drug) with a commonly used antibiotic\\n  in children with Mycoplasma pneumoniae (a specific bacterium) induced\\n  community-acquired pneumonia. The main question it aims to answer is:\\n\\n  Is antibiotic treatment needed in Mycoplasma pneumoniae (a specific\\n  bacterium) induced pneumonia?\\n\\n  Participants will receive either a placebo or a antibiotic treatment and\\n  track their symptoms and vital signs until they are healthy.\\n\\n  Researchers will then compare the length of symptoms between the placebo\\n  and the antibiotic group.\\nStudy Results: NO\\nConditions:\\n  Community Acquired Pneumonia in Children|Mycoplasma\\n  Pneumoniae|Mycoplasma Pneumoniae Pneumonia\\nInterventions: DRUG: Azithromycin Pfizer\\u00ae|DRUG: Placebo\\nPhases: NA\\nEnrollment: 376\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2025-01-28\\nCompletion Date: 2028-12-31\\n\\n# Record 27\\nNct Number: NCT06528444\\nStudy Title:\\n  Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone\\n  Compared to Placebo in Patients With Severe Influenza\\nStudy Url: https://clinicaltrials.gov/study/NCT06528444\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Clinical trial with an active ingredient of a pharmaceutical specialty\\n  marketed in Spain vs. placebo.\\n\\n  Randomized, double-blind, multicenter phase III clinical trial that\\n  evaluates the efficacy and safety of dexamethasone compared to placebo\\n  in patients with severe influenza.\\nStudy Results: NO\\nConditions: Influenza\\nInterventions: DRUG: Grup 1 placebo|DRUG: Grup 2 dexametasona\\nPhases: PHASE3\\nEnrollment: 42\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE\\n  (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT\\nStart Date: 2024-10-01\\nCompletion Date: 2028-10-31\\n\\n# Record 28\\nNct Number: NCT06076304\\nStudy Title:\\n  Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for\\n  Effective Management of Sinusitis\\nStudy Url: https://clinicaltrials.gov/study/NCT06076304\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Sinus infections are sometimes treated with oral antibiotics or nasal\\n  steroid sprays, while some patients get better on their own. Some\\n  patients may wait a few days or use common over-the-counter remedies to\\n  see if their symptoms improve without further treatment. Sometimes this\\n  is enough to help patients wait a few days to see if their infection\\n  clears up without needing to use antibiotics or nasal steroid sprays.\\n  The overall goal of this clinical trial to see which specific groups of\\n  patients benefit more from which intervention or combination of\\n  intervention, and which improve with supportive care alone.\\nStudy Results: NO\\nConditions: Sinus Infection|Acute Sinusitis\\nInterventions:\\n  DRUG: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|DRUG:\\n  Placebo|DRUG: Budesonide nasal spray|OTHER: C-reactive protein\\nPhases: PHASE4\\nEnrollment: 3720\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2023-11-21\\nCompletion Date: 2028-12\\n\\n# Record 29\\nNct Number: NCT04488081\\nStudy Title:\\n  I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill\\n  Patients\\nStudy Url: https://clinicaltrials.gov/study/NCT04488081\\nStudy Status: RECRUITING\\nBrief Summary:\\n  The goal of this project is to rapidly screen promising agents, in the\\n  setting of an adaptive platform trial, for treatment of critically ill\\n  COVID-19 patients. In this phase 2 platform design, agents will be\\n  identified with a signal suggesting a big impact on reducing mortality\\n  and the need for, as well as duration, of mechanical ventilation.\\nStudy Results: NO\\nConditions: COVID-19\\nInterventions:\\n  DRUG: Remdesivir|DRUG: Imatinib Mesylate|DRUG: Dexamethasone|DRUG:\\n  Cenicriviroc|DRUG: Icatibant|DRUG: Apremilast|BIOLOGICAL: dornase\\n  alfa|DRUG: Celecoxib|DRUG: Famotidine|BIOLOGICAL: IC14|DRUG:\\n  Aviptadil|BIOLOGICAL: narsoplimab|DRUG: Cyproheptadine|DRUG:\\n  Cyclosporine\\nPhases: PHASE2\\nEnrollment: 1500\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2020-07-31\\nCompletion Date: 2030-07-31\\n\\n# Record 30\\nNct Number: NCT06907251\\nStudy Title: Dapagliflozin for Long COVID Syndrome\\nStudy Url: https://clinicaltrials.gov/study/NCT06907251\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  This is a randomized, placebo-controlled study. Patients with long COVID\\n  will be randomized to receive dapagliflozin or placebo for 12 months.\\nStudy Results: NO\\nConditions: COVID - 19|Long COVID Syndrome\\nInterventions: DRUG: Dapagliflozin (DAPA)|DRUG: Placebo\\nPhases: PHASE3\\nEnrollment: 192\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2025-06-01\\nCompletion Date: 2029-06-30\\n\\n# Record 31\\nNct Number: NCT07000877\\nStudy Title:\\n  Nasal Decongestant to Reduce Perioperative Adverse Events in Children\\n  With Upper Respiratory Track Infections Having Anesthesia.\\nStudy Url: https://clinicaltrials.gov/study/NCT07000877\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  The goal of this multicentre, double-blind, randomised controlled trial\\n  study is to learn if the use of a nasal spray to open the nasal passages\\n  and increase airflow before surgery can reduce the occurrence of\\n  perioperative respiratory adverse events in children with upper\\n  respiratory tract infection who are undergoing anesthesia.\\n\\n  The main questions it aims to answer are:\\n\\n  * Does use of a nasal decongestant (Oxymetazoline 0.05%) reduce\\n  perioperative respiratory adverse events during emergence (when waking\\n  up from anesthesia) or in the post-anesthesia care unit in children.\\n  * Is it easy and acceptable to doctors, children and parents to use the\\n  nasal decongestant treatment? Researchers will compare the nasal\\n  decongestant to a placebo (a look-alike substance that contains no drug)\\n  to see if it works to reduce perioperative respiratory adverse effects.\\n\\n  Participants will:\\n\\n  * Take a nasal decongestant or a placebo prior to surgery (just before\\n  anaesthesia is given)\\n  * Be monitored during and after surgery in the post-anaesthesia care\\n  unit for any perioperative respiratory adverse events.\\n  * Be asked about how acceptable they found the treatment.\\nStudy Results: NO\\nConditions: Perioperative Respiratory Adverse Events|Anesthesia Outcomes\\nInterventions:\\n  DRUG: Decongestant nasal spray (oxymetazoline hydrochloride\\n  (0.05%))|DRUG: PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium\\n  chloride 0.02%\\nPhases: PHASE4\\nEnrollment: 200\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: PREVENTION\\nStart Date: 2025-05-30\\nCompletion Date: 2028-05-30\\n\\n# Record 32\\nNct Number: NCT05848713\\nStudy Title:\\n  AntiThrombotic Therapy to Ameliorate Clinical Complications in Community\\n  Acquired Pneumonia\\nStudy Url: https://clinicaltrials.gov/study/NCT05848713\\nStudy Status: RECRUITING\\nBrief Summary:\\n  This is an international, open-label, stratified randomized controlled\\n  trial with Bayesian adaptive stopping rules to compare the effects of\\n  therapeutic-dose heparin vs. usual care pharmacological\\n  thromboprophylaxis on outcomes in patients admitted to hospital with\\n  community acquired pneumonia (CAP).\\nStudy Results: NO\\nConditions: Community-acquired Pneumonia\\nInterventions: DRUG: Heparin\\nPhases: PHASE3\\nEnrollment: 4000\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2023-10-10\\nCompletion Date: 2029-03-31\\n\\n# Record 33\\nNct Number: NCT06819592\\nStudy Title:\\n  PRophylaxis Against Early VENTilator-associated Infections in Acute\\n  Brain Injury\\nStudy Url: https://clinicaltrials.gov/study/NCT06819592\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  This research is about whether treatment with a commonly used antibiotic\\n  can prevent infections in airway and lungs and improves the chance of\\n  surviving, if it is given soon after patients commence mechanical\\n  ventilation when they have been admitted to hospital with an acute\\n  severe brain injury.\\n\\n  An acute severe brain injury can occur as a result of a stroke, a\\n  traumatic injury or due to lack of oxygen to the brain that happens as a\\n  result of a cardiac arrest.\\n\\n  Patients who are unconscious after an acute severe brain injury often\\n  need assistance to breath adequately, and this assistance is given by a\\n  breathing tube, connected to a mechanical ventilator. This treatment is\\n  an emergency medical treatment. The breathing tube is inserted into the\\n  patients' airway by either their mouth or neck. For patients who need\\n  assistance with their breathing from a mechanical ventilator, infections\\n  in the airways and lungs, known as pneumonia, are a common complication.\\n  Everyone naturally has bacteria in their mouth, esophagus and stomach.\\n  Clinicians think that during the process of inserting the breathing\\n  tube, small amounts of these bacteria can be introduced into the airways\\n  and lung when people are unconscious following an acute severe brain\\n  injury, or during the process of placing the breathing tube into the\\n  airways. These bacteria are now in a place they aren't meant to be and\\n  can cause an infections in the airways and lungs known as pneumonia.\\n\\n  The purpose of this research is to see if giving one dose of a common\\n  antibiotic can prevent patients developing pneumonia, which is\\n  associated with having a breathing tube inserted and being on a\\n  ventilator, improving the chance of recovery following the acute severe\\n  brain injury and ultimately improving the chance of surviving.\\n\\n  When patients have a known infection, current guidelines are to treat\\n  them with antibiotics. Antibiotics work to kill the bacteria causing the\\n  infection. When a patient has an infection in their lungs, they often\\n  need to stay on the mechanical ventilator for longer. While current\\n  practice is to give patients with a proven infection in their airways\\n  and lungs (pneumonia) antibiotics, it is unknown if giving an antibiotic\\n  to patients to prevent these infections before they show signs of\\n  pneumonia may lead to better outcomes.\\nStudy Results: NO\\nConditions:\\n  All-cause Mortality|Quality of Life|Disability,\\n  Intellectual|Neurological Disorder|Acute Brain Injury|Ventilation,\\n  Mechanical|Intensive Care Medicine\\nInterventions:\\n  DRUG: Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride|DRUG: Placebo\\n  comparator - no ceftriaxone\\nPhases: PHASE3\\nEnrollment: 3100\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: PREVENTION\\nStart Date: 2025-04-01\\nCompletion Date: 2029-01-30\\n\\n# Record 34\\nNct Number: NCT05967052\\nStudy Title:\\n  Investigation of Treating Chronic Fatigue Syndrome After COVID With\\n  Pharmacotherapy (Pregabalin) or Complex Rehabilitation\\nStudy Url: https://clinicaltrials.gov/study/NCT05967052\\nStudy Status: RECRUITING\\nBrief Summary:\\n  This is a single-center, prospective, randomized, double-blind\\n  (pharmacotherapy), placebo-controlled, and comprehensive rehabilitation\\n  phase II clinical trial to determine the usefulness of pregabalin in a\\n  new indication (post-COVID chronic fatigue syndrome).\\n\\n  Patients will be randomized in a 1:1:1:1 ratio to pregabalin (75-300 mg\\n  daily in two divided doses), comprehensive rehabilitation with a placebo\\n  drug, comprehensive rehabilitation with pregabalin (75-300 mg in two\\n  divided doses), or placebo (two divided doses) for 6 months (177-187\\n  days).\\n\\n  There will be 4 outpatient visits to the research center and 12\\n  telephone consultations.\\n\\n  The procedures and assessments performed as part of the study are listed\\n  in the study schedule.\\n\\n  It is planned to include 132 patients in the study, which, assuming a\\n  10% level of non-completion of the program, will result in the\\n  examination of 120 patients (30 in each arm).\\n\\n  Patients will be recruited during an outpatient medical consultation\\n  with a general practitioner or neurologist, psychiatrist, psychologist\\n  or other specialists, as well as with the use of information materials\\n  in the form of leaflets and advertisements on the Internet.\\nStudy Results: NO\\nConditions: Chronic Fatigue Syndrome|COVID-19, Long Haul\\nInterventions:\\n  DRUG: Pregabalin|BEHAVIORAL: Independent walking training|DRUG:\\n  Placebo|BEHAVIORAL: Gradual movement therapy in the ward|BEHAVIORAL:\\n  Telerehabilitation|BEHAVIORAL: Psychotherapy\\nPhases: PHASE2\\nEnrollment: 132\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE\\n  (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT\\nStart Date: 2023-10-24\\nCompletion Date: 2028-03-01\\n\\n# Record 35\\nNct Number: NCT04851015\\nStudy Title:\\n  Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis\\n  Jirovecii Pneumonia\\nStudy Url: https://clinicaltrials.gov/study/NCT04851015\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal\\n  infection of immunocompromised hosts which causes in significant\\n  morbidity and mortality. The current standard of care, trimethoprim-\\n  sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is\\n  associated with serious adverse events, including hypersensitivity\\n  reactions, drug-induced liver injury, cytopenia, and renal failure\\n  occurring among 20-60% of patients. The frequency of adverse events\\n  increases in a dose dependent manner and commonly limits the use of TMP-\\n  SMX.\\n\\n  Reduced treatment doses of TMP-SMX for PJP reduced ADEs without\\n  mortality differences in a recent meta-analysis of observational\\n  studies. We therefore propose a Phase III randomized, placebo-controlled\\n  trial to directly compare the efficacy and safety of low dose (10\\n  mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among\\n  patients with PJP for the primary outcome of death, new mechanical\\n  ventilation, and change of treatment.\\nStudy Results: NO\\nConditions:\\n  Pneumocystis|Pneumocystis Pneumonia|Pneumocystis Jirovecii\\n  Infection|Pneumocystis Infections|Pneumocystis Carinii\\n  Infection|Pneumocystosis; Pneumonia (Etiology)|Pneumocystis Carinii;\\n  Infection, Resulting From HIV Disease|Pneumocystosis Associated With\\n  AIDS\\nInterventions: DRUG: trimethoprim-sulfamethoxazole|DRUG: trimethoprim-sulfamethoxazole\\nPhases: PHASE3\\nEnrollment: 300\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2025-01\\nCompletion Date: 2028-06\\n\\n# Record 36\\nNct Number: NCT04712539\\nStudy Title:\\n  Baloxavir and Oseltamivir for the Treatment of Severe Influenza\\n  Infection in Immunocompromised Patients\\nStudy Url: https://clinicaltrials.gov/study/NCT04712539\\nStudy Status: RECRUITING\\nBrief Summary:\\n  This phase II trial studies the effect of baloxavir in combination with\\n  oseltamivir in treating severe influenza infection in patients who have\\n  previously received a hematopoietic (blood) stem cell transplant or have\\n  a hematological malignancy. Baloxavir is an antiviral drug that inhibits\\n  the growth of influenza virus, reduces viral load and prevents further\\n  influenza infection. Osetamivir is an antiviral drug that blocks enzymes\\n  on the surfaces of influenza viruses, interfering with cell release of\\n  complete viral particles. Giving baloxavir in combination with\\n  oseltamivir may shorten or decrease the intensity of influenza infection\\n  compared to oseltamivir alone.\\nStudy Results: NO\\nConditions: Hematopoietic and Lymphoid Cell Neoplasm|Influenza\\nInterventions: DRUG: Baloxavir Marboxil|DRUG: Oseltamivir\\nPhases: PHASE2\\nEnrollment: 60\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking:\\n  NONE|Primary Purpose: TREATMENT\\nStart Date: 2021-10-11\\nCompletion Date: 2028-02-28\\n\\n# Record 37\\nNct Number: NCT07048262\\nStudy Title:\\n  Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in\\n  Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)\\nStudy Url: https://clinicaltrials.gov/study/NCT07048262\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  This study is a phase 2b, multicenter, randomized, double-blind,\\n  placebo-controlled, parallel-group, dose range finding study designed to\\n  explore the efficacy, safety, and tolerability of 2 active treatment\\n  regimens of CSL787 (nebulized immunoglobulin G \\\\[IgG\\\\]) compared with\\n  placebo over 6 to 12 months to prolong the time to first (TTF)\\n  exacerbation as a primary endpoint.\\n\\n  The primary aim of the study is to characterize the overall effect of\\n  CSL787 as well as the dose response of 2 active treatment regimens of\\n  inhaled CSL787 administered to participants with NCFB over a period of\\n  greater than or equal to (\\\\>=) 6 months but not exceeding 12 months\\n  toward prolonging the TTF exacerbation.\\nStudy Results: NO\\nConditions: Non-cystic Fibrosis Bronchiectasis\\nInterventions: BIOLOGICAL: CSL787|DRUG: Placebo|DEVICE: Nebulizer\\nPhases: PHASE2\\nEnrollment: 450\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2025-09-27\\nCompletion Date: 2028-03-28\\n\\n# Record 38\\nNct Number: NCT06920628\\nStudy Title:\\n  PET Imaging of Cyclooxygenase-1 in Participants With Neurological\\n  Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)\\nStudy Url: https://clinicaltrials.gov/study/NCT06920628\\nStudy Status: RECRUITING\\nBrief Summary:\\n  Background:\\n\\n  SARS-CoV-2 is the virus that causes COVID-19. Some people who recover\\n  from COVID-19 have long-term symptoms that affect the brain. These\\n  include headaches; loss of taste and smell; sleep problems; thinking\\n  problems; depression; and anxiety. Researchers want to know if a tracer\\n  (a substance that is injected into a person s body before an imaging\\n  scan) can help identify inflammation in people with these brain\\n  disorders.\\n\\n  Objective:\\n\\n  To see if a radioactive tracer (\\\\[11C\\\\]PS13) can highlight brain\\n  inflammation in those who had COVID-19 but still have symptoms that\\n  affect the brain.\\n\\n  Eligibility:\\n\\n  Adults aged 18 to 70 years with post COVID-19 brain disorders who are\\n  enrolled in protocol 000089 or 000711. Healthy volunteers are also\\n  needed.\\n\\n  Design:\\n\\n  Participants will have up to 5 clinic visits.\\n\\n  Participants will be screened. They will have blood tests and a test of\\n  their heart function.\\n\\n  They will have imaging scans:\\n\\n  Magnetic resonance imaging (MRI): They will lie on a table that slides\\n  into a metal tube. Pictures will be taken of the brain.\\n\\n  Positron emission tomography (PET): A needle attached to a thin tube\\n  will be inserted into a vein in the arm. The tracer will be injected\\n  through the tube. Another needle attached to a thin tube will be\\n  inserted into the wrist or inside of the elbow of the other arm to draw\\n  blood. They will lie still on a bed while a machine captures images of\\n  their brain. The scan will last about 2 hours.\\n\\n  Study involvement is 11 to 14 weeks....\\nStudy Results: NO\\nConditions: Long COVID|Post Acute Sequelae of COVID-19\\nInterventions: DRUG: 11C-PS13\\nPhases: PHASE1\\nEnrollment: 60\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary\\n  Purpose: DIAGNOSTIC\\nStart Date: 2025-06-18\\nCompletion Date: 2029-02-22\\n\\n# Record 39\\nNct Number: NCT06721949\\nStudy Title: Taurine Supplementation in Long COVID\\nStudy Url: https://clinicaltrials.gov/study/NCT06721949\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  The COVID-19 pandemic has swept across the globe, affecting millions of\\n  individuals with varying degrees of severity. While many individuals\\n  recover from the acute phase of the infection, a significant proportion\\n  continue to experience persistent and debilitating symptoms long after\\n  the initial SARS-CoV-2 infection. This condition, known as Long COVID\\n  (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-\\n  acute sequelae of COVID-19, has emerged as a complex multisystemic\\n  condition and challenging health issue, affecting approximately 10% of\\n  COVID-19 patients. Various symptoms characterize LC, including fatigue,\\n  sleep disturbances, cognitive impairment, and mood disturbances. Some of\\n  the symptoms are shared with Myalgic Encephalomyelitis/Chronic Fatigue\\n  Syndrome (ME/CFS) - a condition marked by debilitating fatigue and a\\n  host of other symptoms without precise biomarkers or objective tests for\\n  diagnosis. Effective LC treatments remain elusive and LC patients\\n  continue to grapple with persistent symptoms that significantly impact\\n  their quality of life. Given the lack of effective treatments, it is\\n  imperative to explore novel therapeutic approaches that may alleviate\\n  the suffering of this patient population.\\nStudy Results: NO\\nConditions: Long COVID\\nInterventions: DRUG: Taurine|DRUG: Placebo\\nPhases: PHASE2|PHASE3\\nEnrollment: 300\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE\\n  (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary\\n  Purpose: TREATMENT\\nStart Date: 2025-10\\nCompletion Date: 2028-12\\n\\n# Record 40\\nNct Number: NCT07089719\\nStudy Title:\\n  Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety\\n  (Pilot Study)\\nStudy Url: https://clinicaltrials.gov/study/NCT07089719\\nStudy Status: NOT_YET_RECRUITING\\nBrief Summary:\\n  The aim of this research is to evaluate an innovative treatment,\\n  Bevacizumab, in patients suffering from respiratory complications\\n  related to COVID-19. These complications, particularly difficulty\\n  breathing (dyspnea) and impaired lung function, are common in some\\n  individuals after infection. The study seeks to determine whether\\n  Bevacizumab can improve breathing capacity by acting on vascular\\n  mechanisms that may be responsible for these issues. A total of 21\\n  patients with these persistent symptoms will be included in the study,\\n  with close medical monitoring to assess both the effectiveness of the\\n  treatment and its safety.\\n\\n  This research aims to assess the effectiveness and safety of\\n  Bevacizumab, a medication known for its anti-angiogenic properties\\n  (which prevent the formation of new blood vessels), in patients\\n  experiencing persistent respiratory problems after COVID-19 infection.\\n  In other words, this research is based on the idea that inhibiting blood\\n  vessel formation with Bevacizumab may improve clinical outcomes in\\n  patients with severe forms of COVID-19 by reducing vascular\\n  complications associated with the infection.\\n\\n  To answer this research question, 21 individuals with persistent\\n  respiratory symptoms (significant dyspnea) and reduced lung diffusing\\n  capacity (DLCO less than 75% of the predicted value) at least three\\n  months after their initial COVID-19 infection will be included. The\\n  study is being conducted at H\\u00f4pital Europ\\u00e9en Georges Pompidou, in Paris.\\n\\n  The total expected duration of the research is 31 months, and each\\n  patient's participation will last 7 months, which includes 2 months of\\n  treatment (five Bevacizumab injections) followed by five additional\\n  months of medical follow-up.\\n\\n  In this research project, we will be evaluating Bevacizumab, an\\n  experimental drug in the context of Long COVID. Bevacizumab is a\\n  monoclonal antibody used to inhibit angiogenesis (the abnormal formation\\n  of new blood vessels). While commonly used in oncology, in this study,\\n  its use aims to improve lung function in patients suffering from\\n  persistent respiratory complications after COVID-19 infection.\\n\\n  Bevacizumab will be administered as an intravenous infusion. The\\n  infusion lasts between 30 and 90 minutes. The dosage is 10 mg/kg every\\n  two weeks, for a total of five infusions over a two-month period.\\n  Additional follow-up visits will be conducted one month and five months\\n  after the end of treatment. Monitoring will include clinical\\n  examinations, laboratory tests, and lung function assessments.\\nStudy Results: NO\\nConditions: Dyspnea Caused by 2019-nCoV\\nInterventions: DRUG: Bevacizumab Injection\\nPhases: PHASE2\\nEnrollment: 21\\nStudy Type: INTERVENTIONAL\\nStudy Design:\\n  Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary\\n  Purpose: TREATMENT\\nStart Date: 2025-10-01\\nCompletion Date: 2028-05-01\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Analyze the entirety of the data and detailed participant health outcomes recorded in the clinical research trial designated by code NCT04280705, ensuring the evaluation methodically incorporates interconnected trends across all measured parameters, study phases, and their potential implications."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_outcomes",
                    "arguments": {
                        "nct_id": "NCT04280705"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_outcomes",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Url: https://clinicaltrials.gov/study/NCT04280705\\n\\n# Protocol Section\\n\\n## Outcomes Module\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Race\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Ethnicity\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Primary Outcomes\\nMeasure: Time to Recovery by Sex\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Alanine Transaminase (ALT)\\nDescription:\\n  Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Aspartate Transaminase (AST)\\nDescription:\\n  Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Creatinine\\nDescription:\\n  Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Glucose\\nDescription:\\n  Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Hemoglobin\\nDescription:\\n  Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Platelets\\nDescription:\\n  Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Prothrombin Time (PT)\\nDescription:\\n  Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Total Bilirubin\\nDescription:\\n  Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in White Blood Cell Count (WBC)\\nDescription:\\n  Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Neutrophils\\nDescription:\\n  Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Lymphocytes\\nDescription:\\n  Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Monocytes\\nDescription:\\n  Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Basophils\\nDescription:\\n  Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change From Baseline in Eosinophils\\nDescription:\\n  Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n### Secondary Outcomes\\nMeasure: Change in National Early Warning Score (NEWS) From Baseline\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome.\\nTime Frame: Days 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 1\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 1\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 3\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 3\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 5\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 5\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 8\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 8\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 11\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 11\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 15\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 15\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 22\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 22\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 29\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nTime Frame: Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Reporting Grade 3 and 4 Clinical and/or\\n  Laboratory Adverse Events (AEs)\\nDescription:\\n  Grade 3 AEs are defined as events that interrupt usual activities of\\n  daily living, or significantly affects clinical status, or may require\\n  intensive therapeutic intervention. Severe events are usually\\n  incapacitating. Grade 4 AEs are defined as events that are potentially\\n  life threatening.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Percentage of Participants Reporting Serious Adverse Events (SAEs)\\nDescription:\\n  An SAE is defined as an AE or suspected adverse reaction is considered\\n  serious if, in the view of either the investigator or the sponsor, it\\n  results in death, a life-threatening AE, inpatient hospitalization or\\n  prolongation of existing hospitalization, a persistent or significant\\n  incapacity or substantial disruption of the ability to conduct normal\\n  life functions, or a congenital anomaly/birth defect.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Discontinued or Temporarily Suspended From\\n  Investigational Therapeutics\\nDescription:\\n  Participants may have been discontinued from investigational\\n  therapeutics due to discharge or death. The halting or slowing of the\\n  infusion for any reason was collected, as was missed doses in the series\\n  of 10 doses.\\nTime Frame: Day 1 through Day 10\\n\\n### Secondary Outcomes\\nMeasure: Duration of Hospitalization\\nDescription:\\n  Duration of hospitalization was determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Duration of New Non-invasive Ventilation or High Flow Oxygen Use\\nDescription:\\n  Duration of new non-invasive ventilation or high flow oxygen use was\\n  measured in days among participants who were not on non-invasive\\n  ventilation or high-flow oxygen use at baseline, determined two ways.\\n  The first includes imputations for participants who died. The second\\n  method is restricted to participants who did not die\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Duration of New Oxygen Use\\nDescription:\\n  Duration of new oxygen use was measured in days among participants who\\n  were not on oxygen at baseline, determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die\\n\\n  .\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO)\\n  Use\\nDescription:\\n  Duration of new ventilator or ECMO use was measured in days among\\n  participants who were not on a ventilator or ECMO at baseline,\\n  determined two ways. The first includes imputations for participants who\\n  died. The second method is restricted to participants who did not die\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Requiring New Non-invasive Ventilation or\\n  High-flow Oxygen Use\\nDescription:\\n  New non-invasive ventilation or high-flow oxygen use was determined as\\n  the percentage of subject not on non-invasive ventilation or high-flow\\n  oxygen at baseline.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Percentage of Participants Requiring New Oxygen Use\\nDescription:\\n  The percentage of participants requiring new oxygen use was determined\\n  as the percentage of participants not requiring oxygen at baseline\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Percentage of Participants Requiring New Ventilator or Extracorporeal\\n  Membrane Oxygenation (ECMO) Use\\nDescription:\\n  The percentage of participants requiring new ventilator or ECMO use was\\n  determined as the percentage not on a ventilator or ECMO at baseline\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Mean Change in the Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. A positive change indicates a worsening and a negative\\n  change is an improvement.\\nTime Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n### Secondary Outcomes\\nMeasure: 14-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 15.\\nTime Frame: Day 1 through Day 15\\n\\n### Secondary Outcomes\\nMeasure: 29-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 29.\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Time to an Improvement by at Least One Category Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least one category was determined\\n  for each participant\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure: Time to an Improvement of at Least Two Categories Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 1) Death; 2)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 4) Hospitalized, requiring\\n  supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 6)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 7) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 8) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least two categories was\\n  determined for each participant\\nTime Frame: Day 1 through Day 29\\n\\n### Secondary Outcomes\\nMeasure:\\n  Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours,\\n  Whichever Occurs First\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome. The time to discharge or a\\n  NEWS of less than or equal to 2 was determined for each participant.\\nTime Frame: Day 1 through Day 29\\n\\n# Results Section\\n\\n## Participant Flow Module\\nRecruitment Details:\\n  Participants were recruited at the participating sites from those\\n  admitted with symptoms of COVID-19 confirmed by PCR. Enrollment occurred\\n  between 21FEB2020 and 20APR2020.\\n\\n### Groups\\nId: FG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n  Placebo: The supplied placebo lyophilized formulation is identical in\\n  physical appearance to the active lyophilized formulation and contains\\n  the same inactive ingredients. Alternatively, a placebo of normal saline\\n  of equal volume may be given if there are limitations on matching\\n  placebo supplies.\\n\\n### Groups\\nId: FG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n  Remdesivir: Drug Remdesivir is a single diastereomer monophosphoramidate\\n  prodrug designed for the intracellular delivery of a modified adenine\\n  nucleoside analog GS-441524. In addition to the active ingredient, the\\n  lyophilized formulation of Remdesivir contains the following inactive\\n  ingredients: water for injection, sulfobutylether beta-cyclodextrin\\n  sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.\\n\\n### Periods\\nTitle: Overall Study\\n\\n#### Milestones\\nType: STARTED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 521\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 541\\n\\n#### Milestones\\nType: Received Treatment\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 517\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 531\\n\\n#### Milestones\\nType: COMPLETED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 508\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 517\\n\\n#### Milestones\\nType: NOT COMPLETED\\n\\n##### Achievements\\nGroup Id: FG000\\nNum Subjects: 13\\n\\n##### Achievements\\nGroup Id: FG001\\nNum Subjects: 24\\n\\n#### Drop Withdraws\\nType: Enrolled but not treated\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 4\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 10\\n\\n#### Drop Withdraws\\nType: Physician Decision\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 1\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 0\\n\\n#### Drop Withdraws\\nType: Withdrawal by Subject\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 7\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 9\\n\\n#### Drop Withdraws\\nType: Adverse Event\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 0\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 4\\n\\n#### Drop Withdraws\\nType: Transferred to another hospital\\n\\n##### Reasons\\nGroup Id: FG000\\nNum Subjects: 1\\n\\n##### Reasons\\nGroup Id: FG001\\nNum Subjects: 1\\n\\n## Baseline Characteristics Module\\n\\n### Groups\\nId: BG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n### Groups\\nId: BG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n### Groups\\nId: BG002\\nTitle: Total\\nDescription: Total of all reporting groups\\n\\n### Denoms\\nUnits: Participants\\n\\n#### Counts\\nGroup Id: BG000\\nValue: 521\\n\\n#### Counts\\nGroup Id: BG001\\nValue: 541\\n\\n#### Counts\\nGroup Id: BG002\\nValue: 1062\\n\\n### Measures\\nTitle: Age, Categorical\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: <=18 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 0\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 0\\n\\n##### Categories\\nTitle: Between 18 and 65 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 324\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 354\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 678\\n\\n##### Categories\\nTitle: >=65 years\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 197\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 187\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 384\\n\\n### Measures\\nTitle: Age, Continuous\\nParam Type: MEAN\\nDispersion Type: STANDARD_DEVIATION\\nUnit Of Measure: years\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 59.2\\nSpread: 15.4\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 58.6\\nSpread: 14.6\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 58.9\\nSpread: 15.0\\n\\n### Measures\\nTitle: Sex: Female, Male\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: Female\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 189\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 189\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 378\\n\\n##### Categories\\nTitle: Male\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 332\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 352\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 684\\n\\n### Measures\\nTitle: Ethnicity (NIH/OMB)\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: Hispanic or Latino\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 116\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 134\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 250\\n\\n##### Categories\\nTitle: Not Hispanic or Latino\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 373\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 382\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 755\\n\\n##### Categories\\nTitle: Unknown or Not Reported\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 32\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 25\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 57\\n\\n### Measures\\nTitle: Race (NIH/OMB)\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\n\\n##### Categories\\nTitle: American Indian or Alaska Native\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 3\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 7\\n\\n##### Categories\\nTitle: Asian\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 56\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 79\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 135\\n\\n##### Categories\\nTitle: Native Hawaiian or Other Pacific Islander\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 4\\n\\n##### Categories\\nTitle: Black or African American\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 117\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 109\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 226\\n\\n##### Categories\\nTitle: White\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 287\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 279\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 566\\n\\n##### Categories\\nTitle: More than one race\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 1\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 2\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 3\\n\\n##### Categories\\nTitle: Unknown or Not Reported\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 55\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 66\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 121\\n\\n### Measures\\nTitle: Region of Enrollment\\nParam Type: NUMBER\\nUnit Of Measure: participants\\n\\n#### Classes\\nTitle: Greece\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 19\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 14\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 33\\n\\n#### Classes\\nTitle: South Korea\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 12\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 9\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 21\\n\\n#### Classes\\nTitle: Singapore\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 9\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 16\\n\\n#### Classes\\nTitle: United States\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 410\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 427\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 837\\n\\n#### Classes\\nTitle: Japan\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 8\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 15\\n\\n#### Classes\\nTitle: Denmark\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 21\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 22\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 43\\n\\n#### Classes\\nTitle: Mexico\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 6\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 4\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 10\\n\\n#### Classes\\nTitle: United Kingdom\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 21\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 25\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 46\\n\\n#### Classes\\nTitle: Germany\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 6\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 7\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 13\\n\\n#### Classes\\nTitle: Spain\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 12\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 16\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 28\\n\\n### Measures\\nTitle: Disease severity\\nDescription:\\n  Mild-moderate disease: SpO2 \\\\> 94% and respiratory rate \\\\< 24\\n  breaths/min without supplemental oxygen.\\n\\n  Severe disease: requiring mechanical ventilation, requiring oxygen, a\\n  SpO2 = 94% on room air, or tachypnea (respiratory rate = 24\\n  breaths/min).\\nParam Type: COUNT_OF_PARTICIPANTS\\nUnit Of Measure: Participants\\n\\n#### Classes\\nTitle: Mild-to-moderate disease severity\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 50\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 55\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 105\\n\\n#### Classes\\nTitle: Severe disease severity\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: BG000\\nValue: 471\\n\\n##### Measurements\\nGroup Id: BG001\\nValue: 486\\n\\n##### Measurements\\nGroup Id: BG002\\nValue: 957\\n\\n## Outcome Measures Module\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 9\\nUpper Limit: 11\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.12\\nCi Upper Limit: 1.49\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Alanine Transaminase (ALT)\\nDescription:\\n  Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: Units/Liter (U/L)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 465\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 465\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14.3\\nSpread: 88\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2.9\\nSpread: 31.5\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 403\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 398\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23.1\\nSpread: 70.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.8\\nSpread: 55.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 327\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 296\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24.2\\nSpread: 79.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 8.9\\nSpread: 54.2\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 227\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 27.7\\nSpread: 89.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.4\\nSpread: 48.4\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 242\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 257\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 28.1\\nSpread: 110.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.7\\nSpread: 47.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 180\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -3.9\\nSpread: 62.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -6.8\\nSpread: 43.7\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Aspartate Transaminase (AST)\\nDescription:\\n  Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: Units/Liter (U/L)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 438\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 445\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 438\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 445\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13.7\\nSpread: 90.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.0\\nSpread: 29.1\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 384\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 380\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.8\\nSpread: 66.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6.0\\nSpread: 58.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 315\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 285\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13.1\\nSpread: 114.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.1\\nSpread: 55.9\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 247\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 219\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11.5\\nSpread: 78.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 51.7\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 236\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 248\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.2\\nSpread: 73.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.3\\nSpread: 60.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 170\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 208\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -18.4\\nSpread: 47.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -14.0\\nSpread: 52.2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Creatinine\\nDescription:\\n  Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: milligrams/deciliter (mg/dL)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 482\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 482\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.037\\nSpread: 0.517\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.038\\nSpread: 0.569\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 418\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 411\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.695\\nSpread: 17.552\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.075\\nSpread: 0.762\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 335\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 309\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.882\\nSpread: 19.637\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.158\\nSpread: 0.951\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 234\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.173\\nSpread: 15.440\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.236\\nSpread: 1.057\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 249\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 262\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.239\\nSpread: 22.755\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.319\\nSpread: 2.147\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 229\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.863\\nSpread: 26.093\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.075\\nSpread: 0.644\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Glucose\\nDescription:\\n  Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: mg/dL\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.2\\nSpread: 53.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.0\\nSpread: 49.4\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 407\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 395\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6.3\\nSpread: 60.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2.1\\nSpread: 63.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 323\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 301\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.2\\nSpread: 73.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.2\\nSpread: 68.0\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 260\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 228\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.0\\nSpread: 70.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.1\\nSpread: 77.4\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 250\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -2.8\\nSpread: 64.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.9\\nSpread: 75.4\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 180\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 219\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -13.5\\nSpread: 96.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -11.7\\nSpread: 75.4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Hemoglobin\\nDescription:\\n  Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: grams/deciliter (g/dL)\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 475\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.52\\nSpread: 1.10\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.69\\nSpread: 5.36\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 420\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 406\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.83\\nSpread: 1.22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.99\\nSpread: 5.83\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 334\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 310\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.22\\nSpread: 1.42\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.49\\nSpread: 6.54\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 230\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.66\\nSpread: 1.67\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.29\\nSpread: 1.93\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 253\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 260\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.51\\nSpread: 2.02\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.02\\nSpread: 3.04\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 227\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.02\\nSpread: 2.38\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.21\\nSpread: 7.91\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Platelets\\nDescription:\\n  Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 471\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 474\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 471\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 474\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 39.3\\nSpread: 60.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 46.0\\nSpread: 62.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 419\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 403\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 76.5\\nSpread: 100.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 90.1\\nSpread: 99.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 332\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 308\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 111.8\\nSpread: 137.4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 130.8\\nSpread: 128.1\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 269\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 229\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 109.3\\nSpread: 149.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 101.0\\nSpread: 145.0\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 252\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 258\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 96.5\\nSpread: 154.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 71.1\\nSpread: 133.3\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 224\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32.7\\nSpread: 124.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 39.6\\nSpread: 107.4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Prothrombin Time (PT)\\nDescription:\\n  Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: seconds\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 339\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 339\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.18\\nSpread: 4.28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.44\\nSpread: 5.22\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 296\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 306\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.30\\nSpread: 4.72\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.15\\nSpread: 5.72\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 246\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 234\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.01\\nSpread: 2.59\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.43\\nSpread: 3.89\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 199\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 182\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.86\\nSpread: 7.85\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1.88\\nSpread: 5.68\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 193\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.34\\nSpread: 4.33\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.03\\nSpread: 4.25\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 134\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 163\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.28\\nSpread: 3.20\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.63\\nSpread: 3.37\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Total Bilirubin\\nDescription:\\n  Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and\\n  11 while participants were inpatient, and at Days 15 and 29, with the\\n  Day 1 assessment serving as baseline. Participants who had been\\n  discharged had blood collected if infection control measures allowed for\\n  in-person visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: mg/dL\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 451\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 456\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 451\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 456\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.08\\nSpread: 1.25\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.04\\nSpread: 0.75\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 394\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.58\\nSpread: 4.13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.03\\nSpread: 1.03\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 315\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 288\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.22\\nSpread: 2.56\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.01\\nSpread: 1.38\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 247\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.23\\nSpread: 2.79\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.07\\nSpread: 1.48\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 237\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 254\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.00\\nSpread: 1.80\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.09\\nSpread: 1.54\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 178\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 216\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.17\\nSpread: 1.65\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.12\\nSpread: 1.77\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in White Blood Cell Count (WBC)\\nDescription:\\n  Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while\\n  participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 474\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 474\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 475\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 18.691\\nSpread: 424.837\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -18.970\\nSpread: 301.944\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 419\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 405\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9.886\\nSpread: 566.175\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -28.209\\nSpread: 412.615\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 333\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 310\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 27.223\\nSpread: 479.095\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -45.997\\nSpread: 602.461\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 268\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 230\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.967\\nSpread: 16.042\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -34.702\\nSpread: 574.065\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 252\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 260\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 56.311\\nSpread: 620.551\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -70.884\\nSpread: 600.011\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 226\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.898\\nSpread: 17.801\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.251\\nSpread: 3.987\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Neutrophils\\nDescription:\\n  Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9.429\\nSpread: 260.345\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -8.093\\nSpread: 135.068\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.177\\nSpread: 362.782\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -15.067\\nSpread: 216.532\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 317\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 298\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17.916\\nSpread: 305.321\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -28.179\\nSpread: 365.099\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3.010\\nSpread: 27.502\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -21.773\\nSpread: 354.025\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36.024\\nSpread: 389.093\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -39.988\\nSpread: 333.088\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.269\\nSpread: 7.160\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.840\\nSpread: 3.666\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Lymphocytes\\nDescription:\\n  Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 459\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5.883\\nSpread: 118.740\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -7.847\\nSpread: 131.548\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 389\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4.064\\nSpread: 141.580\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -11.723\\nSpread: 167.428\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 317\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 299\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8.006\\nSpread: 137.149\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -15.455\\nSpread: 194.111\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.393\\nSpread: 1.371\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -12.016\\nSpread: 183.060\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14.793\\nSpread: 159.583\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -23.836\\nSpread: 218.653\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.668\\nSpread: 1.406\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.743\\nSpread: 0.664\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Monocytes\\nDescription:\\n  Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 458\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 463\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 458\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.448\\nSpread: 41.304\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.940\\nSpread: 46.752\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 406\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 388\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.498\\nSpread: 57.686\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.628\\nSpread: 39.329\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 316\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 299\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2.324\\nSpread: 36.626\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.645\\nSpread: 48.636\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 257\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 220\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.383\\nSpread: 0.744\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.539\\nSpread: 43.454\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 241\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 253\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6.475\\nSpread: 69.019\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -8.738\\nSpread: 74.365\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 177\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.125\\nSpread: 0.485\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.117\\nSpread: 0.340\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Basophils\\nDescription:\\n  Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 455\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 452\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 455\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 452\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.020\\nSpread: 0.257\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.043\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 394\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 380\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.038\\nSpread: 0.501\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.370\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 309\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 293\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.196\\nSpread: 3.132\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.005\\nSpread: 0.368\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 253\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.024\\nSpread: 0.042\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.028\\nSpread: 0.053\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 235\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 248\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.158\\nSpread: 1.913\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.058\\nSpread: 1.028\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 216\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.040\\nSpread: 0.073\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.029\\nSpread: 0.054\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change From Baseline in Eosinophils\\nDescription:\\n  Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11\\n  while participants were inpatient, and at Days 15 and 29, with the Day 1\\n  assessment serving as baseline. Participants who had been discharged had\\n  blood collected if infection control measures allowed for in-person\\n  visits after discharge.\\nPopulation Description:\\n  The safety population includes all treated participants with available\\n  data at baseline and the post baseline assessment point, analyzed as\\n  treated.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: 10^9 cells/liter\\nTime Frame: Days 1, 3, 5, 8, 11, 15 and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 455\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 456\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 455\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.634\\nSpread: 10.614\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.016\\nSpread: 0.727\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 397\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 387\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.666\\nSpread: 11.977\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.066\\nSpread: 2.807\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 311\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 293\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.596\\nSpread: 8.875\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.221\\nSpread: 4.108\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 254\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 218\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.093\\nSpread: 0.190\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.088\\nSpread: 2.973\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 237\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 251\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1.992\\nSpread: 20.365\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.420\\nSpread: 5.378\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 176\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 217\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.241\\nSpread: 0.324\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.211\\nSpread: 0.267\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Change in National Early Warning Score (NEWS) From Baseline\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized with data at baseline and at each timepoint.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: units on a scale\\nTime Frame: Days 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 499\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 502\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 499\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 502\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.1\\nSpread: 2.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 2.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 447\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 438\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.3\\nSpread: 3.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.4\\nSpread: 2.9\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 348\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 321\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.3\\nSpread: 3.8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.5\\nSpread: 3.2\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 291\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 254\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.3\\nSpread: 4.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.5\\nSpread: 3.5\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 290\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 301\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 4.2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.7\\nSpread: 3.6\\n\\n#### Classes\\nTitle: Day 22\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 151\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 120\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 4.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.7\\nSpread: 4.1\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 221\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 251\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -3.2\\nSpread: 4.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -3.3\\nSpread: 3.2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 1\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 30\\nLower Limit: 26\\nUpper Limit: 34\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 21\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 18\\nLower Limit: 15\\nUpper Limit: 21\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 39\\nLower Limit: 35\\nUpper Limit: 43\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 43\\nLower Limit: 39\\nUpper Limit: 47\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 10\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 14\\nLower Limit: 11\\nUpper Limit: 17\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 3\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 3\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36\\nLower Limit: 32\\nUpper Limit: 40\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 25\\nUpper Limit: 32\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 16\\nLower Limit: 13\\nUpper Limit: 19\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 37\\nLower Limit: 33\\nUpper Limit: 41\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 5\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 5\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 37\\nLower Limit: 33\\nUpper Limit: 41\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 24\\nUpper Limit: 32\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 26\\nLower Limit: 23\\nUpper Limit: 30\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 28\\nLower Limit: 24\\nUpper Limit: 31\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 8\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 15\\nLower Limit: 12\\nUpper Limit: 18\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 9\\nUpper Limit: 15\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 8\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 8\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 33\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 21\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 19\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 10\\nLower Limit: 8\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 30\\nLower Limit: 27\\nUpper Limit: 34\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 11\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 11\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8\\nLower Limit: 6\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 28\\nLower Limit: 25\\nUpper Limit: 32\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 10\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.4\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 33\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 44\\nLower Limit: 40\\nUpper Limit: 48\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 15\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 15\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 15\\nLower Limit: 13\\nUpper Limit: 19\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 11\\nLower Limit: 9\\nUpper Limit: 14\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 8\\nUpper Limit: 13\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 6\\nLower Limit: 5\\nUpper Limit: 9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 14\\nUpper Limit: 21\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 22\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 22\\nLower Limit: 19\\nUpper Limit: 26\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 29\\nLower Limit: 25\\nUpper Limit: 33\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\nLower Limit: 3\\nUpper Limit: 7\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 22\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 22\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 16\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 8\\nLower Limit: 6\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 5\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5\\nLower Limit: 4\\nUpper Limit: 8\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 18\\nLower Limit: 15\\nUpper Limit: 22\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 23\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 29\\nUpper Limit: 37\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 39\\nLower Limit: 35\\nUpper Limit: 43\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Completed study without reporting score\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants at Each Clinical Status Using Ordinal Scale\\n  at Day 29\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Death at or before study Visit\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15\\nLower Limit: 12\\nUpper Limit: 18\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 8\\nUpper Limit: 14\\n\\n#### Classes\\nTitle: Hospitalized, on invasive mech. vent. or ECMO\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 7\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 6\\nLower Limit: 4\\nUpper Limit: 8\\n\\n#### Classes\\nTitle: Hospitalized, on non-invasive vent./high flow O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Hospitalized, requiring supplemental oxygen\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 3\\nUpper Limit: 6\\n\\n#### Classes\\nTitle: Hospitalized, not on O2, requiring ongoing care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Hospitalized, not requiring O2, no longer req care\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 0\\nUpper Limit: 2\\n\\n#### Classes\\nTitle: Not hospitalized, limit on activities/req home O2\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 19\\nLower Limit: 16\\nUpper Limit: 23\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 20\\nLower Limit: 17\\nUpper Limit: 23\\n\\n#### Classes\\nTitle: Not hospitalized, no limitations on activities\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 36\\nLower Limit: 32\\nUpper Limit: 41\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 46\\nLower Limit: 42\\nUpper Limit: 50\\n\\n#### Classes\\nTitle: No clinical status score reported - Hospitalized\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nLower Limit: 0\\nUpper Limit: 1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0\\nLower Limit: 0\\nUpper Limit: 1\\n\\n#### Classes\\nTitle: No clinical status score reported - Discharged\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 1\\nLower Limit: 1\\nUpper Limit: 3\\n\\n#### Classes\\nTitle: No clinical status score reported - Discontinued\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5\\nLower Limit: 3\\nUpper Limit: 7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 5\\nUpper Limit: 9\\n\\n#### Classes\\nTitle: Completed study without reporting score\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Reporting Grade 3 and 4 Clinical and/or\\n  Laboratory Adverse Events (AEs)\\nDescription:\\n  Grade 3 AEs are defined as events that interrupt usual activities of\\n  daily living, or significantly affects clinical status, or may require\\n  intensive therapeutic intervention. Severe events are usually\\n  incapacitating. Grade 4 AEs are defined as events that are potentially\\n  life threatening.\\nPopulation Description:\\n  The safety population includes all participants with available data post\\n  baseline, analyzed as treated.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 516\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 532\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 57\\nLower Limit: 52.8\\nUpper Limit: 61.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 51\\nLower Limit: 47.0\\nUpper Limit: 55.6\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.058\\nStatistical Method: Barnard's Exact Test\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Percentage of Participants Reporting Serious Adverse Events (SAEs)\\nDescription:\\n  An SAE is defined as an AE or suspected adverse reaction is considered\\n  serious if, in the view of either the investigator or the sponsor, it\\n  results in death, a life-threatening AE, inpatient hospitalization or\\n  prolongation of existing hospitalization, a persistent or significant\\n  incapacity or substantial disruption of the ability to conduct normal\\n  life functions, or a congenital anomaly/birth defect.\\nPopulation Description:\\n  The safety population includes all participants with available data post\\n  baseline, analyzed as treated.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 516\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 532\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 32\\nLower Limit: 27.7\\nUpper Limit: 35.7\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 24\\nLower Limit: 20.9\\nUpper Limit: 28.3\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.010\\nStatistical Method: Barnard's Exact Test\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Discontinued or Temporarily Suspended From\\n  Investigational Therapeutics\\nDescription:\\n  Participants may have been discontinued from investigational\\n  therapeutics due to discharge or death. The halting or slowing of the\\n  infusion for any reason was collected, as was missed doses in the series\\n  of 10 doses.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 10\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Discontinued due to discharge\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 30\\nLower Limit: 26\\nUpper Limit: 34\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 41\\nLower Limit: 37\\nUpper Limit: 45\\n\\n#### Classes\\nTitle: Discontinued due to death\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 5\\n\\n#### Classes\\nTitle: Any infusions halted or slowed\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 2\\nLower Limit: 1\\nUpper Limit: 4\\n\\n#### Classes\\nTitle: Missed any maintenance dose\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 21\\nLower Limit: 18\\nUpper Limit: 25\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 16\\nLower Limit: 13\\nUpper Limit: 19\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of Hospitalization\\nDescription:\\n  Duration of hospitalization was determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Including imputation for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 17\\nLower Limit: 8\\nUpper Limit: 28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 12\\nLower Limit: 6\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Restricted to participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 443\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 480\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 7\\nUpper Limit: 27\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10\\nLower Limit: 5\\nUpper Limit: 21\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of New Non-invasive Ventilation or High Flow Oxygen Use\\nDescription:\\n  Duration of new non-invasive ventilation or high flow oxygen use was\\n  measured in days among participants who were not on non-invasive\\n  ventilation or high-flow oxygen use at baseline, determined two ways.\\n  The first includes imputations for participants who died. The second\\n  method is restricted to participants who did not die\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on non-invasive ventilation or high-flow oxygen at baseline but\\n  who subsequently required non-invasive or high-flow oxygen.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 64\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 64\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 23.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 10.5\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 50\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 43\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 2\\nUpper Limit: 6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 6\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Duration of New Oxygen Use\\nDescription:\\n  Duration of new oxygen use was measured in days among participants who\\n  were not on oxygen at baseline, determined two ways. The first includes\\n  imputations for participants who died. The second method is restricted\\n  to participants who did not die\\n\\n  .\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on oxygen at baseline but who subsequently required oxygen.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 28\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 27\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 28\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 27\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 5.5\\nLower Limit: 1\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 4\\nLower Limit: 2\\nUpper Limit: 12\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 25\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 24\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 3\\nLower Limit: 1\\nUpper Limit: 13\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 3.5\\nLower Limit: 2\\nUpper Limit: 5.5\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO)\\n  Use\\nDescription:\\n  Duration of new ventilator or ECMO use was measured in days among\\n  participants who were not on a ventilator or ECMO at baseline,\\n  determined two ways. The first includes imputations for participants who\\n  died. The second method is restricted to participants who did not die\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not on\\n  a ventilator or ECMO at baseline but who subsequently required a\\n  ventilator or ECMO.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: Inter-Quartile Range\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 82\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n#### Classes\\nTitle: Including imputations for participants who died\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 82\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 52\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23\\nLower Limit: 12\\nUpper Limit: 28\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 21.5\\nLower Limit: 9\\nUpper Limit: 28\\n\\n#### Classes\\nTitle: Among participants who did not die\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 57\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 39\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 16\\nLower Limit: 9\\nUpper Limit: 24\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 14\\nLower Limit: 5\\nUpper Limit: 26\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Requiring New Non-invasive Ventilation or\\n  High-flow Oxygen Use\\nDescription:\\n  New non-invasive ventilation or high-flow oxygen use was determined as\\n  the percentage of subject not on non-invasive ventilation or high-flow\\n  oxygen at baseline.\\nPopulation Description:\\n  The analysis population is restricted to randomized participants who\\n  were not on non-invasive or high-flow oxygen at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 266\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 307\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24\\nLower Limit: 19\\nUpper Limit: 30\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 17\\nLower Limit: 13\\nUpper Limit: 22\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Percentage of Participants Requiring New Oxygen Use\\nDescription:\\n  The percentage of participants requiring new oxygen use was determined\\n  as the percentage of participants not requiring oxygen at baseline\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not\\n  requiring oxygen at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 63\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 75\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 44\\nLower Limit: 33\\nUpper Limit: 57\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 36\\nLower Limit: 26\\nUpper Limit: 47\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Percentage of Participants Requiring New Ventilator or Extracorporeal\\n  Membrane Oxygenation (ECMO) Use\\nDescription:\\n  The percentage of participants requiring new ventilator or ECMO use was\\n  determined as the percentage not on a ventilator or ECMO at baseline\\nPopulation Description:\\n  The analysis population is restricted to randomized participants not on\\n  a ventilator or ECMO at baseline.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: percentage of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 364\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 402\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 23\\nLower Limit: 19\\nUpper Limit: 27\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 13\\nLower Limit: 10\\nUpper Limit: 17\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Mean Change in the Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. A positive change indicates a worsening and a negative\\n  change is an improvement.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized reporting a clinical score. Missing values were imputed using\\n  Last Observation Carried Forward. Clinical scores of 8 were carried\\n  forward from the date of death for participants who died.\\nReporting Status: POSTED\\nParam Type: MEAN\\nDispersion Type: Standard Deviation\\nUnit Of Measure: units on a scale\\nTime Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 518\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 533\\n\\n#### Classes\\nTitle: Day 3\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.2\\nSpread: 0.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.1\\nSpread: 0.6\\n\\n#### Classes\\nTitle: Day 5\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.1\\nSpread: 0.9\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.0\\nSpread: 0.8\\n\\n#### Classes\\nTitle: Day 8\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.0\\nSpread: 0.1\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.2\\nSpread: 1.0\\n\\n#### Classes\\nTitle: Day 11\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -0.1\\nSpread: 1.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -0.3\\nSpread: 1.1\\n\\n#### Classes\\nTitle: Day 15\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.4\\nSpread: 2.3\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -1.9\\nSpread: 2.1\\n\\n#### Classes\\nTitle: Day 22\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -1.9\\nSpread: 2.5\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.4\\nSpread: 2.2\\n\\n#### Classes\\nTitle: Day 29\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: -2.3\\nSpread: 2.6\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: -2.7\\nSpread: 2.3\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: 14-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 15.\\nPopulation Description: The ITT population consists of all participants as randomized.\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Proportion of participants\\nTime Frame: Day 1 through Day 15\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.12\\nLower Limit: 0.09\\nUpper Limit: 0.15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.07\\nLower Limit: 0.05\\nUpper Limit: 0.09\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: 29-day Participant Mortality\\nDescription:\\n  The mortality rate was determined as the proportion of participants who\\n  died by study Day 29.\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: NUMBER\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Proportion of participants\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 0.15\\nLower Limit: 0.12\\nUpper Limit: 0.19\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 0.11\\nLower Limit: 0.09\\nUpper Limit: 0.15\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Time to an Improvement by at Least One Category Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 8) Death; 7)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 5) Hospitalized, requiring\\n  supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 3)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 1) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least one category was determined\\n  for each participant\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 9\\nLower Limit: 8\\nUpper Limit: 11\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 7\\nLower Limit: 6\\nUpper Limit: 8\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: 0.002\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.23\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.08\\nCi Upper Limit: 1.41\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle: Time to an Improvement of at Least Two Categories Using an Ordinal Scale\\nDescription:\\n  The ordinal scale is an assessment of the clinical status at the first\\n  assessment of a given study day. The scale is as follows: 1) Death; 2)\\n  Hospitalized, on invasive mechanical ventilation or extracorporeal\\n  membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive\\n  ventilation or high flow oxygen devices; 4) Hospitalized, requiring\\n  supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen\\n  - requiring ongoing medical care (COVID-19 related or otherwise); 6)\\n  Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 7) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 8) Not hospitalized, no limitations on\\n  activities. Time to improvement by at least two categories was\\n  determined for each participant\\nPopulation Description: The ITT population includes all participants as randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 14\\nLower Limit: 13\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11\\nLower Limit: 10\\nUpper Limit: 13\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.12\\nCi Upper Limit: 1.48\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: SECONDARY\\nTitle:\\n  Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours,\\n  Whichever Occurs First\\nDescription:\\n  The NEW score has demonstrated an ability to discriminate patients at\\n  risk of poor outcomes. This score is based on 7 clinical parameters\\n  (respiration rate, oxygen saturation, any supplemental oxygen,\\n  temperature, systolic blood pressure, heart rate, level of\\n  consciousness). The NEW Score is being used as an efficacy measure. The\\n  minimum score is 0, representing the better outcome, and the maximum\\n  value is 19, representing the worse outcome. The time to discharge or a\\n  NEWS of less than or equal to 2 was determined for each participant.\\nPopulation Description: The ITT population includes all participants as randomized.\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12\\nLower Limit: 10\\nUpper Limit: 15\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 8\\nLower Limit: 7\\nUpper Limit: 9\\n\\n#### Analyses\\nNon Inferiority Type: SUPERIORITY\\nP Value: <0.001\\nStatistical Method: Log Rank\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.27\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 1.46\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Race\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Asian\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 56\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 79\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.0\\nLower Limit: 9.0\\nUpper Limit: 15.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 11.0\\nLower Limit: 9.0\\nUpper Limit: 15.0\\n\\n#### Classes\\nTitle: Black or African American\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 117\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 109\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 10.0\\nUpper Limit: 21.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 7.0\\nUpper Limit: 16.0\\n\\n#### Classes\\nTitle: White\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 287\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 279\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Other\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 61\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 74\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 24.0\\nLower Limit: 15.0\\nUpper Limit: NA\\nComment:\\n  A large number of participants at the median estimate resulted in little\\n  variability at the 50th percentile and the methodology described by\\n  Klein and Moeschberger (1997) was unable to compute an upper confidence\\n  limit.\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 6.0\\nUpper Limit: 14.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Asian participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.07\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.73\\nCi Upper Limit: 1.58\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Black or African American participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.25\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.91\\nCi Upper Limit: 1.72\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for White participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.29\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.06\\nCi Upper Limit: 1.57\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Race of Other participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.68\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 2.58\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Ethnicity\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized and for whom Ethnicity was reported\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 489\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 516\\n\\n#### Classes\\nTitle: Not Hispanic or Latino\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 373\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 382\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 13.0\\nUpper Limit: 18.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Hispanic or Latino\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 116\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 134\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 12.5\\nLower Limit: 9.0\\nUpper Limit: 22.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 7.0\\nUpper Limit: 14.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Not Hispanic or Latino participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.31\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.10\\nCi Upper Limit: 1.55\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Hispanic or Latino participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.28\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 0.94\\nCi Upper Limit: 1.73\\nGroup Ids: OG000, OG001\\n\\n### Outcome Measures\\nType: PRIMARY\\nTitle: Time to Recovery by Sex\\nDescription:\\n  Day of recovery is defined as the first day on which the subject\\n  satisfies one of the following three categories from the ordinal scale:\\n  1) Hospitalized, not requiring supplemental oxygen - no longer requires\\n  ongoing medical care; 2) Not hospitalized, limitation on activities\\n  and/or requiring home oxygen; 3) Not hospitalized, no limitations on\\n  activities.\\nPopulation Description:\\n  The intent-to-treat (ITT) population includes all participants who were\\n  randomized\\nReporting Status: POSTED\\nParam Type: MEDIAN\\nDispersion Type: 95% Confidence Interval\\nUnit Of Measure: Days\\nTime Frame: Day 1 through Day 29\\n\\n#### Groups\\nId: OG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\n\\n#### Groups\\nId: OG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\n\\n#### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 521\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 541\\n\\n#### Classes\\nTitle: Male\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 332\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 352\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 9.0\\nLower Limit: 8.0\\nUpper Limit: 12.0\\n\\n#### Classes\\nTitle: Female\\n\\n##### Denoms\\nUnits: Participants\\n\\n##### Counts\\nGroup Id: OG000\\nValue: 189\\n\\n##### Counts\\nGroup Id: OG001\\nValue: 189\\n\\n##### Categories\\n\\n##### Measurements\\nGroup Id: OG000\\nValue: 15.0\\nLower Limit: 12.0\\nUpper Limit: 19.0\\n\\n##### Measurements\\nGroup Id: OG001\\nValue: 10.0\\nLower Limit: 8.0\\nUpper Limit: 13.0\\n\\n#### Analyses\\nGroup Description: This analysis is for Male participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.30\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.09\\nCi Upper Limit: 1.56\\nGroup Ids: OG000, OG001\\n\\n#### Analyses\\nGroup Description: This analysis is for Female participants\\nNon Inferiority Type: SUPERIORITY\\nParam Type: Cox Proportional Hazard\\nParam Value: 1.31\\nCi Pct Value: 95\\nCi Num Sides: TWO_SIDED\\nCi Lower Limit: 1.03\\nCi Upper Limit: 1.66\\nGroup Ids: OG000, OG001\\n\\n## Adverse Events Module\\nFrequency Threshold: 5\\nTime Frame:\\n  Grade 3 and 4 serious and non-serious adverse events were collected for\\n  29 days after the first dose. Laboratory values were systematically\\n  assessed at Days 1, 3, 5, 8, and 11 while participants were inpatient,\\n  and at Days 15 and 29.\\nDescription:\\n  Given the nature of severity of the underlying illness, participants\\n  were expected to have many symptoms and abnormalities in vital signs and\\n  laboratory values. All Grade 3 and 4 AEs were captured as AEs in this\\n  trial. In addition, any Grade 2 or higher, suspected drug-related\\n  hypersensitivity reaction was to be reported as an AE in this trial. All\\n  cause mortality was calculated for the ITT population, while SAEs and\\n  AEs reflect the as treated population.\\n\\n### Event Groups\\nId: EG000\\nTitle: Placebo\\nDescription:\\n  200 mg of Remdesivir placebo administered intravenously on Day 1,\\n  followed by a 100 mg once-daily maintenance dose of Remdesivir placebo\\n  while hospitalized for up to a 10 days total course.\\nDeaths Num Affected: 77\\nDeaths Num At Risk: 521\\nSerious Num Affected: 163\\nSerious Num At Risk: 516\\nOther Num Affected: 295\\nOther Num At Risk: 516\\n\\n### Event Groups\\nId: EG001\\nTitle: Remdesivir\\nDescription:\\n  200 mg of Remdesivir administered intravenously on Day 1, followed by a\\n  100 mg once-daily maintenance dose of Remdesivir while hospitalized for\\n  up to a 10 days total course.\\nDeaths Num Affected: 59\\nDeaths Num At Risk: 541\\nSerious Num Affected: 131\\nSerious Num At Risk: 532\\nOther Num Affected: 276\\nOther Num At Risk: 532\\n\\n### Serious Events\\nTerm: Coagulopathy\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Febrile neutropenia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Anaemia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac arrest\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 10\\nNum Affected: 10\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Atrial fibrillation\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardio-respiratory arrest\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myocardial infarction\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Supraventricular tachycardia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ventricular tachycardia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute myocardial infarction\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac failure\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiogenic shock\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute coronary syndrome\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Arrhythmia\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Palpitations\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulseless electrical activity\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ventricular fibrillation\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cardiac tamponade\\nOrgan System: Cardiac disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Intestinal ischaemia\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Diarrhoea\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Duodenal perforation\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Gastrointestinal haemorrhage\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Small intestinal perforation\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haematemesis\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Peptic ulcer haemorrhage\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Small intestinal obstruction\\nOrgan System: Gastrointestinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Multiple organ dysfunction syndrome\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pyrexia\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Chest pain\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Death\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hepatitis\\nOrgan System: Hepatobiliary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ischaemic hepatitis\\nOrgan System: Hepatobiliary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Drug hypersensitivity\\nOrgan System: Immune system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Septic shock\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 15\\nNum Affected: 15\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 8\\nNum Affected: 8\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: COVID-19\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: COVID-19 pneumonia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Sepsis\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumonia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Catheter bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Gangrene\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Infectious pleural effusion\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Staphylococcal bacteraemia\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Urinary tract infection\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Bacterial sepsis\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Endocarditis bacterial\\nOrgan System: Infections and infestations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hip fracture\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Infusion related reaction\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Procedural pneumothorax\\nOrgan System: Injury, poisoning and procedural complications\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Glomerular filtration rate decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemoglobin decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Oxygen saturation decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Blood creatinine increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Lymphocyte count decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acidosis\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Dehydration\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypernatraemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hyponatraemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Decreased appetite\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pain in extremity\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myalgia\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Myopathy\\nOrgan System: Musculoskeletal and connective tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebrovascular accident\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Seizure\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebellar infarction\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Cerebral haemorrhage\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Encephalopathy\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Subarachnoid haemorrhage\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Depressed level of consciousness\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemorrhagic transformation stroke\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hemiparesis\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Intensive care unit acquired weakness\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Ischaemic stroke\\nOrgan System: Nervous system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Mental status changes\\nOrgan System: Psychiatric disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Psychotic disorder\\nOrgan System: Psychiatric disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute kidney injury\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 12\\nNum Affected: 12\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Renal failure\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Renal impairment\\nOrgan System: Renal and urinary disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 59\\nNum Affected: 58\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 36\\nNum Affected: 35\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 14\\nNum Affected: 14\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 8\\nNum Affected: 8\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory distress\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 11\\nNum Affected: 11\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 6\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Acute respiratory distress syndrome\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumothorax\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulmonary embolism\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypoxia\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pneumonia aspiration\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Dyspnoea\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Respiratory disorder\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 2\\nNum Affected: 2\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Chronic respiratory failure\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Haemoptysis\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Pulmonary haemorrhage\\nOrgan System: Respiratory, thoracic and mediastinal disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Subcutaneous emphysema\\nOrgan System: Skin and subcutaneous tissue disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Endotracheal intubation\\nOrgan System: Surgical and medical procedures\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 9\\nNum Affected: 9\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 6\\nNum Affected: 6\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Mechanical ventilation\\nOrgan System: Surgical and medical procedures\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 3\\nNum Affected: 3\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Hypotension\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 7\\nNum Affected: 7\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Shock\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 4\\nNum Affected: 4\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 5\\nNum Affected: 5\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Deep vein thrombosis\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Embolism venous\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Peripheral artery occlusion\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Serious Events\\nTerm: Shock haemorrhagic\\nOrgan System: Vascular disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: NON_SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 0\\nNum Affected: 0\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 1\\nNum Affected: 1\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Glomerular filtration rate decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 81\\nNum Affected: 74\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 59\\nNum Affected: 55\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Haemoglobin decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 69\\nNum Affected: 62\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 51\\nNum Affected: 48\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Lymphocyte count decreased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 63\\nNum Affected: 54\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 56\\nNum Affected: 44\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Anaemia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 58\\nNum Affected: 52\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 52\\nNum Affected: 42\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Pyrexia\\nOrgan System: General disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 37\\nNum Affected: 32\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 52\\nNum Affected: 38\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Hyperglycaemia\\nOrgan System: Metabolism and nutrition disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 43\\nNum Affected: 34\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 36\\nNum Affected: 34\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Blood creatinine increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 41\\nNum Affected: 36\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 33\\nNum Affected: 31\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Blood glucose increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 31\\nNum Affected: 27\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 45\\nNum Affected: 39\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Aspartate aminotransferase increased\\nOrgan System: Investigations\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 35\\nNum Affected: 33\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 19\\nNum Affected: 18\\nNum At Risk: 532\\n\\n### Other Events\\nTerm: Lymphopenia\\nOrgan System: Blood and lymphatic system disorders\\nSource Vocabulary: MedDRA (23.0)\\nAssessment Type: SYSTEMATIC_ASSESSMENT\\n\\n#### Stats\\nGroup Id: EG000\\nNum Events: 34\\nNum Affected: 30\\nNum At Risk: 516\\n\\n#### Stats\\nGroup Id: EG001\\nNum Events: 15\\nNum Affected: 13\\nNum At Risk: 532\\n\\n## More Info Module\\n\\n### Certain Agreement\\nPi Sponsor Employee: False\\nRestriction Type: LTE60\\nRestrictive Agreement: True\\n\\n### Point Of Contact\\nTitle: John Beigel, MD\\nOrganization: Organization:NIAID\\nEmail: jbeigel@niaid.nih.gov\\nPhone: 3014519881\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Analyze the biochemical consequences and clinical significance of the genetic variant \"chr3:g.101928474A>T\" by mapping its regulatory interactions and associated disease mechanisms."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_variant_details",
                    "arguments": {
                        "variant_id": "chr3:g.101928474A>T"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_variant_details",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"# Record 1\\nError: Error 404: {\\\"code\\\":404,\\\"success\\\":false,\\\"error\\\":\\\"Not Found.\\\"}\\n\"}], \"isError\": false}"
        }
    ],
    [
        {
            "role": "user",
            "content": "Identify and compile comprehensive data on all genetic variants and their associated research studies, including their dbSNP IDs, that are linked to the disease under the clinical trial with the NCT ID \"NCT04386834,\" ensuring relationships are validated through cross-referencing genomic and trial-specific annotations."
        },
        {
            "role": "assistant",
            "content": "",
            "tool_calls": {
                "type": "function",
                "function": {
                    "name": "biomcp_trial_references",
                    "arguments": {
                        "nct_id": "NCT04386834"
                    }
                }
            }
        },
        {
            "role": "tool",
            "tool_call_id": 0,
            "name": "biomcp_trial_references",
            "content": "{\"content\": [{\"type\": \"text\", \"text\": \"Error: API Error 404\\nDetails: NCT number NCT04386834 not found\\n\"}], \"isError\": false}"
        }
    ]
]